<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006105.pub3" GROUP_ID="MENSTR" ID="294306010212313084" MERGED_FROM="" MODIFIED="2015-04-16 04:05:16 +0100" MODIFIED_BY="Helen Nagels" REVIEW_NO="LDT1201" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-04-16 04:05:16 +0100" MODIFIED_BY="Helen Nagels">
<TITLE MODIFIED="2008-09-08 16:34:05 +1200" MODIFIED_BY="[Empty name]">Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome</TITLE>
<CONTACT MODIFIED="2015-04-16 04:05:16 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="98F49F5382E26AA2012C734C4DCC0AC8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leopoldo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Tso</LAST_NAME><POSITION>Doctor</POSITION><EMAIL_1>leotso@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Gynecology</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Av. Dr. Altino Arantes, 865. Ap. 124</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04042-034</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 50786506</PHONE_1><PHONE_2>+55 11 81116304</PHONE_2><FAX_1>+55 12 55745441</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-04-16 04:05:16 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="98F49F5382E26AA2012C734C4DCC0AC8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leopoldo</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Tso</LAST_NAME><POSITION>Doctor</POSITION><EMAIL_1>leotso@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Gynecology</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Av. Dr. Altino Arantes, 865. Ap. 124</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04042-034</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 50786506</PHONE_1><PHONE_2>+55 11 81116304</PHONE_2><FAX_1>+55 12 55745441</FAX_1></ADDRESS></PERSON><PERSON ID="16927" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Costello</LAST_NAME><POSITION>Senior Lecturer in Obstetrics &amp; Gynaecology</POSITION><EMAIL_1>mfcostello@unsw.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Division of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>School of Women's &amp; Children's Health, Royal Hospital for Women and IVF Australia</ORGANISATION><ADDRESS_1>Barker Street</ADDRESS_1><ADDRESS_2>Randwick</ADDRESS_2><CITY>Sydney</CITY><ZIP>NSW 2031</ZIP><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9382 6777</PHONE_1><FAX_1>+61 2 9382 6444</FAX_1></ADDRESS></PERSON><PERSON ID="14536" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luiz Eduardo</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Albuquerque</LAST_NAME><POSITION>Director - Fertivitro</POSITION><EMAIL_1>leta@osite.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Human Reproduction Center</DEPARTMENT><ORGANISATION>Fertivitro Centro de Reprodução Humana</ORGANISATION><ADDRESS_1>Av. Indianopolis 843</ADDRESS_1><ADDRESS_2>B. Moema</ADDRESS_2><CITY>São Paulo</CITY><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5081 2031</PHONE_1><PHONE_2>+55 11 8148 7878</PHONE_2><FAX_1>+55 11 5081 2031</FAX_1></ADDRESS></PERSON><PERSON ID="20062" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Régis</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Andriolo</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>regis.andriolo@gmail.com</EMAIL_1><MOBILE_PHONE>+55 (91) 3132-4127</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health</DEPARTMENT><ORGANISATION>Universidade do Estado do Pará</ORGANISATION><ADDRESS_1>Travessa Perebebuí, 2623</ADDRESS_1><CITY>Belém</CITY><ZIP>66087-670</ZIP><REGION>Pará</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 (91) 3276-2023</PHONE_1><FAX_1>+55 (91) 3230-1029</FAX_1></ADDRESS></PERSON><PERSON ID="62E0491B82E26AA201F801F7BD1071A6" ROLE="AUTHOR"><FIRST_NAME>Cristiane</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Macedo</LAST_NAME><POSITION>Researcher/Trials Search Co-ordinator</POSITION><EMAIL_1>crisrufa@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde</ORGANISATION><ADDRESS_1>Rua Borges Lagoa, 564 cj 63</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04038-000</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>55 11 55752970</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-11-14 11:15:00 +1300" MODIFIED_BY="Helen Nagels">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="10" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-16 15:03:37 +1200" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-04-16 15:03:37 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="16" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>Correction of text error in Abstract and Plain language summary, and addition of search result numbers in Appendix 1.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-04-16 14:45:38 +1200" MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-16 14:45:34 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="15" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>One new co-author was added for the update of this review (Cristiane R Macedo).</P>
<P>Three new trials were added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-04-16 14:45:38 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="15" MONTH="10" YEAR="2014"/>
<DESCRIPTION>
<P>With the addition of three new studies (<LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>), totalling 816 participants, the conclusions of the review have changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>The search was updated on 5 November 2012.</P>
<P>Three new trials were included (<LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>) totalling 801 participants. The conclusions of the review changed: the clinical pregnancy rate was significantly higher in the metformin group. </P>
<P>Two new co-authors were added (Luiz Eduardo T Albuquerque and Cristiane R Macedo).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>The 'Risk of bias' table was completed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-04-04 14:24:22 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>The review was converted to the new format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Federal University of São Paulo (UNIFESP/EPM)</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Nuffield Department of Obstetrics and Gynecology</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>School of Women's and Children's Health, Division of Obstetrics and Gynecology, Royal Hospital for Women</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-04-16 14:47:30 +1200" MODIFIED_BY="Helen E Nagels">
<SUMMARY MODIFIED="2015-04-16 14:46:45 +1200" MODIFIED_BY="Helen E Nagels">
<TITLE MODIFIED="2013-02-22 06:56:56 +1300" MODIFIED_BY="[Empty name]">Metformin in women with polycystic ovary syndrome for improving fertility</TITLE>
<SUMMARY_BODY MODIFIED="2015-04-16 14:46:45 +1200" MODIFIED_BY="Helen E Nagels">
<P>
<B>Review question:</B> The aim of this Cochrane review was to determine the effectiveness and safety of metformin, an insulin-sensitising agent, for improving ART outcomes, especially, live birth and clinical pregnancy rates, in women with PCOS undergoing in vitro fertilisation (IVF) treatment.</P>
<P>
<B>Background: </B>Polycystic ovary syndrome (PCOS) is a condition characterised by chronic failure or absence of ovulation (anovulation) and excessive production of male hormones (hyperandrogenism). The main symptoms of this disorder are irregular menstrual cycles, infertility, hirsutism (excessive hair growth) and acne. This condition is the most common endocrine disorder in women, affecting approximately 5% to 10% of all women of reproductive age.</P>
<P>
<B>Study characteristics: </B>The review included nine randomised controlled trials involving a total of 816 women who were randomised to receive metformin (411) versus placebo or no treatment (405). The trials were conducted in the Czech Republic, Italy, Jordan, Norway, Turkey and the United Kingdom. The evidence is current to October 2014.</P>
<P>
<B>Key results: </B>When metformin was compared with placebo or no treatment, there was no conclusive evidence of a difference between the groups in live birth rates, but pregnancy rates were higher in the metformin group, and the risk of OHSS was lower. We estimated that for a woman with a 32 % chance of achieving a live birth using placebo, the corresponding chance using metformin would be between 28% and 53%. For a woman with a 31% chance of achieving a clinical pregnancy without metformin, the corresponding chance using metformin would be between 32% and 49%. For a woman with a 27% risk of ovarian hyperstimulation syndrome (OHSS) without metformin, the corresponding chance using metformin would be between 6% and 15%. Side effects (mostly gastrointestinal) were more common in the metformin group, though only four studies reported this outcome.</P>
<P>
<B>Quality of the evidence: </B>The overall quality of the evidence was moderate for the outcomes of clinical pregnancy, OHSS and miscarriage, and low for other outcomes. The main limitations in the evidence were imprecision and inconsistency.</P>
<P>
<B>Conclusion: </B>We found no conclusive evidence that metformin treatment before or during ART cycles improved live birth rates in women with PCOS. However, the use of this insulin-sensitising agent increased clinical pregnancy rates and decreased the risk of OHSS.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-04-16 14:46:40 +1200" MODIFIED_BY="Helen E Nagels">
<ABS_BACKGROUND MODIFIED="2014-11-13 10:30:46 +1300" MODIFIED_BY="[Empty name]">
<P>The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied. Metformin reduces hyperinsulinaemia and suppresses the excessive ovarian production of androgens. As a consequence, it is suggested that metformin could improve assisted reproductive techniques (ART) outcomes, such as ovarian hyperstimulation syndrome (OHSS), pregnancy and live birth rates.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and safety of metformin as a co-treatment during IVF or intracytoplasmic sperm injection (ICSI) in achieving pregnancy or live birth in women with PCOS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-10-24 06:08:58 +1300" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>), MEDLINE, EMBASE, LILACS, the <I>meta</I>Register of Controlled Trials and reference lists of articles (up to 15 October 2014).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-13 10:30:56 +1300" MODIFIED_BY="[Empty name]">
<P>Types of studies: randomised controlled trials (RCTs) comparing metformin treatment with placebo or no treatment in women with PCOS who underwent IVF or ICSI treatment.</P>
<P>Types of participants: women of reproductive age with anovulation due to PCOS with or without co-existing infertility factors.</P>
<P>Types of interventions: metformin administered before and during IVF or ICSI treatment.</P>
<P>Types of outcome measures: live birth rate, clinical pregnancy rate, miscarriage rate, incidence of ovarian hyperstimulation syndrome , incidence of participant-reported side effects, serum oestradiol level on the day of trigger, serum androgen level, and fasting insulin and glucose levels.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-10-08 13:36:23 +1300" MODIFIED_BY="[Empty name]">
<P>Two review authors independently selected the studies, extracted the data according to the protocol and assessed study quality. The overall quality of the evidence was assessed using GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-04-16 14:46:40 +1200" MODIFIED_BY="Helen E Nagels">
<P>We included nine randomised controlled trials involving a total of 816 women with PCOS. When metformin was compared with placebo there was no clear evidence of a difference between the groups in live birth rates (OR 1.39, 95% CI 0.81 to 2.40, five RCTs, 551 women, I<SUP>2 </SUP>= 52%, low-quality evidence). Our findings suggest that for a woman with a 32 % chance of achieving a live birth using placebo, the corresponding chance using metformin treatment would be between 28% and 53%.</P>
<P>When metformin was compared with placebo or no treatment, clinical pregnancy rates were higher in the metformin group (OR 1.52; 95% CI 1.07 to 2.15; eight RCTs, 775 women, I<SUP>2 </SUP>= 18%, moderate-quality evidence). This suggests that for a woman with a 31% chance of achieving a clinical pregnancy using placebo or no treatment, the corresponding chance using metformin treatment would be between 32% and 49%.</P>
<P>The risk of ovarian hyperstimulation syndrome was lower in the metformin group (OR 0.29; 95% CI 0.18 to 0.49, eight RCTs, 798 women, I<SUP>2 </SUP>= 11%, moderate-quality evidence). This suggests that for a woman with a 27% risk of having OHSS without metformin the corresponding chance using metformin treatment would be between 6% and 15%.</P>
<P>Side effects (mostly gastrointestinal) were more common in the metformin group (OR 4.49, 95% CI 1.88 to 10.72, for RCTs, 431 women, I<SUP>2</SUP>=57%, low quality evidence<B>)</B>
</P>
<P>The overall quality of the evidence was moderate for the outcomes of clinical pregnancy, OHSS and miscarriage, and low for other outcomes. The main limitations in the evidence were imprecision and inconsistency.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<P>This review found no conclusive evidence that metformin treatment before or during ART cycles improved live birth rates in women with PCOS. However, the use of this insulin-sensitising agent increased clinical pregnancy rates and decreased the risk of OHSS. <BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-04-16 14:47:30 +1200" MODIFIED_BY="Helen E Nagels">
<BACKGROUND MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="jane clarke">
<CONDITION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Polycystic ovary syndrome (PCOS) is a disorder characterised by chronic anovulation (failure or absence of ovulation) and hyperandrogenism (excessive production of male hormones in women) and is associated with irregular menstrual cycles, infertility, hirsutism and acne (<LINK REF="REF-Speroff-1995" TYPE="REFERENCE">Speroff 1995</LINK>). This condition is the most common endocrine disorder in women, affecting approximately 5% to 10% of all women of reproductive age (<LINK REF="REF-Frank-1995" TYPE="REFERENCE">Frank 1995</LINK>; <LINK REF="REF-Knochenhauer-1998" TYPE="REFERENCE">Knochenhauer 1998</LINK>).</P>
<P>PCOS is a heterogenous condition, from a clinical as well as from a biochemical perspective. According to the recommendations proposed by an international consensus group (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>), the diagnosis of PCOS is made when at least two of the following criteria are met:</P>
<OL>
<LI>oligo- or anovulation (infrequent or no ovulation);</LI>
<LI>clinical or biochemical signs of hyperandrogenism, or both;</LI>
<LI>polycystic ovaries on ultrasound.</LI>
</OL>
<P>Other causes of hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome or androgen-secreting tumours) should have been excluded.</P>
<P>Although the primary aetiology of PCOS is unknown (<LINK REF="REF-Balen-2004" TYPE="REFERENCE">Balen 2004</LINK>), insulin resistance with compensatory hyperinsulinaemia is a prominent feature of the syndrome and seems to play an important physiopathological role in hyperandrogenism, both in lean and obese women with PCOS (<LINK REF="REF-Dunaif-1989" TYPE="REFERENCE">Dunaif 1989</LINK>; <LINK REF="REF-Tsilchorozidou-2004" TYPE="REFERENCE">Tsilchorozidou 2004</LINK>). Hyperinsulinaemia increases ovarian androgen biosynthesis, both in vivo and in vitro (<LINK REF="REF-Adashi-1985" TYPE="REFERENCE">Adashi 1985</LINK>; <LINK REF="REF-Barbieri-1986" TYPE="REFERENCE">Barbieri 1986</LINK>), and decreases the hepatic production of sex hormone-binding globulin (SHBG) (<LINK REF="REF-Nestler-1991" TYPE="REFERENCE">Nestler 1991</LINK>) thus leading to increased bioavailability of free androgens.</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Several treatments have been used to induce ovulation and pregnancy in infertile anovulatory women with PCOS. The use of clomiphene citrate as first-line treatment leads to modest pregnancy rates (<LINK REF="REF-Barbieri-2000" TYPE="REFERENCE">Barbieri 2000</LINK>; <LINK REF="REF-Kocak-2002" TYPE="REFERENCE">Kocak 2002</LINK>; <LINK REF="REF-Thessaloniki-ESHRE_x002f_ASRM_x002d_Sponsored-PCOS-2008" TYPE="REFERENCE">Thessaloniki ESHRE/ASRM-Sponsored PCOS 2008</LINK>). Based on the association between insulin resistance and anovulation in PCOS participants, insulin-sensitising agents, such as metformin, have been recently added to the treatment protocols of these women (<LINK REF="REF-Costello-2007" TYPE="REFERENCE">Costello 2007</LINK>; <LINK REF="REF-Nestler-2002" TYPE="REFERENCE">Nestler 2002</LINK>; <LINK REF="REF-Jungheim-2010" TYPE="REFERENCE">Jungheim 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin is an orally active, water-soluble biguanide used for the treatment type 2 diabetes mellitus. The drug has an antihyperglycaemic effect and does not cause hypoglycaemia. It enhances insulin sensitivity both in the liver, by inhibiting hepatic glucose production, and in peripheral tissues, such as muscle cells, by increasing glucose uptake and utilisation (<LINK REF="REF-Barbieri-1986" TYPE="REFERENCE">Barbieri 1986</LINK>; <LINK REF="REF-Dunn-1995" TYPE="REFERENCE">Dunn 1995</LINK>; <LINK REF="REF-Nardo-2001" TYPE="REFERENCE">Nardo 2001</LINK>). There is a good physiological rationale for believing that suppression of insulin levels, through the use of insulin-sensitising agents such as metformin, may be useful in women with PCOS who are undergoing in vitro fertilisation (IVF) with or without intracytoplasmic sperm injection (ICSI). Suppression of insulin levels might ameliorate the adverse effects of ovarian stimulation and improve treatment outcomes such as ovulation and pregnancy rates (<LINK REF="REF-Dunaif-1989" TYPE="REFERENCE">Dunaif 1989</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). In addition, metformin may also act directly on ovarian thecal cells, decreasing androgen production (<LINK REF="REF-Attia-2001" TYPE="REFERENCE">Attia 2001</LINK>; <LINK REF="REF-Palomba-2010" TYPE="REFERENCE">Palomba 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<P>Women with PCOS who are undergoing ovarian stimulation with follicle-stimulating hormone (FSH) are considered to be at increased risk for ovarian hyperstimulation syndrome (OHSS), one of the most important complications of assisted reproductive technology (ART). Higher total FSH doses lead to a larger number of follicles and oocytes, high serum oestradiol (E<SUP>2</SUP>) levels, increased risk of OHSS, elevated cancellation rates and lower conception rates (<LINK REF="REF-Aboulghar-2003" TYPE="REFERENCE">Aboulghar 2003</LINK>; <LINK REF="REF-Yarali-2004" TYPE="REFERENCE">Yarali 2004</LINK>). Therefore it is important to assess the effects of metformin on the clinical, biochemical and laboratory profiles of PCOS women undergoing ART cycles. Several adequately designed trials have addressed this question (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and safety of metformin as a co-treatment during IVF or intracytoplasmic sperm injection (ICSI) in achieving pregnancy or live birth in women with PCOS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-13 10:31:16 +1300" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-01-30 23:04:07 +1300" MODIFIED_BY="[Empty name]">
<P>The review included randomised controlled trials (RCTs) comparing metformin treatment with placebo or no treatment in women with PCOS undergoing IVF or ICSI treatment.</P>
<P>Quasi-randomised trials were not included. Only the first part of cross-over trials was considered in the meta-analysis.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Women of reproductive age with anovulation attributed to PCOS, with or without another cause of couple infertility, who were treated with metformin before and during an IVF or ICSI cycle were eligible.</P>
<P>The aetiology of infertility leading to treatment by IVF or ICSI was defined by individual study authors. The diagnosis of PCOS was based on the ESHRE/ASRM criteria (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>). Due to the wide variation of diagnostic criteria used for PCOS, studies that used different diagnostic criteria were included in the review if the broad definition included in the study matched the ESHRE/ASRM criteria. According to the recommendations proposed by that group, the diagnosis of PCOS is made when at least two of the following criteria are met:</P>
<OL>
<LI>oligo- or anovulation (infrequent or no ovulation);</LI>
<LI>clinical or biochemical (or both) signs of hyperandrogenism;</LI>
<LI>polycystic ovaries on ultrasound.</LI>
</OL>
<P>Other causes of hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome or androgen-secreting tumours) should have been excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin versus no treatment or placebo before or during IVF or ICSI treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-01-31 03:07:02 +1300" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-12-19 13:29:25 +1300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Live birth rate (per woman), defined as a baby born after 20 weeks of gestation.</LI>
<LI>Clinical pregnancy rate (per woman), defined as the identification of an intrauterine gestational sac on ultrasound scan.</LI>
<LI>Incidence of OHSS (per woman), defined according to the definition of reporting authors.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-01-31 03:07:02 +1300" MODIFIED_BY="[Empty name]">
<P> 4. Miscarriage rate (per woman), defined as the involuntary loss of a pregnancy before 20 weeks gestation.<BR/> 5. Incidence of participant-reported side effects.<BR/> 6. Number of oocytes retrieved.<BR/> 7. Total dose of FSH (in IU).<BR/> 8. Number of days of gonadotrophin treatment.<BR/> 9. Cycle cancellation rate (per woman).<BR/> 10. Serum oestradiol level on the day of human chorionic gonadotrophin (hCG) trigger injection.<BR/> 11. Serum androgen level (total testosterone, sex hormone-binding globulin (SHBG) or free-androgen index).<BR/> 12. Fasting insulin and glucose levels.<BR/> 13. Fertilisation rate, defined as normal fertilisation with two pronuclei-stage embryos. The fertilisation rate was defined as the number of normally fertilised oocytes divided by the number of oocytes retrieved per cycle.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-10-24 06:18:58 +1300" MODIFIED_BY="[Empty name]">
<P>We sought all relevant RCTs of metformin co-treatment (prior to or during ovarian stimulation) in women with PCOS undergoing IVF or ICSI treatment, without language restriction. Searching was originally done in 2008. We carried out updated searches in November 2012, September 2013 and 15 October 2014. Our searches were performed in consultation with the Cochrane Menstrual Disorders and Subfertility Group Trials Search Co-ordinator.</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-10-24 06:06:51 +1300" MODIFIED_BY="[Empty name]">
<P>For the identification of relevant studies, we developed detailed search strategies for each specific database. These were based on the search strategy developed for MEDLINE (OVID) and revised appropriately for each database. We searched the following databases: Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched 15 October 2014), Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2014, Issue 10), MEDLINE (1966 to October 2014), EMBASE (1980 to October 2014) and LILACS (1982 to October 2014). We also searched trial registers for ongoing and registered trials: <A HREF="http://www.controlled-trials.com">http://www.controlled-trials.com</A>; <A HREF="http://clinicaltrials.gov/ct2/home">http://clinicaltrials.gov/ct2/home</A>; <A HREF="http://www.who.int/trialsearch/Default.aspx">http://www.who.int/trialsearch/Default.aspx</A>. Search details are available in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (October 2014).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-01-31 03:08:10 +1300" MODIFIED_BY="[Empty name]">
<P>We checked the citation lists of relevant publications, review articles and included studies. We handsearched references of identified selected articles for additional relevant citations. We also contacted experts in the field for additional relevant citations.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-13 10:31:16 +1300" MODIFIED_BY="[Empty name]">
<P>We analysed data using Review Manager 5.1 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
<STUDY_SELECTION MODIFIED="2014-10-09 10:53:17 +1300" MODIFIED_BY="[Empty name]">
<P>For the 2014 update, two authors (LOT and LETA) independently selected the trials included in this review in accordance with the aforementioned criteria. Disagreements were settled by a third review author (CRM). Particular attention was paid to whether there were differences in the characteristics of the women in the comparison groups as to:</P>
<UL>
<LI>age;</LI>
<LI>body mass index (BMI);</LI>
<LI>duration and causes of infertility;</LI>
<LI>dose and duration of metformin co-treatment;</LI>
<LI>androgen levels (total testosterone, SHBG, free-androgen index);</LI>
<LI>fasting glucose and insulin levels;</LI>
<LI>number of embryos transferred;</LI>
<LI>previous ovarian surgery.</LI>
</UL>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-01-31 03:09:28 +1300" MODIFIED_BY="[Empty name]">
<P>Two authors (LOT and LETA) extracted all data independently using forms designed according to Cochrane guidelines. We sought additional information from authors of trials that appeared to meet the eligibility criteria but had unclear methodological details. We also sought further trial data when the data in the reports were presented in a form that was unsuitable for meta-analysis.</P>
<P>Differences of opinion were registered and resolved by consensus. The review authors planned to perform a series of analyses on the results. These analyses were not always possible due to an insufficient number of trials reporting on a particular outcome.</P>
<P>We extracted the following information from the studies included in the review and this is presented in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<OL>
<LI>Trial characteristics</LI>
<OL>
<LI>Randomisation</LI>
<LI>Allocation concealment</LI>
<LI>Trial design: multicentre or single centre, single phase or cross-over design</LI>
<LI>Number of participants randomised, excluded and analysed</LI>
<LI>Duration, timing and location of the trial</LI>
<LI>Source of funding</LI>
</OL>
<LI> Baseline characteristics of the studied groups</LI>
<OL>
<LI>Definition of PCOS and duration of pre-existing infertility</LI>
<LI>Age of the participants</LI>
<LI>Investigative work-up</LI>
<LI>Other causes of infertility</LI>
<LI>Previously administered infertility treatment(s)</LI>
<LI>BMI</LI>
</OL>
<LI> Interventions </LI>
<OL>
<LI>Type of intervention and control</LI>
<LI>Dose regimen and duration</LI>
</OL>
<LI> Outcomes</LI>
<OL>
<LI>Outcomes reported</LI>
<LI>Definition of outcomes</LI>
<LI>Measurement of outcomes</LI>
<LI>Timing of outcome measurement</LI>
</OL>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Two review authors (LEO and CRM) independently assessed the risk of bias of the included studies using the tools described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>version 5.1.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The domains investigated were: allocation (random sequence generation and allocation concealment); blinding of participants, personnel and outcome assessors; completeness of outcome data; selective reporting and other biases.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>For dichotomous data, we expressed the results for each study as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous data, we measured the mean post-treatment intervention values and standard deviations for each group and calculated mean differences (MDs) with 95% CIs. If similar outcomes were reported using different scales, we calculated the standard mean differences (SMDs) with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-01-31 03:10:16 +1300" MODIFIED_BY="[Empty name]">
<P>We analysed the primary outcomes and the miscarriage outcomes per woman randomised. Some of the included studies reported our primary outcomes using other units of analysis (e.g. per cycle, per embryo transfer). These data were not included in the review because they were not randomised comparisons but applied only to selected subsets of participants, such as those who underwent repeated cycles or those who underwent embryo transfer.</P>
<P>We reported and pooled the review outcomes <I>number of gonadotrophin units used </I>and <I>number of days of gonadotrophin treatment</I>, because all women underwent one treatment cycle. For studies that performed more than one cycle per woman, only the data from the first cycle were included in the meta-analyses.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>As far as possible, we analysed data on an intention-to-treat (ITT) basis and made attempts to obtain missing data from the original trials. Where data were unavailable, we only analysed the available data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity using the I<SUP>2 </SUP>statistic; I<SUP>2</SUP> &gt; 50% was interpreted as being indicative of substantial heterogeneity among studies.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by undertaking a comprehensive search for eligible studies and by paying attention to data duplication. We planned to use a funnel plot to explore the possibility of publication bias, if enough studies (10 or more) were found for any of the primary analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>We combined data for meta-analysis with the RevMan software using a random-effects model. For reporting purposes we translated primary outcomes to absolute risks.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-11-13 10:31:16 +1300" MODIFIED_BY="[Empty name]">
<P>We performed a stratified meta-analysis according to the type of stimulation protocol (long GnRH-agonist or short GnRH-antagonist). This stratification was added in the 2014 update of the review, to examine any possible difference in effect related to type of stimulation.</P>
<P>If there was a clinically important difference in drug regimen (outside normal clinical practice) among studies, we planned to examine the possible effects by performing subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-10-16 10:33:22 +1300" MODIFIED_BY="[Empty name]">
<P>We conducted sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if:·</P>
<OL>
<LI>Eligibility were restricted to studies without high risk of bias·</LI>
<LI>A fixed effect model had been adopted·</LI>
<LI>The summary effect measure had been relative risk rather than odds ratio.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="3">Overall quality of the body of evidence: 'Summary of findings' table</HEADING>
<P>We generated a 'Summary of findings' table using <LINK REF="REF-GRADEpro-2011" TYPE="REFERENCE">GRADEpro 2011</LINK> software. This table evaluated the overall quality of the body of evidence for main review outcomes, using GRADE criteria (study limitations i.e. risk of bias, consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate or low) were justified, documented and incorporated into the reporting of results for each outcome.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-04-16 14:47:30 +1200" MODIFIED_BY="Helen E Nagels">
<STUDY_DESCRIPTION MODIFIED="2015-04-16 14:47:30 +1200" MODIFIED_BY="Helen E Nagels">
<SEARCH_RESULTS MODIFIED="2014-10-24 06:04:21 +1300" MODIFIED_BY="Helen E Nagels">
<P>The 2014 search retrieved 185 citations. After screening the titles and abstracts of these citations, we selected 25 for full-text reading, of which we excluded 15. One study (<LINK REF="STD-Tang-2010" TYPE="STUDY">Tang 2010</LINK>) is awaiting classification and nine matched the selection criteria and were included in the review (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the study selection process). There were three duplicate publications: <LINK REF="STD-Stadtmauer-1999" TYPE="STUDY">Stadtmauer 1999</LINK> and Stadtmauer 2000, the latter being a continuation of the former; Visnova 2002 and <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>, one in English and the other in Czech; Kjotrod 2003a, <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK> and Kjotrod 2008a, all generated from the same trial.</P>
<P>Three new studies were included in this updated version of the 2009 systematic review (<LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>). Therefore nine studies in total met the inclusion criteria and were included in the review (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). We sent emails to the authors of three studies to obtain more details on study characteristics and methodological quality that were unclear in the published article. Three author groups (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) answered our queries. See the tables <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. All trials reported that only one cycle per participant was permitted, with the exception of <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK> (a cross-over trial).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-04-16 14:47:30 +1200" MODIFIED_BY="Helen E Nagels">
<SUBSECTION>
<HEADING LEVEL="4">Study design and setting</HEADING>
<P>Nine parallel-design randomised controlled trials (RCTs) and one cross-over trial were included in the review. A total of 816 participants were randomised.</P>
<UL>
<LI>Six were prospective, randomised, double-blind, placebo-controlled trials (metformin versus placebo): <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>.</LI>
<LI>One was a prospective, open-label, randomised, placebo-controlled, cross-over trial: <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>. Only data from the pre-cross-over phase of this study were considered for meta-analysis.</LI>
<LI>Two were prospective, randomised controlled trials (metformin versus no treatment): <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>; <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All participants were women undergoing IVF or ICSI treatments. A total of 816 women were randomised: 405 to the placebo and 411 to the metformin groups, respectively.</P>
<SUBSECTION>
<HEADING LEVEL="5">Baseline characteristics of the studied groups</HEADING>
<P>Eight studies met the Rotterdam criteria (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>) for PCOS: <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>. One study (<LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not meet the Rotterdam criteria because other causes for hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome or androgen-secreting tumours) were not reported as excluded.</P>
<P>Five studies did not report the cause(s) of infertility (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>).</P>
<P>Six studies (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) provided full baseline characteristics of the participants in both groups (age, BMI, duration of infertility, previously used treatment). Two studies (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) provided incomplete baseline characteristics of the study participants (only age and BMI). <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> did not report any baseline characteristics of the participants. One study (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>) did not report what the exclusion criteria were.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>A single study started metformin on the day of ovulation induction with FSH (<LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>); the other eight studies used metformin before and during ovulation induction for IVF or ICSI treatment. Metformin commencement varied from 16 weeks before (earliest) to the first day (latest) of GnRH-agonist administration in the studies reporting metformin use before FSH treatment and continued at least until the day of the hCG trigger.</P>
<P>
<LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK> used metformin 500 mg twice daily; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK> and <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> used metformin 850 mg twice daily; <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>, <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK> and <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK> used metformin 500 mg three times daily; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> used metformin 850 mg twice daily (BMI &lt; 28 kg/m<SUP>2</SUP>) or three times daily (BMI &gt;= 28 kg/m<SUP>2</SUP>); <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK> used metformin 1 g twice daily. <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK> gradually increased the dose of metformin from 500 gm to 2 g per day during the first week of treatment.</P>
<P>Eight of the nine studies used long-protocol GnRH-agonist with recombinant FSH (rec-FSH); <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> used the short protocol GnRH-antagonist with rec-FSH. Only <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK> used either rec-FSH or highly purified FSH (hp-FSH) and only <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK> used HMG (hp-urinary gonadotrophin).</P>
<P>The method of oocyte fertilisation varied among the trials and included IVF alone (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>), ICSI alone (<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>) or a combination of IVF and ICSI, depending on the cause of infertility (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). One trial (<LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not report whether IVF or ICSI was performed.</P>
<P>A maximum of two embryos were transferred on day two after oocyte retrieval by <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> and on day three by <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK> and <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>. A maximum of three embryos were transferred on day two by <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> and on day three by <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>. <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK> transferred up to two embryos on day two or three. <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK> transferred two to four embryos on day three. <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK> transferred a maximum of two embryos on day two, three or five (blastocyst stage). One study (<LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not report on the number of embryos transferred. Two authors (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) reported performing embryo transfer under ultrasound guidance.</P>
<P>The type of luteal phase support also varied among the trials and included vaginal progesterone capsules (Progestan 200 mg three times daily) (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>), vaginal progesterone gel (Crinone 90 mg (8%) daily) (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>), vaginal progesterone pessaries (Cyclogest 400 mg daily) (<LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) intramuscular progesterone (25 mg daily and 50 mg daily) (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>), and progesterone, yet the type and dose were selected by the physician (<LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK> ). Two studies (<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not report what type of medication was used for luteal phase support.</P>
<P>
<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> performed selective assisted hatching with laser when: the participant was over 35 years of age; the zona pellucida was considered thick; an abnormally shaped zona was present; or excessive embryo fragmentation or slowly developing embryos were noted. We considered this procedure to be substantially different from the other trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<UL>
<LI>5/9 studies reported live birth rate (per woman) (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>).</LI>
<LI>8/9 studies reported clinical pregnancy rate (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>).</LI>
<LI>8/9 studies reported OHSS (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>).</LI>
</UL>
<P>The publication by <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> did not provide the live birth rate and we obtained this information after contacting the author by email.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<UL>
<LI>6/9 studies reported miscarriage rate (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). Miscarriage was defined as the involuntary loss of a pregnancy before 20 weeks gestation.</LI>
<LI>4/9 studies reported participant-reported side effects (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>).</LI>
<LI>8/9 studies reported the number of oocytes retrieved, total dose of FSH and the number of days of gonadotrophin treatment per woman (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). Only <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK> did not report these outcomes and we were unsuccessful in contacting the author.</LI>
<LI>6/9 studies reported cancellation rates (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>).</LI>
<LI>5/9 trials reported serum oestradiol level on the day of hCG (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>).</LI>
<LI>Only <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported fertilisation rate as the main outcome measure.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-09-11 17:32:59 +1200" MODIFIED_BY="Helen E Nagels">
<P>We excluded 10 studies after full-text reading. Reasons for exclusion are in parentheses:</P>
<UL>
<LI>
<LINK REF="STD-Demirol-2006" TYPE="STUDY">Demirol 2006</LINK> (not a randomised controlled trial);</LI>
<LI>
<LINK REF="STD-Egbase-2001" TYPE="STUDY">Egbase 2001</LINK> (data irregularities);</LI>
<LI>
<LINK REF="STD-Geusa-2002" TYPE="STUDY">Geusa 2002</LINK> (data irregularities);</LI>
<LI>
<LINK REF="STD-Kahraman-2001" TYPE="STUDY">Kahraman 2001</LINK> (control group treated with oral contraceptives and not placebo or no treatment);</LI>
<LI>
<LINK REF="STD-Palomba-2011b" TYPE="STUDY">Palomba 2011b</LINK> (participants were poor responders);</LI>
<LI>
<LINK REF="STD-Schachter-2007" TYPE="STUDY">Schachter 2007</LINK> (women specifically undergoing ICSI were not randomised separately);</LI>
<LI>
<LINK REF="STD-Stadtmauer-1999" TYPE="STUDY">Stadtmauer 1999</LINK> (participants acted as their own control);</LI>
<LI>
<LINK REF="STD-Stadtmauer-2001" TYPE="STUDY">Stadtmauer 2001</LINK> (retrospective data analysis);</LI>
<LI>
<LINK REF="STD-Stadtmauer-2002" TYPE="STUDY">Stadtmauer 2002</LINK> (not a randomised controlled trial);</LI>
<LI>
<LINK REF="STD-Tasdemir-2004" TYPE="STUDY">Tasdemir 2004</LINK> (participants undergoing ovulation induction cycles; not IVF or ICSI cycle</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. <I>
<BR/>
</I>
</P>
<ALLOCATION MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>Six trials reported acceptable methods of sequence generation and we classified them as being at low risk of bias for this domain (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). Four used computer randomisation (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>) and two a random numbers table (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). The other three studies (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not report what methods were used for sequence generation and we classified them as having an unclear risk of bias for this domain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Five studies were at low risk of bias for allocation concealment because they used either sequentially numbered sealed envelopes (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>) or codes kept by a third party such as the pharmacy department (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>) or a trial office (<LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>). Four studies (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) did not report  the allocation concealment method used and we classified them as having an unclear risk of bias.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<P>We did not consider that blinding was likely to influence findings for the primary review outcomes (live birth rate, clinical pregnancy rate and incidence of OHSS). However for side effects, blinding status could potentially affect findings. Five studies reported double-blinding (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) and we classified them as being at low risk of bias for this domain. Three studies were open-label comparisons (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>; <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>) and one was single-blind (<LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>) and therefore we classified it as being at high risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<P>We judged seven studies (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) to be at low risk of bias because they analysed their data on an intention-to-treat basis (trial participants were analysed in the groups to which they were randomised; all participants were included as there were no withdrawals). One study (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>) did not report the reasons for withdrawals and we judged it to be at unclear risk of bias for this domain. One study (<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>) conducted available case analyses (trial participants were analysed in the groups to which they were randomised and only participants who completed the trials were included) and we judged it to be at high risk of bias for this domain.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>, <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>, <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK> and <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported live birth and clinical pregnancy rates and OHSS (the primary outcomes of this review); therefore we classified them as being at low risk of bias.</P>
<P>We judged five studies (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) to be at unclear risk for selective reporting bias because they failed to report at least one of the following outcomes: live birth, clinical pregnancy or OHSS (the primary outcomes of this review).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> did not report baseline characteristics of the participants nor the causes of infertility and we judged it to be at high risk of bias. We also rated <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK> as being at high risk of bias in this domain, due to a data discrepancy. We attempted without success to contact the authors to clarify this.</P>
<P>
<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK> and <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK> did not report the causes of infertility and we thus deemed them to be at unclear risk of bias.</P>
<P>The remaining six studies (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>) reported similar baseline characteristics for participants in both groups and we found no other potential sources of within-study bias. Therefore, we classified these six studies as being at low risk of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-13 10:33:03 +1300" MODIFIED_BY="Helen E Nagels">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison of metformin versus placebo or no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Live birth rate (per woman)</HEADING>
<P>This was reported by five studies (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>), all of which utilised long GnRH-agonist stimulation protocol. There was no evidence of a difference in live birth rates between the metformin group and the placebo group (OR 1.39; 95% CI 0.81 to 2.40, five RCTs, 551 women, I<SUP>2</SUP>=52%, low quality evidence) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>;<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> ). This suggests that for a woman with a 32% chance of achieving a live birth using placebo, the corresponding chance using metformin would be between 28% and 53%.</P>
<P>There was substantial statistical heterogeneity in this analysis (I<SUP>2</SUP> = 52%, P = 0.08). Exclusion from analysis of one of the studies (<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>) reduced the I<SUP>2</SUP> statistic to 20%. The only obvious difference between this study and the others was that <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> used assisted hatching. As it does not appear biologically plausible that this would account for the difference, we were unable to account for the heterogeneity.</P>
<P>We conducted a post-hoc sensitivity analysis due to a data discrepancy in one of the studies (<LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>). According to the study publication, in both the metformin group and the placebo group the clinical pregnancy rate was <I>lower</I> than the live birth rate (pregnancy 26/60, 24/60; live birth 29/60, 27/60). Attempts to contact the first author have so far received no response. Sensitivity analysis excluding this study yielded an OR of 1.48 (95% CI 0.72 to 3.02) for live birth, which did not substantially change our findings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Clinical pregnancy rate (per woman)</HEADING>
<P>Eight studies reported this outcome (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>), all of which utilised long GnRH-agonist stimulation protocol. Clinical pregnancy rates were higher in the metformin group than in the placebo or no treatment group (OR 1.52; 95% CI 1.07 to 2.15, 8 studies, 775 women, I<SUP>2 </SUP>= 18%, moderate quality evidence) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Heterogeneity was low in this analysis (I<SUP>2 </SUP>= 18%, P = 0.28). Our findings suggest that for a woman with a 30% chance of achieving a clinical pregnancy using placebo or no treatment, the corresponding chance using metformin would be between 32% and 48%.</P>
<P>As noted above, we conducted a post-hoc sensitivity analysis due to a data discrepancy in one of the studies (<LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>). Sensitivity analysis excluding this study yielded an OR of 1.61 (95% CI 1.08 to 2.40) for pregnancy, which did not substantially change our findings.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Incidence of OHSS</HEADING>
<P>Eight studies reported this outcome (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). The incidence of OHSS was lower in the metformin group than in the placebo or no treatment group (OR 0.29; 95% CI 0.18 to 0.49, eight RCTs, 798 women, I<SUP>2</SUP>=11%, moderate quality evidence) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). This suggests that for a woman with a 27% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 15%.</P>
<P>This outcome was also analysed according to two subcategories: studies which used a long protocol with a GnRH-agonist and those using a short protocol with a GnRH-antagonist. The pooled analysis of the seven studies (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>) which used the long protocol revealed a benefit from metformin, with lower incidence of OHSS (OR 0.29; 95% CI 0.16 to 0.51, 758 women, I<SUP>2 </SUP>= 23%). <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> used a short-protocol antagonist and found no difference between the two groups (OR 0.30; 95% CI 0.03 to 3.15, 40 women).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Miscarriage rate (per woman)</HEADING>
<P>Six studies were included in this analysis (<LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>), all of which utilised long GnRH-agonist stimulation protocol. There was no evidence of a difference in miscarriage rates between the groups (OR 0.76; 95% CI 0.43 to 1.37, six RCTs, 521 women, I<SUP>2</SUP>=0%, moderate quality evidence) <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Incidence of participant-reported side effects</HEADING>
<P>Four studies reported this outcome (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>), all of which utilised long GnRH-agonist stimulation protocol. Metformin treatment was associated with more side effects (76/216, 35.1%) than placebo (OR 4.49; 95% CI 1.88 to 10.72, four RCTs, 431 women, I<SUP>2</SUP> = 57%) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>There was substantial heterogeneity for this analysis (I<SUP>2</SUP>=57%). In three of the four individual trials there were more side effects in the group taking metformin (<LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>), while the results of <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> were considerably different. There were no apparent reasons for the observed heterogeneity among studies in terms of study methodology or clinical parameters (participants, exposure, outcomes). The doses and duration of metformin treatment used in the four trials were similar.</P>
<P>According to <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK> and <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>, the most frequent side effects associated with metformin were gastrointestinal and included nausea, vomiting, diarrhoea, abdominal discomfort or pain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6 Number of oocytes retrieved per woman</HEADING>
<P>Eight studies were included in this analysis (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). The mean number of oocytes retrieved per woman did not differ between the two groups (MD -0.76; 95% CI -2.02 to 0.50, eight RCTs, 635 women, I<SUP>2</SUP> = 36%) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>These studies were subdivided into two subcategories: those using a long protocol with GnRH-agonist and those using a short protocol with GnRH-antagonist. Only <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> used the short-protocol GnRH-antagonist. There was no difference between the results of the two subcategories, and only one individual trial (<LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>) demonstrated a significant difference in the number of oocytes collected between the two treatment groups, with fewer oocytes collected in the metformin group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7 Total dose of FSH (IU) per woman</HEADING>
<P>Eight studies were included in this analysis (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). The data were not pooled due to extreme heterogeneity (I<SUP>2</SUP> = 97%). Most of the heterogeneity seemed to be due to <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009,</LINK> and exclusion of this study reduced heterogeneity to I<SUP>2</SUP> = 54%. However we did not identify any clear difference between this study and the others. Six of the eight studies found no evidence of a difference between the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8 Mean number of days of gonadotrophin treatment</HEADING>
<P>Eight studies reported this outcome (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). The mean number of days of gonadotrophin treatment did not differ significantly between the groups (MD -0.19 days, 95% CI -0.77 to 0.40, eight studies, 643 women, I<SUP>2</SUP>=56%) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). There was statistical heterogeneity in this comparison (I<SUP>2</SUP>=56%), which disappeared (I<SUP>2</SUP>=0%) when we excluded <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>, but we could not identify any clear difference between this study and the others.</P>
<P>This outcome was also analysed by subdividing studies into two subcategories: those using a long protocol with GnRH-agonist and those using a short protocol with GnRH-antagonist. <LINK REF="STD-Fedorcsak-2003" TYPE="STUDY">Fedorcsak 2003</LINK>, <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>, <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>, <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>, <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>, <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> and <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK> used the long protocol and there were no statistically significant differences between the groups (MD -0.22 days; 95% CI -0.89 to 0.45, seven RCTs, 603 women). <LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK> used the short-protocol GnRH-antagonist and did not find any evidence of a difference between the groups (MD 0.00 days; 95% CI -1.30 to 1.30, 40 women).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.9 Cycle cancellation rate</HEADING>
<P>Six studies were included in this analysis (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Kjotrod-2011" TYPE="STUDY">Kjotrod 2011</LINK>; <LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>; <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). There was no evidence of a difference between the groups in cancellation rates (OR 0.64; 95% CI 0.32 to 1.29, six RCTs, 624 women, I<SUP>2</SUP> = 27%) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.10 Serum oestradiol level (on the day of hCG): mean level per woman</HEADING>
<P>Five studies reported this outcome (<LINK REF="STD-Doldi-2006" TYPE="STUDY">Doldi 2006</LINK>; <LINK REF="STD-Kjotrod-2004" TYPE="STUDY">Kjotrod 2004</LINK>; <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK>; <LINK REF="STD-Qublan-2009" TYPE="STUDY">Qublan 2009</LINK>; <LINK REF="STD-Visnova-2003" TYPE="STUDY">Visnova 2003</LINK>). These studies were not pooled due to very high heterogeneity (I<SUP>2</SUP>=91%) which could not be explained. Three of the five studies reported lower serum oestradiol levels in the metformin group, while the other two studies found no evidence of a difference between the groups.</P>
<P>
<LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported serum oestradiol levels using multiple linear regression analysis. After adjustment for the total FSH dose and the number of follicles, metformin treatment reduced oestradiol concentration on the day of hCG administration (coefficient = -35.6, P = 0.048).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.13 Serum androgen levels (testosterone, SHBG, free-androgen index)</HEADING>
<P>
<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> and <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported serum androgens levels on the day of hCG. It was not possible to pool these data because they were reported as median and range by <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> and as geometric measures by <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>.</P>
<P>
<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> found no difference in total testosterone between the metformin group (median 3.1, range 2.5 to 3.9) and the placebo group (median 3.1, range 2.4 to 3.9, p=0.646) and <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported that while testosterone levels did not change in the metformin group (baseline geometric mean: 2.03 nmol/l, geometric mean on the day of hCG administration: 1.97 nmol/l; P = 0.892), the placebo group had an increase in testosterone levels (baseline geometric mean: 2.06 nmol/l, geometric mean on the day of hCG administration: 2.52 nmol/l; P = 0.040). In the metformin group, on the day of hCG administration, there was a decrease in testosterone concentration (geometric mean: 1.96 versus 2.52 nmol/l; P = 0.029) and in the free-androgen index (geometric mean: 2.43 versus 3.34; P = 0.004). See <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.14 Fasting insulin and glucose levels</HEADING>
<P>
<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> and <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported fasting insulin and glucose levels on the day of hCG. It was not possible to pool their data because they were reported as glucose/insulin ratio (median and range) by <LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> and as Quantitative Insulin Sensitivity Check Index (QUICKI) by <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK>.</P>
<P>
<LINK REF="STD-Onalan-2005" TYPE="STUDY">Onalan 2005</LINK> found no difference in the glucose/insulin ratio between the metformin group (median 6; range 2.4-8.8) and the placebo group (median 6; range 3-10, p=0.81). <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> found no difference in the insulin sensitivity test results (QUICKI) between baseline and the day of oocyte retrieval in either group (metformin group - baseline: 0.377 and 0.417 at the day of oocyte retrieval (P = 0.2) and placebo group - baseline: 0.386 and 0.400 at the day of oocyte retrieval (P = 0.572)). See <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.15 Fertilisation rate</HEADING>
<P>Only <LINK REF="STD-Tang-2006" TYPE="STUDY">Tang 2006</LINK> reported fertilisation rate per oocyte retrieved. Metformin did not improve the overall fertilisation rate (52.9% versus 54.9%, P = 0.641) (Data not shown) (Analysis 1.18).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other analyses</HEADING>
<P>Sensitivity analyses for the primary outcomes did not substantially influence any of our findings. There were too few studies to compile a funnel plot in order to assess publication bias.</P>
<P>We conducted a post-hoc sensitivity analysis for our primary outcomes after noting a data discrepancy in one of the studies (<LINK REF="STD-Palomba-2011" TYPE="STUDY">Palomba 2011</LINK>). However, exclusion of this study did not substantially change our findings.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-10-31 16:22:55 +1300" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-10-31 16:22:55 +1300" MODIFIED_BY="[Empty name]">
<P>We found no conclusive evidence that the co-administration of metformin to women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment increases the live birth rates. However there was evidence that metformin increases clinical pregnancy rates and reduces the rate of OHSS. No difference was found between the groups in miscarriage rates. Adverse events such as gastrointestinal problems were only reported by four studies, but were higher in the metformin group.</P>
<P>Metformin co-treatment appeared to decrease serum oestradiol levels on the day of hCG, but there was no evidence that it had an effect on other ovarian stimulation parameters (total dose of gonadotrophin, number of days of gonadotrophin stimulation, number of oocytes collected and cycle cancellation rate) or embryological outcomes (fertilisation rate).</P>
<P>Metformin reduced the risk of ovarian hyperstimulation syndrome (OHSS) by approximately 63% but increased the risk of side effects three-fold. Although the reason why metformin reduces the risk of OHSS is not clear, it has been hypothesised that since it decreases hyperinsulinaemia, it could also reduce the production of vascular endothelial growth factor (VEGF), one of the most important factors involved in the pathophysiology of the syndrome. In addition, metformin is associated with a statistically significant effect on oestradiol levels, an important risk factor for OHSS.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-10-08 14:58:52 +1300" MODIFIED_BY="[Empty name]">
<P>The increased number of studies included in this updated version of the review has improved the statistical power of our meta-analyses. Five of the nine trials performed a priori sample size calculations to assess their primary outcome measures. A total of 816 participants under 40 years of age were included. Eight of the nine included studies met the Rotterdam consensus criteria (<LINK REF="REF-ESHRE_x002f_ASRM-2003" TYPE="REFERENCE">ESHRE/ASRM 2003</LINK>) for the diagnosis of PCOS and excluded other causes of hyperandrogenism. The only study that did not meet the Rotterdam consensus criteria may have included women with other causes for hyperandrogenism that mimic PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome and androgen-secreting tumours). None of the nine trials reported previous ovarian surgery in their baseline characteristics and three trials did not report the cause of infertility.</P>
<P>Eight of the nine trials included in this review provided data on clinical pregnancy. However, only four trials reported live birth and none reported the rate of healthy take-home baby, which is considered the most important long-term outcome of interest to consumers.The primary endpoints of the five trials were either not clearly reported or were related to ovarian response parameters.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="[Empty name]">
<P>See Summary of findings table 1. The table was developed in <LINK REF="REF-GRADEpro-2011" TYPE="REFERENCE">GRADEpro 2011</LINK>. The overall quality of the evidence was moderate for the outcomes of clinical pregnancy, OHSS and miscarriage, and low for other outcomes. The main limitations in the evidence were imprecision and inconsistency. We conducted a post-hoc sensitivity analysis for our primary outcomes after noting a data discrepancy in one of the studies. However, exclusion of this study did not substantially change our findings</P>
<P>Four of the nine included studies were at low risk of bias in all domains. Limitation in the other studies included failure to report details of study methods and lack of blinding. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for the 'Risk of bias' graph and summary. Heterogeneity was moderate or low for clinical outcomes. Data for two of the laboratory outcomes (FSH dose and serum oestradiol level) were not pooled due to very high levels of unexplained heterogeneity.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-10-08 15:08:03 +1300" MODIFIED_BY="[Empty name]">
<P>A limitation of this review is the lack of full data from some studies, despite our attempts to obtain missing information from study authors. Whenever possible, we performed analyses based on intention-to-treat, to minimise bias. Additionally, since the number of included studies was small, it was not possible to assess the risk of publication bias. </P>
<P>We conducted a through search and are confident that we have included in the review all existing randomised trials which have assessed the use of metformin in PCOS women undergoing ART cycles and which reported clinically relevant outcomes (live birth rate, clinical pregnancy rate and incidence of OHSS).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-01-31 02:32:27 +1300" MODIFIED_BY="[Empty name]">
<P>The results of this updated review are in agreement with other reviews (<LINK REF="REF-Costello-2006" TYPE="REFERENCE">Costello 2006</LINK>; <LINK REF="REF-Tang-2012" TYPE="REFERENCE">Tang 2012</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-10-08 15:09:52 +1300" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-10-08 15:09:07 +1300" MODIFIED_BY="[Empty name]">
<P>This review found no conclusive evidence that metformin treatment before or during ART cycles improves live birth rates in women with PCOS. However, the use of this insulin-sensitising agent increased clinical pregnancy rates and decreased the risk of OHSS. <BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-10-08 15:09:52 +1300" MODIFIED_BY="[Empty name]">
<P>Further large, well-designed and well-executed randomised controlled trials are necessary to answer definitively the question of whether the use of metformin in women with polycystic ovary syndrome and undergoing assisted reproductive technology improves the live birth rate. All studies should report OHSS and other adverse events.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-03-27 06:56:14 +1300" MODIFIED_BY="[Empty name]">
<P>The review authors wish to express their gratitude to the Brazilian Cochrane Centre and the Menstrual Disorders and Subfertility Group, especially to Ms Helen Nagels and to Marian Showell, for their thoughtful comments and suggestions and for their continued support in developing and updating this systematic review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-14 11:44:08 +1300" MODIFIED_BY="Helen E Nagels">
<P>Review author Dr Michael Costello is a member of the pharmaceutical company Merck Sharp and Dohme (MSD) Australia Elonva Advisory Board Committee. He has received funding to attend ART Scientific Meetings including to present papers not on the review topic. These relationships are declared in the interests of transparency and do not constitute a conflict of interest in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>For the present update of this review:</P>
<UL>
<LI>CRM: revised and updated the review.</LI>
<LI>LT: revised and updated the review.</LI>
<LI>MFC: revised and updated the review.</LI>
<LI>LA: revised and updated the review.</LI>
<LI>RA: revised and updated the review.</LI>
</UL>
<P>For the protocol and review.</P>
<UL>
<LI>LA: initiated and conceptualised the protocol and the initial version of the review.</LI>
<LI>RA: initiated and conceptualised the protocol and the initial version of the review.</LI>
<LI>MFC: contributed to the protocol and the initial version of the review.</LI>
<LI>VF: contributed to the protocol and the initial version of the review.</LI>
<LI>LT: contributed to the protocol and the initial version of the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-13 10:33:03 +1300" MODIFIED_BY="[Empty name]">
<P>The following outcomes were in the original protocol and have since been removed: clinical pregnancy rate (per transfer), pregnancy rate (per transfer and per woman), number of follicles and embryo quality (<LINK TAG="METHODS" TYPE="SECTION">Methods</LINK>; <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>). Absolute risk was calculated for the primary outcomes.</P>
<P>After the publication of the protocol we decided to stratify the main analysis by type of stimulation protocol used (long GnRH-agonist or short GnRH-antagonist), in order to determine whether the type of stimulation used had an influence on the outcomes.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="Helen E Nagels">
<STUDIES MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="Helen E Nagels">
<INCLUDED_STUDIES MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="Helen E Nagels">
<STUDY DATA_SOURCE="MIX" ID="STD-Doldi-2006" MODIFIED="2013-02-27 02:43:37 +1300" MODIFIED_BY="jane clarke" NAME="Doldi 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-27 02:43:37 +1300" MODIFIED_BY="jane clarke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Doldi N, Persico P, Di Sebastiano F, Marsiglio E, Ferrari A</AU>
<TI>Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>5</NO>
<PG>235-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fedorcsak-2003" MODIFIED="2014-01-31 02:18:34 +1300" MODIFIED_BY="jane clarke" NAME="Fedorcsak 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-01-31 02:18:34 +1300" MODIFIED_BY="jane clarke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fedorcsak P, Dale PO, Storeng R, Abyholm T, Tanbo T</AU>
<TI>The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>207-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjotrod-2004" MODIFIED="2014-09-11 17:22:30 +1200" MODIFIED_BY="Helen E Nagels" NAME="Kjotrod 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-11 17:22:28 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjøtrød SB, Romundstad P, von Düring V, Sunde A, Carlsen SM</AU>
<TI>Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>3</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-11 17:21:01 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjotrod S, von Düring V, Sunde A, Carlsen SM</AU>
<TI>Metformin treatment before IVF/ICSI in polycystic ovary syndrome women: a prospective, randomized, double-blind study</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18 Suppl 1</VL>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-17 11:30:29 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kjotrod SB, von Düring V, Carlsen SM</AU>
<TI>Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study</TI>
<SO>Human Reproduction</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1315-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kjotrod-2011" MODIFIED="2014-09-11 17:25:20 +1200" MODIFIED_BY="Helen E Nagels" NAME="Kjotrod 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-09-11 17:24:31 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kjotrod S, Carlsen SM, Rasmussen PE, Holst-Larsen T, Mellembakken J, Thurin-Kjellberg A, et al</AU>
<TI>Metformin treatment before and during IVF or ICSI in PCOS women with BMI &lt; 28 kg/m2</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>i286-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-11 17:25:20 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kjotrod SB, Carlsen SM, Rasmussen PE, Holst-Larsen T, Mellembakken J, Thurin-Kjellberg A, et al</AU>
<TI>Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study</TI>
<SO>Human Reproduction</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>8</NO>
<PG>2045-53</PG>
<IDENTIFIERS MODIFIED="2012-12-18 23:54:24 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21606131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onalan-2005" NAME="Onalan 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Onalan G, Pabuccu R, Goktolga U, Ceyhan T, Bagis T, Cincik M</AU>
<TI>Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>3</NO>
<PG>798-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palomba-2011" MODIFIED="2014-10-16 10:54:38 +1300" MODIFIED_BY="[Empty name]" NAME="Palomba 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-10-08 15:18:47 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T, et al</AU>
<TI>Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2011</YR>
<VL>96</VL>
<PG>1384-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qublan-2009" MODIFIED="2014-01-31 02:19:28 +1300" MODIFIED_BY="[Empty name]" NAME="Qublan 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-01-31 02:19:28 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qublan HS, Al-Khaderei S, Abu-Salem AN, Al-Zpoon A, Al-Khateeb M, Al-Ibrahim N, et al</AU>
<TI>Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial</TI>
<SO>Journal of Obstetrics and Gynecology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>7</NO>
<PG>651-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2006" MODIFIED="2008-05-08 14:55:14 +1200" MODIFIED_BY="jane clarke" NAME="Tang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-05-08 14:55:14 +1200" MODIFIED_BY="jane clarke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tang T, Glanville J, Orsi N, Barth JH, Balen AH</AU>
<TI>The use of metformin for women with PCOS undergoing IVF treatment</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1416-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visnova-2003" MODIFIED="2014-09-11 17:26:56 +1200" MODIFIED_BY="Helen E Nagels" NAME="Visnova 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Visnova H, Ventruba P, Crha I, Zakova J</AU>
<TI>Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome</TI>
<TO>Význam senzitizace inzulinových receptoru pro prevenci ovariálního hyperstimulacního syndromu</TO>
<SO>Ceská Gynekologie</SO>
<YR>2003</YR>
<VL>68</VL>
<NO>3</NO>
<PG>155-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-11 17:26:54 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visnova H, Ventruba P, Crha I, Zakova J</AU>
<TI>The impact of insulin receptor sensitization on prevention of ovarian hyperstimulation syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17 Suppl</VL>
<PG>180</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-11 17:31:11 +1200" MODIFIED_BY="Helen E Nagels">
<STUDY DATA_SOURCE="PUB" ID="STD-Demirol-2006" MODIFIED="2013-02-27 03:03:44 +1300" MODIFIED_BY="[Empty name]" NAME="Demirol 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-02-27 03:03:44 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demirol A, Sari T, Girgin B, Kent E, Gurgan T</AU>
<TI>The effect of metformin treatment on the ICSI cycle outcome in PCOS patients</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>i88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egbase-2001" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Egbase 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;It wasexcluded because of data irregularities.&lt;/p&gt;" NOTES_MODIFIED="2014-01-31 02:41:42 +1300" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Egbase PE, Al Sharhan M, Buzaber M, Grudzinskas JG</AU>
<TI>Prospective randomised study of metformin in IVF and embryo transfer treatment cycles in obese patients with polycystic ovarian syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2001</YR>
<VL>16 Suppl 1</VL>
<PG>202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geusa-2002" MODIFIED="2008-09-08 19:09:24 +1200" MODIFIED_BY="[Empty name]" NAME="Geusa 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-08 19:09:24 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;It was excluded because of data irregularities.&lt;/p&gt;" NOTES_MODIFIED="2008-09-08 19:09:24 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Geusa S, Stanziano A, Causio F, Pansini N, Sarcina E</AU>
<TI>The efficacy of insulin-sensitizing agent (metformin) in PCOS and insulin resistance patients undergoing IVF treatment</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17 Suppl</VL>
<PG>115</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahraman-2001" MODIFIED="2008-09-08 19:10:05 +1200" MODIFIED_BY="[Empty name]" NAME="Kahraman 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-09-08 19:10:05 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Metformin versus oral contraceptive&lt;/p&gt;" NOTES_MODIFIED="2008-09-08 19:10:05 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kahraman S, Vanlioglu F, Yakin K, Cengiz S, Karlikaya G</AU>
<TI>A comparative trial of metformin and oral contraceptive pretreatment in patients with polycystic ovary syndrome undergoing ICSI for severe male factor infertility</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>76 Suppl 1</VL>
<NO>3</NO>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palomba-2011b" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Palomba 2011b" YEAR="2011">
<REFERENCE MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palomba S, Falbo A, Di Cello A, Cappiello F, Tolino A, Zullo F</AU>
<TI>Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial</TI>
<SO>Fertility and Sterility</SO>
<YR>2011</YR>
<VL>96</VL>
<NO>5</NO>
<PG>1128-33</PG>
<IDENTIFIERS MODIFIED="2013-01-31 09:14:24 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21917254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schachter-2007" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Schachter 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schachter M, Raziel A, Strassburger D, Rotem C, Ron-El R, Friedler S</AU>
<TI>Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2007</YR>
<VL>88</VL>
<NO>1</NO>
<PG>227-30</PG>
<IDENTIFIERS MODIFIED="2008-11-17 12:31:29 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-17 12:31:29 +1300" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stadtmauer-1999" MODIFIED="2014-09-11 17:26:11 +1200" MODIFIED_BY="Helen E Nagels" NAME="Stadtmauer 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-11 17:26:08 +1200" MODIFIED_BY="Helen E Nagels" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stadtmauer L, Riehl R, Toma S, Talbert L</AU>
<TI>Use of metformin in patients with PCOS undergoing IVF-ET improves outcomes</TI>
<SO>International Journal of Gynecology and Obstetrics</SO>
<YR>2000</YR>
<VL>70</VL>
<PG>p.B41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-08 19:11:23 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Patients acted as their own control.&lt;/p&gt;" NOTES_MODIFIED="2008-09-08 19:11:23 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stadtmauer LA, Riehl RM, Toma SK, Huang S, Barker S, Talbert LM</AU>
<TI>Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin-like growth factor</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>72 Suppl 1</VL>
<NO>3</NO>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stadtmauer-2001" MODIFIED="2014-09-11 17:31:11 +1200" MODIFIED_BY="Helen E Nagels" NAME="Stadtmauer 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-05-08 14:56:07 +1200" MODIFIED_BY="jane clarke" NOTES="&lt;p&gt;Metformin group was compared retrospectively to patients who had not recieved metformin.&lt;/p&gt;" NOTES_MODIFIED="2008-05-08 14:56:07 +1200" NOTES_MODIFIED_BY="jane clarke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stadtmauer LA, Toma SK, Riehl RM, Talbert LM</AU>
<TI>Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>75</VL>
<NO>3</NO>
<PG>505-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stadtmauer-2002" MODIFIED="2008-09-08 19:12:32 +1200" MODIFIED_BY="[Empty name]" NAME="Stadtmauer 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-09-08 19:12:32 +1200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;It is not a randomized control trial.&lt;/p&gt;" NOTES_MODIFIED="2008-09-08 19:12:32 +1200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stadtmauer LA, Wong BC, Oehninger S</AU>
<TI>Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>2</NO>
<PG>112-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tasdemir-2004" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Tasdemir 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tasdemir S, Ficicioglu C, Yalti S, Gurbuz B, Basaran T, Yildirim G</AU>
<TI>The effect of metformin treatment to ovarian response in cases with PCOS</TI>
<SO>Archives of Gynecology and Obstetrics</SO>
<YR>2004</YR>
<VL>269</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS MODIFIED="2013-01-31 09:07:56 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12764624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-01-21 13:16:15 +1300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2010" MODIFIED="2014-01-21 13:16:15 +1300" MODIFIED_BY="[Empty name]" NAME="Tang 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-01-18 06:59:41 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tang T, Barth JH, Balen AH</AU>
<TI>Effect of metformin on follicular anti-Mullerian hormone concentrations in women with PCOS undergoing IVF treatment</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>i68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-01-31 03:11:29 +1300" MODIFIED_BY="jane clarke">
<ADDITIONAL_REFERENCES MODIFIED="2014-01-31 03:11:29 +1300" MODIFIED_BY="jane clarke">
<REFERENCE ID="REF-Aboulghar-2003" NAME="Aboulghar 2003" TYPE="JOURNAL_ARTICLE">
<AU>Aboulghar MA, Mansour RT</AU>
<TI>Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures</TI>
<SO>Human Reproduction Update</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>275-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adashi-1985" NAME="Adashi 1985" TYPE="JOURNAL_ARTICLE">
<AU>Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, Van Wyk JJ</AU>
<TI>Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function</TI>
<SO>Endocrine Review</SO>
<YR>1985</YR>
<VL>6</VL>
<PG>400-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Attia-2001" NAME="Attia 2001" TYPE="JOURNAL_ARTICLE">
<AU>Attia GR, Rainey WE, Carr BR</AU>
<TI>Metformin directly inhibits androgen production in human thecal cells</TI>
<SO>Fertility and Sterility</SO>
<YR>2001</YR>
<VL>76</VL>
<PG>517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balen-2004" MODIFIED="2008-09-08 19:21:16 +1200" MODIFIED_BY="[Empty name]" NAME="Balen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Balen A</AU>
<TI>The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology</TI>
<SO>Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>685-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbieri-1986" NAME="Barbieri 1986" TYPE="JOURNAL_ARTICLE">
<AU>Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ</AU>
<TI>Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1986</YR>
<VL>62</VL>
<PG>904-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barbieri-2000" MODIFIED="2008-09-08 19:15:09 +1200" MODIFIED_BY="[Empty name]" NAME="Barbieri 2000" TYPE="JOURNAL_ARTICLE">
<AU>Barbieri RL</AU>
<TI>Induction of ovulation in infertile women with hyperandrogenism and insulin resistance</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>183</VL>
<PG>1412-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costello-2006" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Costello 2006" TYPE="JOURNAL_ARTICLE">
<AU>Costello MF, Chapman M, Conway U</AU>
<TI>A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>1387-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costello-2007" MODIFIED="2008-07-17 15:55:17 +1200" MODIFIED_BY="jane clarke" NAME="Costello 2007" TYPE="COCHRANE_REVIEW">
<AU>Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N</AU>
<TI>Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chilchester</CY>
<IDENTIFIERS MODIFIED="2008-05-08 15:01:23 +1200" MODIFIED_BY="jane clarke">
<IDENTIFIER MODIFIED="2008-05-08 15:01:23 +1200" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE="10.1002/14651858.CD005552.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dunaif-1989" NAME="Dunaif 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dunaif A, Segal KR, Futterweit W, Dobrjansky A</AU>
<TI>Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome</TI>
<SO>Diabetes</SO>
<YR>1989</YR>
<VL>38</VL>
<PG>1165-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-1995" NAME="Dunn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dunn CJ, Peters DH</AU>
<TI>Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49</VL>
<PG>721-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESHRE_x002f_ASRM-2003" NAME="ESHRE/ASRM 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group</AU>
<TI>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2004</YR>
<VL>81</VL>
<PG>19-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frank-1995" NAME="Frank 1995" TYPE="JOURNAL_ARTICLE">
<AU>Frank S</AU>
<TI>Polycystic ovary syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>853-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2011" MODIFIED="2014-01-31 03:11:29 +1300" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2011" TYPE="COMPUTER_PROGRAM">
<AU>GRADE Working Group</AU>
<TI>GRADE Profiler</TI>
<YR>2011</YR>
<EN>Version 3.2 for Windows</EN>
<PB>Brozek J, Oxman A, Schünemann H</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-01-31 02:29:13 +1300" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<TI>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jungheim-2010" MODIFIED="2014-01-31 02:29:22 +1300" MODIFIED_BY="[Empty name]" NAME="Jungheim 2010" TYPE="JOURNAL_ARTICLE">
<AU>Jungheim ES, Odibo AO</AU>
<TI>Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents</TI>
<SO>Fertility and Sterility</SO>
<YR>2010</YR>
<VL>94</VL>
<NO>7</NO>
<PG>2659-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knochenhauer-1998" NAME="Knochenhauer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R</AU>
<TI>Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1998</YR>
<VL>83</VL>
<PG>3078-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kocak-2002" NAME="Kocak 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kocak M, Caliskan E, Simsir C, Haberal A</AU>
<TI>Metformin therapy improves ovulatory rates, cervical scores and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<PG>101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nardo-2001" NAME="Nardo 2001" TYPE="JOURNAL_ARTICLE">
<AU>Nardo LG, Rai R</AU>
<TI>Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects</TI>
<SO>Gynecology and Endocrinology</SO>
<YR>2001</YR>
<VL>15</VL>
<PG>373-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nestler-1991" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Nestler 1991" TYPE="JOURNAL_ARTICLE">
<AU>Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al</AU>
<TI>A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1991</YR>
<VL>72</VL>
<PG>83-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nestler-2002" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Nestler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ</AU>
<TI>Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<PG>209-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palomba-2010" MODIFIED="2013-08-29 08:51:21 +1200" MODIFIED_BY="[Empty name]" NAME="Palomba 2010" TYPE="JOURNAL_ARTICLE">
<AU>Palomba S, Falbo A, Russo T, Orio F, Tolino A, Zullo F</AU>
<TI>Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response</TI>
<SO>Human Reproduction</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>4</NO>
<PG>1005-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Speroff-1995" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" NAME="Speroff 1995" TYPE="BOOK_SECTION">
<AU>Speroff L, Glass RH, Kase NG</AU>
<TI>Anovulation and polycystic ovary</TI>
<TO>Anovulação e o Ovário Policístico</TO>
<SO>Clinical Gynecology, Endocrinology and Infertility</SO>
<YR>1995</YR>
<PG>477-502</PG>
<EN>5th</EN>
<PB>Manole</PB>
<CY>São Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2012" MODIFIED="2014-01-31 02:33:01 +1300" MODIFIED_BY="[Empty name]" NAME="Tang 2012" TYPE="COCHRANE_REVIEW">
<AU>Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH</AU>
<TI>Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2014-01-31 02:33:01 +1300" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-01-31 02:33:01 +1300" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003053.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thessaloniki-ESHRE_x002f_ASRM_x002d_Sponsored-PCOS-2008" MODIFIED="2014-01-31 02:33:48 +1300" MODIFIED_BY="[Empty name]" NAME="Thessaloniki ESHRE/ASRM-Sponsored PCOS 2008" TYPE="JOURNAL_ARTICLE">
<AU>Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</AU>
<TI>Consensus on infertility treatment related to polycystic ovary syndrome</TI>
<SO>Fertility and Sterility</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>3</NO>
<PG>505-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsilchorozidou-2004" NAME="Tsilchorozidou 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tsilchorozidou T, Overton C, Conway GS</AU>
<TI>The pathophysiology of polycystic ovary syndrome</TI>
<SO>Clinical Endocrinology</SO>
<YR>2004</YR>
<VL>60</VL>
<NO>1</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yarali-2004" NAME="Yarali 2004" TYPE="JOURNAL_ARTICLE">
<AU>Yarali H, Zeyneloglu HB</AU>
<TI>Gonadotrophin treatment in patients with polycystic ovary syndrome</TI>
<SO>Reproductive Biomedicine Online</SO>
<YR>2004</YR>
<VL>8</VL>
<PG>528-37</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="Helen E Nagels">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="Helen E Nagels" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Doldi-2006">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: not reported</P>
<P>Allocation concealment method: not reported</P>
<P>Blinding method: not reported</P>
<P>Number and reasons for withdrawals: not reported</P>
<P>ITT analysis: yes</P>
<P>The authors did not provide additional information about allocation concealment and generation of allocation sequence methods</P>
<P>Prospective randomised trial<BR/>Metformin versus no treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>40 PCOS participants were randomised (20 in the metformin group and 20 in the placebo group)<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>Exclusion criteria:<BR/>a) congenital adrenal hyperplasia<BR/>b) Cushing's syndrome<BR/>c) androgen-producing tumours<BR/>d) hyperprolactinaemia<BR/>e) thyroid dysfunction<BR/>f) participant age older than 40 years<BR/>g) FSH &gt; 12 mIU/ml<BR/>The causes of infertility were not reported<BR/>Participants did not take any ovulation drugs or hormones for at least 3 months prior to the trial<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>Group A was pretreated for 2 months with metformin 1.5 g/day until the embryo transfer day</P>
<P>
<B>Protocol for controlled ovarian hyperstimulation:</B> short-protocol GnRH-antagonist (cetrorelix acetate, Cetrotide®) with step up rec-FSH (Gonal F® - starting dose 150 IU). GnRH-antagonist, cetrorelix acetate 0.25 mg/day, was started when the leading follicle reached 14 mm diameter on ultrasound scan and stopped on the day of hCG<BR/>Recombinant hCG (Ovitrelle® 250 micrograms) was given when 2 or 3 follicles reached 16 mm in diameter on ultrasound scan. Oocyte retrieval was performed within 36 hrs of hCG injection. No more than 3 oocyte were fertilised (in accordance with Italian law)<BR/>
<B>Assisted reproductive technology (ART):</B> IVF<BR/>
<B>Embryo transfer:</B> maximum of 3 embryos were transferred per participant on day 2 after oocyte retrieval under abdominal US guidance<BR/>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> progesterone 90 mg (Crinone 8®) was given on the day of oocyte retrieval and was continued until menstruation or a positive pregnancy test</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>a) Number of ampoules of rec-FSH<BR/>b) Oestradiol levels<BR/>c) Cancelled cycles<BR/>d) Incidence of OHSS<BR/>e) Number of mature oocytes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:43:21 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Italy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Fedorcsak-2003">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: table of random numbers</P>
<P>Allocation concealment method: sealed, opaque envelopes serially numbered</P>
<P>Blinding method: does not apply (open-label cross-over trial)</P>
<P>Number and reasons for withdrawals: not reported</P>
<P>ITT analysis: yes</P>
<P>Prospective, open-label, randomised cross-over trial. Only data from the pre-cross-over phase of this study were considered for meta-analysis<BR/>Women were randomised to receive 2 consecutive cycles: metformin versus no treatment (control) - no treatment versus metformin<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>17 PCOS participants were randomised (9 in the metformin group and 8 in the placebo group)<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM). All participants had insulin-resistance, based on an insulin resistance index<BR/>Exclusion criteria:<BR/>a) congenital adrenal hyperplasia<BR/>b) Cushing's syndrome<BR/>c) androgen-producing tumours<BR/>d) hyperprolactinaemia<BR/>Age: 23 to 35 years (median 31)<BR/>The causes of infertility were not reported<BR/>Only the first arm was compared: 8 participants in the no treatment group versus 9 participants in the metformin group<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>Metformin 500 mg tid was started 3 weeks before down-regulation with GnRH-agonist began and continued until the day of hCG injection<BR/>
<B>Protocol for controlled ovarian hyperstimulation:</B> long luteal phase pituitary down-regulation using the GnRH analogue buserelin acetate 600 &#956;g (Suprefact®) with step-up rec-FSH (Gonal F® - starting dose 150 IU). hCG (Profasi® 10000 IU) was administered when at least 2 follicles were larger than 18 mm. Oocyte retrieval was performed within 34 to 38 hrs of hCG injection<BR/>
<B>Assisted reproductive technology (ART): </B>IVF or ICSI<BR/>
<B>Embryo transfer: </B>maximum of 2 embryos were transferred per participant on day 3 after oocyte retrieval</P>
<P>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> intramuscular progesterone (25 mg/day) until day 14 after follicle puncture</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
<BR/>a) total dose of FSH given during stimulation<BR/>b) number of collected oocytes</P>
<P>
<B>Secondary outcomes:</B>
<BR/>a) number of days of gonadotrophin<BR/>b) fertilisation rate<BR/>c) number of embryos transferred<BR/>d) pregnancy rate per woman<BR/>e) miscarriage rate<BR/>f) incidence of OHSS<BR/>d) incidence of adverse side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-27 02:31:59 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Norway</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-04 06:40:14 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Kjotrod-2004">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: computer randomisation system</P>
<P>Allocation concealment method: codes were kept by a third party in the pharmacy department</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: reported</P>
<P>ITT analysis: yes</P>
<P>Prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-04 06:40:14 +1200" MODIFIED_BY="jane clarke">
<P>73 PCOS participants were randomised (37 in the metformin group and 36 in the placebo group)<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>4 participants withdrew for personal reasons<BR/>4 women in the metformin group and 2 in the placebo group became pregnant spontaneously<BR/>63 participants started ovulation induction (31 participants in the metformin group and 32 in the placebo group )<BR/>2 women were excluded before oocyte retrieval (1 poor responder and 1 OHSS)<BR/>4 participants dropped out before embryo transfer (2 due to OHSS and 2 due to lack of good quality embryos)<BR/>57 participants received embryos</P>
<P>ITT analysis was performed for primary outcomes<BR/>Infertility factors were reported<BR/>Both groups were matched for age, cause and duration of infertility, BMI and gravity<BR/>Exclusion criteria:<BR/>a) diabetes mellitus<BR/>b) renal insufficiency<BR/>c) liver disease<BR/>d) treatment with oral glucocorticoids<BR/>e) congenital adrenal hyperplasia<BR/>g) androgen-producing tumours<BR/>h) hyperprolactinaemia<BR/>f) thyroid dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>Metformin 500 mg bid (gradually increasing the dose during the first 2 weeks) for at least 16 weeks until the day of hCG injection<BR/>
<B>Protocol for controlled ovarian hyperstimulation: </B>long luteal phase pituitary down-regulation using the GnRH analogue nafarelin 800 &#956;g daily (Synarela®) with rec-FSH (Puregon® 100 IU daily in normal weight women or 150 IU in obese women). Oocyte retrieval was performed within 34 to 36 hrs after hCG injection (Pregnyl® 5000 IU)<BR/>
<B>Assisted reproductive technology (ART): </B>IVF or ICSI<BR/>
<B>Embryo transfer: </B>maximum of 2 embryos were transferred per participant on day 3 after oocyte retrieval</P>
<P>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> vaginal progesterone (Progestan®) for 2 weeks (200 mg tid)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
<BR/>a) number of days of gonadotrophins<BR/>b) serum E2 levels on the day of hCG</P>
<P>
<B>Secondary outcomes:</B>
<BR/>a) total dose of FSH given during stimulation<BR/>b) number of collected oocytes<BR/>c) fertilisation rate<BR/>d) number of good quality embryos<BR/>e) pregnancy rate per woman<BR/>f) clinical pregnancy rate per woman<BR/>g) live birth rate per woman</P>
<P>h) incidence of OHSS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:44:34 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Norway</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kjotrod-2011">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: computer randomisation system</P>
<P>Allocation concealment method: codes were kept by a third party in the pharmacy department</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: reported</P>
<P>ITT analysis: yes</P>
<P>Multi-centre, prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>150 PCOS participants were randomised (74 in the metformin group and 76 in the placebo group); however 1 participant in the placebo group withdrew her consent just after randomisation</P>
<P>The ITT population in the study consisted of 149 women (74 in the metformin group, 75 in the placebo group)<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>A total of 53 participants withdrew during the study period. The most common reason for withdrawal was spontaneous pregnancy (n = 23)<BR/>56 participants in each group (metformin and placebo) started ovulation induction (ART population: 112 women)<BR/>Infertility factors were reported<BR/>Both groups were matched for age, cause and duration of infertility, weight and BMI<BR/>Exclusion criteria:<BR/>a) contraindication for starting dose of 112.5 IU recombinant human follicle-stimulation hormone</P>
<P>b) baseline FSH serum level &gt; 10 IU/l<BR/>c) liver or kidney diseases<BR/>d) treatment with oral glucocorticoids<BR/>e) congenital adrenal hyperplasia<BR/>f) androgen-producing tumours or Cushing's syndrome<BR/>g) hyperprolactinaemia<BR/>h) thyroid dysfunction</P>
<P>i) alcoholism or drug abuse</P>
<P>j) diabetes mellitus</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>The dose of metformin was gradually increased from 500 to 2000 mg per day during the first 2 weeks of treatment for at least 12 weeks prior to controlled ovarian hyperstimulation<BR/>
<B>Protocol for controlled ovarian hyperstimulation: </B>long luteal phase pituitary down-regulation using the GnRH analogue nafarelin 800 &#956;g daily (Synarela®) with rec-FSH (Gonal-f® starting dose of 112.5 IU daily and adjusted according to ovarian response). To induce final follicular maturation, a single dose of hCG (Pregnyl® 5000 or 10000 IU; or Ovitrelle® 250 &#956;g) was given when at least 1 follicle reached a diameter &gt; 17 mm<BR/>
<B>Assisted reproductive technology (ART): </B>IVF, ICSI or both procedures<BR/>
<B>Embryo transfer: </B>maximum of 2 embryos were transferred per participant on day 2 or 3 after oocyte retrieval</P>
<P>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> progesterone, but the type and dose were selected by the physician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
<BR/>a) clinical pregnancy rate per woman (ITT population)<BR/>
</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>a) pregnancy rate</P>
<P>b) spontaneous pregnancy rate<BR/>c) number of collected oocytes<BR/>d) number of good-quality embryos<BR/>e) live birth rate per woman</P>
<P>f) incidence of OHSS</P>
<P>g) total dose of FSH given during stimulation</P>
<P>h) number of days of gonadotrophins</P>
<P>i) miscarriage rate</P>
<P>j) incidence of side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:45:11 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Norway</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Onalan-2005">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: computer randomisation system</P>
<P>Allocation concealment method: not reported</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: reported</P>
<P>ITT analysis: no</P>
<P>Prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>110 PCOS participants without concomitant causes of infertility<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>2 participants withdrew for personal reasons<BR/>108 participants were randomised (53 in the metformin group and 55 in the placebo group)<BR/>Participants &lt; 40 years <BR/>Both groups were matched for age, duration of infertility, BMI and insulin resistance<BR/>All other causes of hyperandrogenism were ruled out before diagnosis of PCOS<BR/>Exclusion criteria: previous treatments with hormonal medications and insulin-lowering agents in the last 3 months<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin 850 mg bid or tid (according to BMI) for 8 weeks before their first ICSI cycle, through the luteal phase and until a positive pregnancy test<BR/>
<B>Protocol for controlled ovarian hyperstimulation:</B> long luteal phase pituitary down-regulation using the GnRH analogue triptorelin 0.1 mg (Decapeptyl®) with rec-FSH (Gonal F® starting dose of 150 IU or 300 IU). Oocyte retrieval was performed within 36 hours after hCG injection (Pregnyl® 10000 IU)<BR/>
<B>Assisted reproductive technology (ART): </B>ICSI<BR/>
<B>Embryo transfer: </B>maximum of 3 embryos were transferred per participant on day 3 after oocyte retrieval<BR/>A selective assisted hatching procedure with laser was used if the participant was &gt; 35 years, the zona pellucida was considered to be thick, abnormally shaped zona, and excessive fragmentation or slowly developing embryos were noted</P>
<P>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>a) Number of days of gonadotrophins<BR/>b) Number of ampoules of gonadotrophins<BR/>c) Number of follicles (&gt; 16 mm)<BR/>d) Number of mature oocytes<BR/>e) Fertilisation rate<BR/>f) Number of embryos transferred<BR/>g) Pregnancy rate per woman<BR/>h) Clinical pregnancy rate per woman<BR/>i) Miscarriage rate<BR/>j) Serum E2 levels<BR/>k) Glucose/insulin rate<BR/>l) Incidence of OHSS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:46:19 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Turkey</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palomba-2011">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: computer randomisation system</P>
<P>Allocation concealment method: random allocation sequence was concealed in the central pharmacy of the University of Catanzaro</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: no participants dropped out</P>
<P>ITT analysis: yes</P>
<P>Prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Number of eligible cycles: 120 infertile women with PCOS who had a history of 1 previous cancelled cycle due to a high risk of OHSS or history of a moderate or severe case of OHSS during their previous IVF cycle<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>120 PCOS participants were screened and underwent 120 consecutive IVF/ICSI cycles<BR/>60 participants were randomised to each group (metformin and placebo)<BR/>No participants dropped out<BR/>Age: younger than 35 years<BR/>Did not report the causes of infertility<BR/>Both groups were matched for age, median duration of infertility, BMI and hirsutism according to modified Ferriman-Gallwey score<BR/>Inclusion criteria - only participants who had received in the previous cycle:<BR/>a) mid-luteal long GnRH agonist and a gonadotropin step-down stimulation protocol with a starting dose of 225 IU daily<BR/>Exclusion criteria:<BR/>a) age &gt; 35 years<BR/>b) FSH level of &gt; 10</P>
<P>c) BMI &gt; 30 kg/m<SUP>2</SUP>
<BR/>d) neoplastic, metabolic, hepatic or cardiovascular disorders or other concurrent medical illness</P>
<P>e) hypothyroidism</P>
<P>f) hyperprolactinaemia</P>
<P>h) Cushing's syndrome</P>
<P>i) nonclassic congenital adrenal hyperplasia</P>
<P>j) alcohol abuse</P>
<P>k) current or previous: a wash-out period of at least 6 months without use of any antidiabetic, obesity or hormonal drugs except those used during the previous IVF cycle</P>
<P>l) male factor infertility</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin 500 mg tid and placebo tablets were started on the same day that down-regulation with GnRH-agonist began and continued until a positive pregnancy test was obtained or menstrual bleeding appeared<BR/>
<B>Protocol for controlled ovarian hyperstimulation:</B> long luteal phase pituitary down-regulation using the GnRH analogue Enantone 1mg® (0.5 mg twice daily, SC) and reduced to 0.5 mg (0.25 mg twice daily) after pituitary suppression with step-down rec-FSH (Gonal F® - starting dose 150 IU). hCG (Profasi® 10000 IU) was administered when at least 3 follicles were larger than 18 mm. Oocyte retrieval was performed within 36 hrs after hCG injection<BR/>
<B>Assisted reproductive technology (ART): </B>IVF or ICSI<BR/>
<B>Embryo transfer: </B>maximum of 2 embryos were transferred per participant on day 2, 3 or 5 after oocyte retrieval without ultrasonographic guidance</P>
<P>Catheter used for transfer: not reported<BR/>
<B>Luteal phase support:</B> intramuscular progesterone (Prontogest® - 50 mg/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes:</B>
<BR/>a) OHSS rate per woman<BR/>
</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>a) live birth rate per woman</P>
<P>b) clinical pregnancy rate<BR/>c) number of collected oocytes<BR/>d) number of good-quality embryos<BR/>
</P>
<P>g) total dose of FSH given during stimulation</P>
<P>h) number of days of gonadotrophins</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:45:43 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Italy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qublan-2009">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: not reported</P>
<P>Allocation concealment method: not reported</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: there were no withdrawals</P>
<P>ITT analysis: yes</P>
<P>Prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>66 clomiphene citrate-resistant PCOS participants were randomised (34 in the metformin group and 32 in the placebo group)<BR/>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>34 women in the metformin group and 32 in the placebo group started controlled ovarian hyperstimulation (66 participants - 4 women in the metformin group and 2 in the placebo group became pregnant spontaneously)</P>
<P>There were no withdrawals<BR/>Infertility factors were reported<BR/>Both groups were matched for age, cause and duration of infertility, BMI and hormonal/ biochemical profiles</P>
<P>All participants were required to have a normal uterine cavity<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin 850 mg tid for a month before their first ICSI cycle, through the luteal phase and until a positive pregnancy test. If the test was positive metformin was continued until 12 weeks of gestation<BR/>
<B>Protocol for controlled ovarian hyperstimulation:</B> long luteal phase pituitary down-regulation using the GnRH analogue triptorelin (Decapeptyl®) with human menopausal gonadotropin - HMG (Menogon®) (starting dose of 150 IU daily and adjusted according to ovarian response). Oocyte retrieval was performed within 36 hrs after hCG injection (10000 IU)<BR/>
<B>Assisted reproductive technology (ART): </B>IVF or ICSI<BR/>
<B>Embryo transfer: </B>2 to 4 embryos were transferred per participant on day 3 after oocyte retrieval<BR/>
<B>Luteal phase support:</B> progesterone pessaries (Cyclogest®)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>a) Number of days of gonadotrophins<BR/>b) Number of ampoules of gonadotrophins<BR/>c) Number of follicles (&gt; 14 mm)<BR/>d) Number of mature oocytes<BR/>e) Fertilisation rate<BR/>f) Number of embryo transferred<BR/>g) Pregnancy rate per woman<BR/>h) Clinical pregnancy rate per woman<BR/>i) Miscarriage rate<BR/>j) Serum E2 levels on day of hCG<BR/>k) Glucose/insulin rate<BR/>l) Incidence of OHSS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:47:22 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Jordan</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2006">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: reported</P>
<P>Allocation concealment method: reported</P>
<P>Blinding method: yes</P>
<P>Number and reasons for withdrawals: reported</P>
<P>ITT analysis: yes</P>
<P>Prospective, randomised, double-blind, placebo-controlled trial<BR/>Metformin versus placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Diagnosis of PCOS followed the Rotterdam criteria (ESHRE/ASRM)<BR/>101 PCOS participants were randomised (52 in the metformin group and 49 in the placebo group)</P>
<P>5 cycles in the metformin group and 2 in the placebo group were abandoned due to poor response<BR/>47 cycles in each arm completed through to oocyte retrieval<BR/>Age: 20 to 39 years <BR/>Did not report the causes of infertility<BR/>Both groups were matched for mean age, median duration of infertility, BMI, nulliparity, participants who had previous IVF cycle, ICSI cycles<BR/>Inclusion criteria:<BR/>a) serum testosterone concentration &lt; 5.0 nmol/l<BR/>b) normal prolactin concentration, thyroid, renal and haematological indices<BR/>Exclusion criteria:<BR/>a) concurrent hormone therapy within the previous 6 weeks<BR/>b) any chronic disease that could interfere with the absorption, distribution, metabolism or excretion of metformin<BR/>c) renal or liver disease<BR/>d) systemic disease or diabetes (types 1 and 2)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin 850 mg bid from the first day of down-regulation GnRH-agonist to the day of oocyte retrieval</P>
<P>
<B>Protocol for controlled ovarian hyperstimulation: </B>long luteal phase pituitary down-regulation using the GnRH analogue nafarelin 600 &#956;g daily (Synarel®) with step up rec-FSH (Puregon® starting dose of 100 IU). hCG (Profasi® 10000 IU) was administered when there were more than 3 follicles over 17 mm in diameter<BR/>Oocyte retrieval was performed within 36 to 38 hrs after hCG injection<BR/>All follicles with a diameter over 14 mm were aspirated and flushed twice with normal saline when oocytes were not found in the first aspirate</P>
<P>
<B>Assisted reproductive technology (ART): </B>IVF or ICSI (4 hours after oocyte retrieval)</P>
<P>
<B>Embryo transfer: </B>maximum of 2 embryos were transferred per participant on day 2 after follicle puncture under abdominal US guidance<BR/>Catheter used for transfer: Wallace<BR/>
<B>Luteal phase support:</B> daily Cyclogest® pessary (400 mg) was used until the day of pregnancy test</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<BR/>Fertilisation rate</P>
<P>Secondary outcomes:<BR/>a) number of days of gonadotrophins<BR/>b) total dose of FSH given during stimulation<BR/>c) number of follicles (&gt; 14 mm)<BR/>d) number of oocytes<BR/>e) number of embryos transferred<BR/>f) implantation rate<BR/>g) pregnancy rate per woman<BR/>h) clinical pregnancy rate per woman<BR/>i) pregnancy rate per transfer<BR/>j) clinical pregnancy rate per transfer<BR/>k) live birth rate<BR/>l) incidence of OHSS that required hospitalisation<BR/>m) side effects<BR/>n) fasting insulin<BR/>o) fasting glucose<BR/>p) SHBG<BR/>q) free androgen index<BR/>r) testosterone</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:44:56 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: United Kingdom</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Visnova-2003">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Generation of the allocation sequence: not reported</P>
<P>Allocation concealment method: not reported</P>
<P>Blinding method: no</P>
<P>Number and reasons for withdrawals: reported</P>
<P>ITT analysis: yes</P>
<P>Prospective randomised controlled trial<BR/>Metformin versus no treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>172 participants were selected but only 141 were randomised because they met the inclusion criteria for PCOS according to the Rotterdam criteria (ESHRE/ASRM)<BR/>72 participants in the metformin group (I), 69 in the no treatment group (II) and 31 in the no PCOS participants group (III) started controlled ovarian hyperstimulation<BR/>1 participant in the metformin group (I) and 3 in the no treatment group (II) were excluded due to a poor response to ovulation induction<BR/>Infertility factors were not reported<BR/>Both groups were matched for age, BMI and hormonal parameters<BR/>Exclusion criteria:<BR/>if the participant did not met the PCOS diagnostic criteria<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin 500 mg bid from the first day of ovulation induction to the day of oocyte retrieval<BR/>Protocol for ovulation induction: long protocol GnRH-agonist with rec-FSH or hp-FSH (150 to 225 IU/day)<BR/>The following were not reported:<BR/>a) which hCG was used<BR/>b) when the oocyte retrieval was performed<BR/>c) how many embryos were transferred<BR/>d) luteal phase support medication used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>a) Incidence of OHSS<BR/>b) Pregnancy rate<BR/>c) Number of oocytes retrieved<BR/>d) Total dose of FSH (IU)<BR/>e) Number of days of gonadotrophin treatment<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-20 06:47:57 +1300" MODIFIED_BY="[Empty name]">
<P>Country of the study: Czech Republic</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AMH: anti-Müllerian hormone<BR/>ART: assisted reproductive technology<BR/>bid: twice a day<BR/>BMI: body mass index<BR/>CI: confidence interval<BR/>E2: oestradiol<BR/>FSH: follicle-stimulating hormone<BR/>GnRH: gonadotrophin-releasing hormone<BR/>hCG: human chorionic gonadotrophin<BR/>ICSI: intracytoplasmic sperm injection<BR/>ITT: intention-to-treat<BR/>IU: international units<BR/>IVF: in vitro fertilisation<BR/>OCP: oral contraceptive pill<BR/>OHSS: ovarian hyperstimulation syndrome<BR/>OR: odds ratio<BR/>PCOS: polycystic ovarian syndrome<BR/>RCT: randomised controlled trial<BR/>SC: subcutaneous<BR/>SD: standard deviation<BR/>SE: standard error<BR/>SHBG: sex hormone-binding globulin<BR/>tid: three times a day<BR/>US: ultrasonography</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-11 17:27:15 +1200" MODIFIED_BY="Helen E Nagels" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demirol-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Egbase-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Data were not properly reported. The study did not state how many participants withdrew from each group (1 and 2). Moreover, the author does not present the means and standard deviations (SD) nor the standard errors (SE)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geusa-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>The study was excluded because of data irregularities (summarised reported data were not consistent with table data). We were not successful in contacting the authors to clarify the queries</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahraman-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Control group was treated with oral contraceptives instead of placebo or no treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palomba-2011b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Participants were poor responder women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schachter-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Participants specifically undergoing ICSI were not randomised separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Stadtmauer-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>It is not a randomised controlled trial<BR/>Prospective controlled analysis<BR/>Participants acted as their own control, when metformin was used in the subsequent cycle<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Stadtmauer-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>It is not a randomised controlled trial<BR/>Retrospective data analysis<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" STUDY_ID="STD-Stadtmauer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke">
<P>The study is not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tasdemir-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Participants undergoing ovulation induction cycles; not IVF or ICSI cycles</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ICSI: intracytoplasmic sperm injection<BR/>IVF: in vitro fertilisation<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2010">
<CHAR_METHODS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>69 PCOS participants were randomised (39 in the metformin group and 38 in the placebo group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-18 07:11:50 +1300" MODIFIED_BY="[Empty name]">
<P>Metformin versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Live birth rate; fertilisation rate; number of follicles; number of oocytes; number of embryos transferred; clinical pregnancy rate per woman; incidence of OHSS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]">
<P>Information retrieved from abstract of congress. Authors were contacted to give more information. We are awaiting more details to classify the study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>PCOS: polycystic ovarian syndrome</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="Helen E Nagels">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-09-11 17:24:44 +1200" MODIFIED_BY="Helen E Nagels" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>Adequate - random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>Adequate - computer randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>Adequate - computer randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Adequate - computer randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>Adequate - computer randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>Adequate - random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-11 17:24:44 +1200" MODIFIED_BY="Helen E Nagels" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>Adequate - sealed, opaque envelopes serially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>Adequate - codes kept by a third party in the pharmacy department</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>Adequate - codes kept by a third party in the pharmacy department</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>Random allocation sequence was concealed in the central pharmacy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>Adequate - codes kept by a third party in the trial office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-09-11 17:24:44 +1200" MODIFIED_BY="Helen E Nagels" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>Open-label cross-over trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Single-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-09-11 17:24:44 +1200" MODIFIED_BY="Helen E Nagels" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>Reasons for withdrawals were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>There were no withdrawals in the phase analysed (pre-cross-over phase)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>Number and reasons for withdrawals were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>Number and reasons for withdrawals were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Intention-to-treat (ITT) was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>There were no withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Intention-to-treat (ITT) was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>Reasons for withdrawals were reported. ITT analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>Reasons for withdrawals were reported. However, 4 participants were excluded due to poor response to ovulation induction after randomisation and were not included in the ITT by study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-09-11 17:24:44 +1200" MODIFIED_BY="Helen E Nagels" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>Live birth and clinical pregnancy rates were not assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>Live birth rate was not evaluated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>All main outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>All main outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Live birth rate was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>All main outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Live birth rate was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>All main outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>Live birth rate was not assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="Helen E Nagels" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Doldi-2006">
<DESCRIPTION>
<P>No power calculation. Neither the causes of infertility nor the baseline characteristics of the 2 groups were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fedorcsak-2003">
<DESCRIPTION>
<P>No power calculation. The causes of infertility were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2004">
<DESCRIPTION>
<P>Power calculation was performed. There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kjotrod-2011">
<DESCRIPTION>
<P>Power calculation was performed. There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Onalan-2005">
<DESCRIPTION>
<P>Power calculation was not performed. There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-24 10:08:00 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Palomba-2011">
<DESCRIPTION>
<P>There is a discrepancy in the data in the published study: in both the Metformin group and the placebo group the clinical pregnancy rate is <I>lower</I> than the live birth rate (pregnancy 26/60, 24/60; live birth 29/60, 27/60). We have attempted to contact the first author (emailed 8/19/14) but have not received a response. </P>
<P>There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Qublan-2009">
<DESCRIPTION>
<P>Power calculation was performed. There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tang-2006">
<DESCRIPTION>
<P>Power calculation was performed. There were no significant differences in the baseline characteristics of the participants between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Visnova-2003">
<DESCRIPTION>
<P>No power calculation was performed. Infertility factors were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-04-10 12:23:08 +1200" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-04-10 12:23:08 +1200" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-10-16 11:24:02 +1300" MODIFIED_BY="[Empty name]">Metformin treatment before and during IVF or ICSI for women with polycystic ovary syndrome</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Metformin treatment before or during IVF or ICSI for women with polycystic ovary syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women with polycystic ovary syndrome<BR/>
<B>Settings:</B> Assisted reproduction<BR/>
<B>Intervention:</B> Metformin treatment before or during IVF or ICSI</P>
<P>
<B>Control:</B> Placebo or no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or no treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Metformin treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Live birth rate (per woman) - ITT</B>
<BR/>Delivery of one or more living infants/pregnancy beyond 20 weeks of gestation.</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>320 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
</P>
<P>
<B>(276 to 530)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.39 </B>
<BR/>(0.81 to 2.40)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>551<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical pregnancy rate (per woman) - ITT</B>
<BR/>Identified by the presence of a gestational sac on ultrasonography</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>307 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>403 per 1000</B>
<BR/>
<B>(322 to 488)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.52 </B>
<BR/>(1.07 to 2.15)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>775<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Incidence of OHSS</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>270 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>97 per 1000</B>
<BR/>
<B>(62 to 153)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.29 </B>
<BR/>(0.18 to 0.49)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>798<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Miscarriage rate (per woman)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>
<B>(65 to 182)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 0.76 </B>
<BR/>(0.43 to 1.37)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>521<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Side effects</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>106 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>347 per 1000</B>
<BR/>
<B>(182 to 559)</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 4.49 </B>
<BR/>(1.88 to 10.72)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>431<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Inconsistency: unexplained heterogeneity (I<SUP>2</SUP> = 52%)</P>
<P>
<SUP>2</SUP> Imprecision: total number of events is fewer than 300</P>
<P>
<SUP>3</SUP>Inconsistency: unexplained heterogeneity (I<SUP>2</SUP> = 57%)</P>
<P>
<SUP>4</SUP>There was a data discrepancy in one of these studies (Palombo 2011). According to the study publication, in both the metformin group and the placebo group the clinical pregnancy rate was <I>lower</I> than the live birth rate. Sensitivity analyses excluding this study yielded an OR of 1.48 (95% CI 0.72 to 3.02) for live birth and 1.61 (95% CI 1.08 to 2.40) for pregnancy, which did not substantially change our findings.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-12-20 07:47:38 +1300" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-04-10 11:53:48 +1200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-04-10 11:53:48 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Metformin versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="8.39009506395707" CI_END="2.3972383875368197" CI_START="0.8098682609861221" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.393358275564336" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="85" I2="52.32473566141625" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.37971122353885234" LOG_CI_START="-0.09158562084963268" LOG_EFFECT_SIZE="0.14406280134460983" METHOD="MH" MODIFIED="2015-04-10 10:40:13 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07828960822842856" P_Q="1.0" P_Z="0.23083264221517852" Q="0.0" RANDOM="YES" SCALE="267.9872123692406" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19756340402357375" TOTALS="YES" TOTAL_1="276" TOTAL_2="275" WEIGHT="100.0" Z="1.1982168160440263">
<NAME>Live birth rate per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metformin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.39009506395707" CI_END="2.3972383875368197" CI_START="0.8098682609861221" DF="4" EFFECT_SIZE="1.393358275564336" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="85" I2="52.32473566141625" ID="CMP-001.01.01" LOG_CI_END="0.37971122353885234" LOG_CI_START="-0.09158562084963268" LOG_EFFECT_SIZE="0.14406280134460983" MODIFIED="2014-10-31 16:04:30 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07828960822842856" P_Z="0.23083264221517852" STUDIES="5" TAU2="0.19756340402357375" TOTAL_1="276" TOTAL_2="275" WEIGHT="100.0" Z="1.1982168160440263">
<NAME>Long protocol GnRH agonist</NAME>
<DICH_DATA CI_END="3.1794436880758163" CI_START="0.4661323593998375" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.5023511374893099" LOG_CI_START="-0.3314907468400573" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2014-10-31 15:57:43 +1300" MODIFIED_BY="[Empty name]" ORDER="5496" O_E="0.0" SE="0.48980285043896654" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="37" TOTAL_2="36" VAR="0.2399068322981366" WEIGHT="17.519259965516294"/>
<DICH_DATA CI_END="3.9173818244641163" CI_START="1.0345697434524863" EFFECT_SIZE="2.013157894736842" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.5929959039900848" LOG_CI_START="0.01475977308353001" LOG_EFFECT_SIZE="0.30387783853680744" MODIFIED="2014-10-31 15:57:43 +1300" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.3396587656095211" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="74" TOTAL_2="75" VAR="0.11536807705538356" WEIGHT="24.49147900003743"/>
<DICH_DATA CI_END="1.395856796954687" CI_START="0.23020326126067175" EFFECT_SIZE="0.5668604651162791" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.14484086564927517" LOG_CI_START="-0.6378885280672993" LOG_EFFECT_SIZE="-0.24652383120901208" MODIFIED="2014-10-31 15:57:43 +1300" MODIFIED_BY="[Empty name]" ORDER="5498" O_E="0.0" SE="0.4597791204421032" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" VAR="0.21139683959451402" WEIGHT="18.740586443050812"/>
<DICH_DATA CI_END="2.343534972472273" CI_START="0.5578295554068083" EFFECT_SIZE="1.1433691756272402" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" LOG_CI_END="0.36987143886258633" LOG_CI_START="-0.2534984792954192" LOG_EFFECT_SIZE="0.05818647978358358" MODIFIED="2014-10-31 15:57:43 +1300" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.3661705756568734" STUDY_ID="STD-Palomba-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.13408089047688604" WEIGHT="23.109563241062382">
<FOOTNOTE>The birth rate in this study is higher than the pregnancy rate and attempts to clarify this with the authors were unsuccessful. However, exclusion of this study does not substantially influence the effect estimate.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="9.771220161278737" CI_START="1.2400733253841985" EFFECT_SIZE="3.480952380952381" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.9899487987467501" LOG_CI_START="0.09344736570113217" LOG_EFFECT_SIZE="0.5416980822239412" MODIFIED="2014-10-31 15:57:43 +1300" MODIFIED_BY="[Empty name]" ORDER="5497" O_E="0.0" SE="0.5266093795246608" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.2773174386033483" WEIGHT="16.139111350333078"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.587480960601667" CI_END="2.1465578847616693" CI_START="1.0726641341169991" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5174108391565855" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="116" I2="18.485991036077277" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3317426042962974" LOG_CI_START="0.03046375967947868" LOG_EFFECT_SIZE="0.18110318198788802" METHOD="MH" MODIFIED="2015-04-10 10:40:22 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2836448675402793" P_Q="1.0" P_Z="0.01845667032461975" Q="0.0" RANDOM="YES" SCALE="99.2772010899798" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04592740899379556" TOTALS="YES" TOTAL_1="391" TOTAL_2="384" WEIGHT="100.0" Z="2.3563268415564576">
<NAME>Clinical pregnancy rate per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metformin</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.587480960601667" CI_END="2.1465578847616693" CI_START="1.0726641341169991" DF="7" EFFECT_SIZE="1.5174108391565855" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="116" I2="18.485991036077277" ID="CMP-001.02.01" LOG_CI_END="0.3317426042962974" LOG_CI_START="0.03046375967947868" LOG_EFFECT_SIZE="0.18110318198788802" MODIFIED="2014-10-31 16:05:25 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2836448675402793" P_Z="0.01845667032461975" STUDIES="8" TAU2="0.04592740899379556" TOTAL_1="391" TOTAL_2="384" WEIGHT="100.0" Z="2.3563268415564576">
<NAME>Long protocol GnRH agonist</NAME>
<DICH_DATA CI_END="12.459310421453043" CI_START="0.1805878434592849" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0954940063323635" LOG_CI_START="-0.7433114882210011" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="5499" O_E="0.0" SE="1.0801234497346435" STUDY_ID="STD-Fedorcsak-2003" TOTAL_1="9" TOTAL_2="8" VAR="1.1666666666666667" WEIGHT="2.582837220822251"/>
<DICH_DATA CI_END="3.313317320998016" CI_START="0.5254352279940745" EFFECT_SIZE="1.3194444444444444" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.5202630308590369" LOG_CI_START="-0.2794808131438783" LOG_EFFECT_SIZE="0.1203911088575793" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="5500" O_E="0.0" SE="0.46977349276318686" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="37" TOTAL_2="36" VAR="0.220687134502924" WEIGHT="11.747045271005373"/>
<DICH_DATA CI_END="3.8770093002133224" CI_START="1.0317230860859452" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="25" LOG_CI_END="0.5884968427989258" LOG_CI_START="0.013563148529036596" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.3377188979818187" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="74" TOTAL_2="75" VAR="0.11405405405405407" WEIGHT="19.576850046856055"/>
<DICH_DATA CI_END="1.4390215077574622" CI_START="0.29238275253397533" EFFECT_SIZE="0.6486486486486487" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.1580672849932974" LOG_CI_START="-0.5340482497040753" LOG_EFFECT_SIZE="-0.18799048235538895" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="5503" O_E="0.0" SE="0.40655209110838775" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" VAR="0.1652846027846028" WEIGHT="14.828385402864255"/>
<DICH_DATA CI_END="2.371430594288517" CI_START="0.554831310604488" EFFECT_SIZE="1.1470588235294117" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.3750104184845791" LOG_CI_START="-0.2558390385160911" LOG_EFFECT_SIZE="0.05958568998424405" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.370564093797369" STUDY_ID="STD-Palomba-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.13731774761186527" WEIGHT="17.09149191377669">
<FOOTNOTE>The birth rate in this study is higher than the pregnancy rate and attempts to clarify this with the authors were unsuccessful. However, exclusion of this study does not substantially influence the effect estimate.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.627210065289742" CI_START="0.723357254906085" EFFECT_SIZE="2.017543859649123" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.7502931277883146" LOG_CI_START="-0.14064715842607395" LOG_EFFECT_SIZE="0.3048229846811203" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.5233427343478758" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" VAR="0.27388761759471136" WEIGHT="9.792951712660228"/>
<DICH_DATA CI_END="8.210386257184293" CI_START="1.2496378908662469" EFFECT_SIZE="3.203125" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.9143635889608284" LOG_CI_START="0.09678418518290584" LOG_EFFECT_SIZE="0.5055738870718671" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="5501" O_E="0.0" SE="0.48025018886247095" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.230640243902439" WEIGHT="11.324292915554608"/>
<DICH_DATA CI_END="4.323243176094958" CI_START="0.7692487910848469" EFFECT_SIZE="1.8236363636363637" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.6358096646490601" LOG_CI_START="-0.11393317759671147" LOG_EFFECT_SIZE="0.2609382435261743" MODIFIED="2014-10-31 15:58:06 +1300" MODIFIED_BY="[Empty name]" ORDER="5502" O_E="0.0" SE="0.44040265682209023" STUDY_ID="STD-Visnova-2003" TOTAL_1="72" TOTAL_2="69" VAR="0.19395450013595578" WEIGHT="13.05614551646053"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.840865156284605" CI_END="0.485835044517312" CI_START="0.17766001329278874" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2937915255194545" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="86" I2="10.724137445606178" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.31351116163553894" LOG_CI_START="-0.7504103097324912" LOG_EFFECT_SIZE="-0.5319607356840151" METHOD="MH" MODIFIED="2015-04-10 11:53:48 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3468354163147591" P_Q="0.9781414912920038" P_Z="1.8165015090534092E-6" Q="7.507055695342368E-4" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05765646260212485" TOTALS="YES" TOTAL_1="402" TOTAL_2="396" WEIGHT="100.0" Z="4.77283550527195">
<NAME>Incidence of OHSS per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.842235492667214" CI_END="0.508463970026718" CI_START="0.16347995406671237" DF="6" EFFECT_SIZE="0.288311752213721" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="83" I2="23.491203425219428" ID="CMP-001.03.01" LOG_CI_END="-0.2937398159427408" LOG_CI_START="-0.7865354929850108" LOG_EFFECT_SIZE="-0.5401376544638757" MODIFIED="2014-10-16 11:30:26 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24989112589091855" P_Z="1.7350950270991353E-5" STUDIES="7" TAU2="0.13375588265500724" TOTAL_1="382" TOTAL_2="376" WEIGHT="95.61631797390788" Z="4.296508264021684">
<NAME>Long protocol GnRH agonist</NAME>
<DICH_DATA CI_END="2.092524710747516" CI_START="0.023599585608593193" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3206705953046877" LOG_CI_START="-1.627095622855375" LOG_EFFECT_SIZE="-0.6532125137753437" MODIFIED="2014-07-05 01:09:55 +1200" MODIFIED_BY="[Empty name]" ORDER="5541" O_E="0.0" SE="1.1441275181454984" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="37" TOTAL_2="36" VAR="1.3090277777777777" WEIGHT="4.819138559993265"/>
<DICH_DATA CI_END="1.3835210218795078" CI_START="0.27151764105010473" EFFECT_SIZE="0.6129032258064516" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.14098576240498575" LOG_CI_START="-0.5662019481678731" LOG_EFFECT_SIZE="-0.21260809288144372" MODIFIED="2014-07-03 06:16:57 +1200" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.41540556182612215" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="74" TOTAL_2="75" VAR="0.1725617807960762" WEIGHT="28.608682895550917"/>
<DICH_DATA CI_END="3.5932386732632566" CI_START="0.16286839066788697" EFFECT_SIZE="0.765" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5554860652532494" LOG_CI_START="-0.7881631949460142" LOG_EFFECT_SIZE="-0.11633856484638239" MODIFIED="2013-09-05 07:03:41 +1200" MODIFIED_BY="[Empty name]" ORDER="5542" O_E="0.0" SE="0.7892662266121541" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" VAR="0.6229411764705882" WEIGHT="9.677143063739363"/>
<DICH_DATA CI_END="0.6178688802133814" CI_START="0.0728235554058542" EFFECT_SIZE="0.21212121212121213" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.20910367805286798" LOG_CI_START="-1.1377281216743933" LOG_EFFECT_SIZE="-0.6734158998636306" MODIFIED="2014-10-16 11:30:26 +1300" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.5454785949484156" STUDY_ID="STD-Palomba-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.29754689754689756" WEIGHT="18.542168968747067"/>
<DICH_DATA CI_END="2.4625375849051148" CI_START="0.006059361931071024" EFFECT_SIZE="0.12215320910973085" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3913828677147571" LOG_CI_START="-2.217573105933493" LOG_EFFECT_SIZE="-0.9130951191093679" MODIFIED="2014-10-08 12:29:26 +1300" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="1.5325136534613348" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" VAR="2.348598098045408" WEIGHT="2.737133813630054"/>
<DICH_DATA CI_END="0.7534948357830262" CI_START="0.032297500718382784" EFFECT_SIZE="0.156" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.12291971985714067" LOG_CI_START="-1.490831083433936" LOG_EFFECT_SIZE="-0.8068754016455384" MODIFIED="2013-09-05 07:09:28 +1200" MODIFIED_BY="[Empty name]" ORDER="5543" O_E="0.0" SE="0.803517906235465" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.6456410256410257" WEIGHT="9.364800574792948"/>
<DICH_DATA CI_END="0.39551648751153445" CI_START="0.05715316067475666" EFFECT_SIZE="0.15034965034965034" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" LOG_CI_END="-0.4028354077768417" LOG_CI_START="-1.2429597473220713" LOG_EFFECT_SIZE="-0.8228975775494565" MODIFIED="2014-10-08 12:29:25 +1300" MODIFIED_BY="[Empty name]" ORDER="5544" O_E="0.0" SE="0.49349319573141903" STUDY_ID="STD-Visnova-2003" TOTAL_1="72" TOTAL_2="69" VAR="0.24353553423320867" WEIGHT="21.867250097454264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1456674740237" CI_START="0.028277129425058976" DF="0" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" NO="2" P_CHI2="1.0" P_Z="0.31416255039697194" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.383682026092118" Z="1.0065261546371438">
<NAME>Short protocol GnRH antagonist</NAME>
<DICH_DATA CI_END="3.1456674740237" CI_START="0.028277129425058976" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="5545" O_E="0.0" SE="1.201993528140841" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" VAR="1.4447884416924663" WEIGHT="4.383682026092118"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9266699088695463" CI_END="1.3664200725475961" CI_START="0.42661518262452136" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7635021603058529" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.13558423312583562" LOG_CI_START="-0.36996369269175106" LOG_EFFECT_SIZE="-0.11718972978295773" METHOD="MH" MODIFIED="2014-10-31 16:21:13 +1300" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8591958169208007" P_Q="1.0" P_Z="0.3635253305070436" Q="0.0" RANDOM="YES" SCALE="72.76042583509388" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="261" TOTAL_2="260" WEIGHT="100.0" Z="0.9086681519308801">
<NAME>Miscarriage rate per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9266699088695463" CI_END="1.3664200725475961" CI_START="0.42661518262452136" DF="5" EFFECT_SIZE="0.7635021603058529" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="30" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.13558423312583562" LOG_CI_START="-0.36996369269175106" LOG_EFFECT_SIZE="-0.11718972978295773" MODIFIED="2014-10-31 16:21:13 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8591958169208007" P_Z="0.3635253305070436" STUDIES="6" TAU2="0.0" TOTAL_1="261" TOTAL_2="260" WEIGHT="100.0" Z="0.9086681519308801">
<NAME>Long protocol GnRH agonist</NAME>
<DICH_DATA CI_END="27.447064534928778" CI_START="0.1457350746893043" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.438495903450854" LOG_CI_START="-0.8364359121228916" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-02-22 06:07:14 +1300" MODIFIED_BY="[Empty name]" ORDER="5504" O_E="0.0" SE="1.3363062095621219" STUDY_ID="STD-Fedorcsak-2003" TOTAL_1="9" TOTAL_2="8" VAR="1.7857142857142856" WEIGHT="4.938418567344764"/>
<DICH_DATA CI_END="5.570804164502404" CI_START="0.19255821062029188" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7459178915826031" LOG_CI_START="-0.7154379584691295" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2014-06-27 08:00:27 +1200" MODIFIED_BY="[Empty name]" ORDER="5505" O_E="0.0" SE="0.8584076601485112" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="31" TOTAL_2="32" VAR="0.7368637110016419" WEIGHT="11.967755302478952"/>
<DICH_DATA CI_END="1.618348637483421" CI_START="0.09700961114450855" EFFECT_SIZE="0.39622641509433965" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20907208651293366" LOG_CI_START="-1.0131852362466733" LOG_EFFECT_SIZE="-0.40205657486686974" MODIFIED="2014-06-27 08:00:46 +1200" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.7179600016603183" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="56" TOTAL_2="56" VAR="0.5154665639840842" WEIGHT="17.10800505930877"/>
<DICH_DATA CI_END="5.397508324948299" CI_START="0.20038875993958943" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7321933208490327" LOG_CI_START="-0.6981266422514719" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2013-02-22 06:07:13 +1300" MODIFIED_BY="[Empty name]" ORDER="5506" O_E="0.0" SE="0.8401770265232417" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" VAR="0.7058974358974359" WEIGHT="12.492756222202127"/>
<DICH_DATA CI_END="3.649935867013385" CI_START="0.2739774167095887" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5622852335395179" LOG_CI_START="-0.5622852335395179" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-19 00:38:36 +1300" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.6605782590758164" STUDY_ID="STD-Palomba-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.4363636363636364" WEIGHT="20.209302172913837"/>
<DICH_DATA CI_END="1.7225485665283684" CI_START="0.22902609510393024" EFFECT_SIZE="0.628099173553719" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.2361714755015388" LOG_CI_START="-0.6401150315728563" LOG_EFFECT_SIZE="-0.20197177803565872" ORDER="5507" O_E="0.0" SE="0.514735031943667" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.26495215311004783" WEIGHT="33.28376267575155"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.0284419571043575" CI_END="10.72383860958316" CI_START="1.8761107354884614" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="4.485432949123709" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="22" I2="57.316286905270715" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.030350269363911" LOG_CI_START="0.2732584685805068" LOG_EFFECT_SIZE="0.6518043689722088" METHOD="MH" MODIFIED="2014-10-31 16:21:23 +1300" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.07099682175038813" P_Q="1.0" P_Z="7.387191800566134E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4455927806042293" TOTALS="YES" TOTAL_1="216" TOTAL_2="215" WEIGHT="100.0" Z="3.3747904463619176">
<NAME>Side effects per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.0284419571043575" CI_END="10.72383860958316" CI_START="1.8761107354884614" DF="3" EFFECT_SIZE="4.485432949123709" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="22" I2="57.316286905270715" ID="CMP-001.05.01" LOG_CI_END="1.030350269363911" LOG_CI_START="0.2732584685805068" LOG_EFFECT_SIZE="0.6518043689722088" MODIFIED="2014-10-31 16:21:23 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07099682175038813" P_Z="7.387191800566134E-4" STUDIES="4" TAU2="0.4455927806042293" TOTAL_1="216" TOTAL_2="215" WEIGHT="100.0" Z="3.3747904463619176">
<NAME>Long protocol GnRH agonist</NAME>
<DICH_DATA CI_END="22.91358888456098" CI_START="2.3219475795423534" EFFECT_SIZE="7.294117647058823" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="1.3600931167185435" LOG_CI_START="0.36585241084937875" LOG_EFFECT_SIZE="0.8629727637839611" MODIFIED="2014-07-05 01:30:11 +1200" MODIFIED_BY="[Empty name]" ORDER="5546" O_E="0.0" SE="0.5840219121984155" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="37" TOTAL_2="36" VAR="0.3410815939278937" WEIGHT="25.14069539890272"/>
<DICH_DATA CI_END="11.545887312069919" CI_START="2.165273168209889" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" LOG_CI_END="1.0624273144665237" LOG_CI_START="0.3355126942055137" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2014-06-27 08:13:17 +1200" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.42699324622672" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="74" TOTAL_2="75" VAR="0.18232323232323233" WEIGHT="31.49711174911408"/>
<DICH_DATA CI_END="3.5932386732632566" CI_START="0.16286839066788697" EFFECT_SIZE="0.765" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5554860652532494" LOG_CI_START="-0.7881631949460142" LOG_EFFECT_SIZE="-0.11633856484638239" MODIFIED="2013-08-08 02:01:44 +1200" MODIFIED_BY="[Empty name]" ORDER="5547" O_E="0.0" SE="0.7892662266121541" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" VAR="0.6229411764705882" WEIGHT="18.509042878128785"/>
<DICH_DATA CI_END="28.457175411603778" CI_START="2.797518261875733" EFFECT_SIZE="8.922413793103448" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="1.4541917908982351" LOG_CI_START="0.4467729302338009" LOG_EFFECT_SIZE="0.9504823605660181" MODIFIED="2013-09-05 07:09:49 +1200" MODIFIED_BY="[Empty name]" ORDER="5548" O_E="0.0" SE="0.5917628255580752" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.35018324171247706" WEIGHT="24.853149973854418"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="10.906726283009823" CI_END="0.49572190728127274" CI_START="-2.0216273066807724" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7629526996997499" ESTIMABLE="YES" I2="35.8194217186472" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2014-10-09 10:26:29 +1300" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.1427398036594536" P_Q="0.8431914693167303" P_Z="0.23481640988141994" Q="0.03912997993976167" RANDOM="YES" SCALE="8.709321604678811" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.1344490514713772" TOTALS="YES" TOTAL_1="320" TOTAL_2="315" UNITS="" WEIGHT="100.0" Z="1.188043204355881">
<NAME>Number of oocytes retrieved per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours metformin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.906013617766376" CI_END="0.7893718484420192" CI_START="-2.124861072252563" DF="6" EFFECT_SIZE="-0.667744611905272" ESTIMABLE="YES" I2="44.98448094521232" ID="CMP-001.06.01" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0913250718148324" P_Z="0.36908867938195566" STUDIES="7" TAU2="1.6507464682206807" TOTAL_1="300" TOTAL_2="295" WEIGHT="87.88076205583967" Z="0.8981817348306383">
<NAME>Long protocol with GnRH agonist</NAME>
<CONT_DATA CI_END="6.184524026311639" CI_START="-5.164524026311639" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" MEAN_1="7.89" MEAN_2="7.38" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5515" SD_1="5.99" SD_2="5.93" SE="2.895218519866467" STUDY_ID="STD-Fedorcsak-2003" TOTAL_1="9" TOTAL_2="8" WEIGHT="4.333537763284531"/>
<CONT_DATA CI_END="4.4824516865414274" CI_START="-2.882451686541426" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="13.9" MEAN_2="13.1" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5516" SD_1="7.82" SD_2="6.8" SE="1.8788364049483233" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="30" TOTAL_2="31" WEIGHT="8.841540949410748"/>
<CONT_DATA CI_END="0.8715593255459337" CI_START="-4.071559325545933" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="13.2" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="69" SD_1="6.1" SD_2="7.2" SE="1.2610228274811568" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="56" TOTAL_2="56" WEIGHT="15.136435129708268"/>
<CONT_DATA CI_END="4.24968408388855" CI_START="-1.3696840838885476" EFFECT_SIZE="1.4400000000000013" ESTIMABLE="YES" MEAN_1="19.51" MEAN_2="18.07" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5517" SD_1="9.03" SD_2="5.33" SE="1.4335386293069559" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" WEIGHT="12.930359405983133"/>
<CONT_DATA CI_END="-1.1382555877747833" CI_START="-4.661744412225221" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" MEAN_1="14.2" MEAN_2="17.1" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="3.1" SD_2="4.1" SE="0.8988657067791214" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" WEIGHT="21.231963783549574"/>
<CONT_DATA CI_END="4.012152699538655" CI_START="-1.812152699538652" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="17.3" MEAN_2="16.2" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5518" SD_1="7.4" SD_2="7.0" SE="1.4858194959240794" STUDY_ID="STD-Tang-2006" TOTAL_1="47" TOTAL_2="47" WEIGHT="12.33985901791073"/>
<CONT_DATA CI_END="1.266779941984935" CI_START="-4.306779941984934" EFFECT_SIZE="-1.5199999999999996" ESTIMABLE="YES" MEAN_1="14.7" MEAN_2="16.22" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5519" SD_1="8.01" SD_2="8.59" SE="1.4218526278884198" STUDY_ID="STD-Visnova-2003" TOTAL_1="71" TOTAL_2="66" WEIGHT="13.067066005992697"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.9520076786391711" CI_START="-3.952007678639171" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5067269819746715" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.119237944160325" Z="0.66394271218277">
<NAME>Short protocol with GnRH antagonist</NAME>
<CONT_DATA CI_END="1.9520076786391711" CI_START="-3.952007678639171" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" MODIFIED="2014-10-08 12:33:24 +1300" MODIFIED_BY="[Empty name]" ORDER="5520" SD_1="4.4" SD_2="5.1" SE="1.5061540425866142" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.119237944160325"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-10-16 10:36:54 +1300" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="325" TOTAL_2="318" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean total dose of FSH (IU) per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="6" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2014-10-08 14:40:28 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="7" TAU2="0.0" TOTAL_1="305" TOTAL_2="298" WEIGHT="0.0" Z="0.0">
<NAME>Long protocol with GnRH agonist</NAME>
<CONT_DATA CI_END="2667.04826999303" CI_START="-468.2282699930299" EFFECT_SIZE="1099.4099999999999" ESTIMABLE="YES" MEAN_1="3641.66" MEAN_2="2542.25" MODIFIED="2014-10-08 14:38:46 +1300" MODIFIED_BY="[Empty name]" ORDER="5521" SD_1="1964.41" SD_2="1299.11" SE="799.8301409405277" STUDY_ID="STD-Fedorcsak-2003" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0"/>
<CONT_DATA CI_END="372.018927305029" CI_START="-784.018927305029" EFFECT_SIZE="-206.0" ESTIMABLE="YES" MEAN_1="1833.0" MEAN_2="2039.0" MODIFIED="2014-10-08 14:33:05 +1300" MODIFIED_BY="[Empty name]" ORDER="5522" SD_1="762.9" SD_2="1470.49" SE="294.91303506817906" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="30" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="248.98930301706466" CI_START="-206.98930301706466" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="1553.0" MEAN_2="1532.0" MODIFIED="2014-10-08 14:33:05 +1300" MODIFIED_BY="[Empty name]" ORDER="71" SD_1="579.0" SD_2="650.0" SE="116.32321043417899" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="56" TOTAL_2="56" WEIGHT="0.0"/>
<CONT_DATA CI_END="153.34855283936287" CI_START="-587.2285528393629" EFFECT_SIZE="-216.94000000000005" ESTIMABLE="YES" MEAN_1="2067.15" MEAN_2="2284.09" MODIFIED="2014-10-08 14:38:57 +1300" MODIFIED_BY="[Empty name]" ORDER="5523" SD_1="1014.79" SD_2="945.76" SE="188.9262026037987" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" WEIGHT="0.0"/>
<CONT_DATA CI_END="2972.0497540822344" CI_START="2270.9762459177655" EFFECT_SIZE="2621.513" ESTIMABLE="YES" MEAN_1="2625.0" MEAN_2="3.487" MODIFIED="2014-10-08 14:40:28 +1300" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="645.0" SD_2="795.0" SE="178.84856907944416" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="307.04957446230674" CI_START="-158.4495744623064" EFFECT_SIZE="74.30000000000018" ESTIMABLE="YES" MEAN_1="1555.9" MEAN_2="1481.6" MODIFIED="2014-10-08 14:38:40 +1300" MODIFIED_BY="[Empty name]" ORDER="5524" SD_1="697.9" SD_2="481.7" SE="118.75196498415559" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" WEIGHT="0.0"/>
<CONT_DATA CI_END="-156.57010003285487" CI_START="-533.4298999671452" EFFECT_SIZE="-345.0" ESTIMABLE="YES" MEAN_1="1850.0" MEAN_2="2195.0" MODIFIED="2014-10-08 14:38:42 +1300" MODIFIED_BY="[Empty name]" ORDER="5525" SD_1="692.1" SD_2="405.9" SE="96.13947065020385" STUDY_ID="STD-Visnova-2003" TOTAL_1="71" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" MODIFIED="2014-10-08 14:33:05 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Short protocol with GnRH antagonist</NAME>
<CONT_DATA CI_END="278.90776453705274" CI_START="-278.90776453705274" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1350.0" MEAN_2="1350.0" MODIFIED="2014-10-08 14:33:05 +1300" MODIFIED_BY="[Empty name]" ORDER="5526" SD_1="450.0" SD_2="450.0" SE="142.30249470757707" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.739045700910255" CI_END="0.39980521547475356" CI_START="-0.7744502807025435" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18732253261389498" ESTIMABLE="YES" I2="55.524622438861336" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-10-09 10:34:17 +1300" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0276104331094964" P_Q="0.7693422925126484" P_Z="0.5317580487816838" Q="0.0859869599213122" RANDOM="YES" SCALE="10.94" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.3309037475089698" TOTALS="YES" TOTAL_1="325" TOTAL_2="318" UNITS="" WEIGHT="100.00000000000003" Z="0.6253245884073423">
<NAME>Mean days of gonadotrophin per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.708001823803498" CI_END="0.4496643678725223" CI_START="-0.887504439097788" DF="6" EFFECT_SIZE="-0.21892003561263287" ESTIMABLE="YES" I2="61.80290741431061" ID="CMP-001.08.01" MODIFIED="2014-10-09 10:34:17 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01541009595669418" P_Z="0.5210245040570014" STUDIES="7" TAU2="0.4104595105793629" TOTAL_1="305" TOTAL_2="298" WEIGHT="88.37465418785833" Z="0.6417669677281269">
<NAME>Long protocol with GnRH agonist</NAME>
<CONT_DATA CI_END="10.297584874713715" CI_START="-0.9175848747137128" EFFECT_SIZE="4.690000000000001" ESTIMABLE="YES" MEAN_1="18.44" MEAN_2="13.75" MODIFIED="2013-09-07 10:43:58 +1200" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="7.4" SD_2="4.1" SE="2.8610652639260863" STUDY_ID="STD-Fedorcsak-2003" TOTAL_1="9" TOTAL_2="8" WEIGHT="1.0536657707954682"/>
<CONT_DATA CI_END="1.4506221549929654" CI_START="-0.850622154992964" EFFECT_SIZE="0.3000000000000007" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="12.1" MODIFIED="2013-08-08 03:03:53 +1200" MODIFIED_BY="[Empty name]" ORDER="47" SD_1="2.9" SD_2="3.3" SE="0.5870629073130554" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="56" TOTAL_2="56" WEIGHT="13.283536526846815"/>
<CONT_DATA CI_END="2.2213616326658903" CI_START="-1.8213616326658881" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="14.4" MEAN_2="14.2" MODIFIED="2013-08-08 03:05:08 +1200" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="3.63" SD_2="4.47" SE="1.0313259062973257" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="30" TOTAL_2="32" WEIGHT="6.434858895007215"/>
<CONT_DATA CI_END="0.5463597312225411" CI_START="-0.4463597312225397" EFFECT_SIZE="0.05000000000000071" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="9.35" MODIFIED="2013-09-07 10:43:59 +1200" MODIFIED_BY="[Empty name]" ORDER="5527" SD_1="1.45" SD_2="1.16" SE="0.2532494143452444" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" WEIGHT="22.715852598480886"/>
<CONT_DATA CI_END="-1.193638246744825" CI_START="-4.606361753255175" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="15.1" MODIFIED="2014-10-09 10:34:17 +1300" MODIFIED_BY="[Empty name]" ORDER="5528" SD_1="3.1" SD_2="3.9" SE="0.8706087288923363" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" WEIGHT="8.241298927323445"/>
<CONT_DATA CI_END="1.046404667978401" CI_START="-0.6464046679784025" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="12.4" MODIFIED="2013-08-08 03:04:52 +1200" MODIFIED_BY="[Empty name]" ORDER="5530" SD_1="2.23" SD_2="2.11" SE="0.4318470516064243" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" WEIGHT="17.343880757914928"/>
<CONT_DATA CI_END="0.2175034679873754" CI_START="-1.2175034679873753" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="10.85" MEAN_2="11.35" MODIFIED="2013-08-08 03:04:49 +1200" MODIFIED_BY="[Empty name]" ORDER="5531" SD_1="2.32" SD_2="1.96" SE="0.36607992475726653" STUDY_ID="STD-Visnova-2003" TOTAL_1="71" TOTAL_2="66" WEIGHT="19.301560711489575"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3015695678395796" CI_START="-1.3015695678395796" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2014-01-31 01:35:10 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.625345812141699" Z="0.0">
<NAME>Short protocol with GnRH antagonist</NAME>
<CONT_DATA CI_END="1.3015695678395796" CI_START="-1.3015695678395796" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="9.9" MEAN_2="9.9" MODIFIED="2013-09-07 10:44:02 +1200" MODIFIED_BY="[Empty name]" ORDER="5532" SD_1="2.1" SD_2="2.1" SE="0.6640783086353597" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.625345812141699"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.860331708719921" CI_END="1.2763105664470542" CI_START="0.3166654197046913" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6357384849114365" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="50" I2="27.117226800495963" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.1059563647322813" LOG_CI_START="-0.49939935958798715" LOG_EFFECT_SIZE="-0.19672149742785291" METHOD="MH" MODIFIED="2014-10-09 10:26:29 +1300" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.23123664012483292" P_Q="0.5252884489985553" P_Z="0.2027156051616571" Q="0.4034976406289422" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.20357712584299884" TOTALS="YES" TOTAL_1="315" TOTAL_2="309" WEIGHT="99.99999999999999" Z="1.2738528255475559">
<NAME>Cycle cancellation rate (after ovulation induction)</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.300448596333214" CI_END="1.449105602826307" CI_START="0.30645038883189696" DF="4" EFFECT_SIZE="0.6663925085447782" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="47" I2="36.51245718712867" ID="CMP-001.09.01" LOG_CI_END="0.16110003561167607" LOG_CI_START="-0.5136398232678506" LOG_EFFECT_SIZE="-0.17626989382808725" MODIFIED="2014-07-03 06:36:57 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17780628790494513" P_Z="0.30581311920743715" STUDIES="5" TAU2="0.2803626350099627" TOTAL_1="295" TOTAL_2="289" WEIGHT="92.32915906768935" Z="1.0240469387282347">
<NAME>Long protocol with GnRH agonist</NAME>
<DICH_DATA CI_END="2.6671588247052105" CI_START="0.07835288618773284" EFFECT_SIZE="0.45714285714285713" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4260488779468317" LOG_CI_START="-1.1059450013355336" LOG_EFFECT_SIZE="-0.3399480616943509" MODIFIED="2014-06-27 08:13:40 +1200" MODIFIED_BY="[Empty name]" ORDER="5533" O_E="0.0" SE="0.8999007881824688" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="37" TOTAL_2="36" VAR="0.8098214285714286" WEIGHT="12.4771739724543"/>
<DICH_DATA CI_END="1.8835226153111289" CI_START="0.49232096312537954" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.2749708391110227" LOG_CI_START="-0.3077516714873615" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2014-07-03 06:36:57 +1200" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.3422940872484393" STUDY_ID="STD-Kjotrod-2011" TOTAL_1="74" TOTAL_2="75" VAR="0.11716524216524216" WEIGHT="39.42213853873409"/>
<DICH_DATA CI_END="0.8886652067114865" CI_START="0.06185309147685489" EFFECT_SIZE="0.23444976076555024" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.05126182312756779" LOG_CI_START="-1.2086385890375129" LOG_EFFECT_SIZE="-0.6299502060825404" MODIFIED="2012-12-19 00:43:08 +1300" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.6798488414028909" STUDY_ID="STD-Palomba-2011" TOTAL_1="60" TOTAL_2="60" VAR="0.4621944471568532" WEIGHT="18.992024561651448"/>
<DICH_DATA CI_END="13.534224274629604" CI_START="0.46179225888223624" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1314333688688223" LOG_CI_START="-0.335553351524747" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="5534" O_E="0.0" SE="0.8617152612605637" STUDY_ID="STD-Tang-2006" TOTAL_1="52" TOTAL_2="49" VAR="0.7425531914893617" WEIGHT="13.364279566173915"/>
<DICH_DATA CI_END="3.053265885416577" CI_START="0.03144590071642983" EFFECT_SIZE="0.30985915492957744" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48476462530792597" LOG_CI_START="-1.502435961101664" LOG_EFFECT_SIZE="-0.5088356678968691" ORDER="5535" O_E="0.0" SE="1.1672914612585419" STUDY_ID="STD-Visnova-2003" TOTAL_1="72" TOTAL_2="69" VAR="1.362569355527102" WEIGHT="8.0735424286756"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1456674740237" CI_START="0.028277129425058976" DF="0" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" MODIFIED="2014-01-31 01:35:25 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.31416255039697194" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.670840932310642" Z="1.0065261546371438">
<NAME>Short protocol with GnRH antagonist</NAME>
<DICH_DATA CI_END="3.1456674740237" CI_START="0.028277129425058976" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="5536" O_E="0.0" SE="1.201993528140841" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" VAR="1.4447884416924663" WEIGHT="7.670840932310642"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2014-10-16 10:37:52 +1300" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="16.11" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="209" TOTAL_2="203" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum oestradiol level (nmol/ l) per woman</NAME>
<GROUP_LABEL_1>Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="3" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2014-10-09 10:40:12 +1300" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="189" TOTAL_2="183" WEIGHT="0.0" Z="0.0">
<NAME>Long protocol with GnRH agonist</NAME>
<CONT_DATA CI_END="1.670771227993007" CI_START="-3.2707712279930066" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="7.6" MODIFIED="2014-10-08 13:06:31 +1300" MODIFIED_BY="[Empty name]" ORDER="5549" SD_1="4.12" SD_2="5.59" SE="1.2606207295042842" STUDY_ID="STD-Kjotrod-2004" TOTAL_1="31" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.3895696930037786" CI_START="-2.289569693003777" EFFECT_SIZE="0.05000000000000071" ESTIMABLE="YES" MEAN_1="14.55" MEAN_2="14.5" MODIFIED="2014-10-08 13:06:31 +1300" MODIFIED_BY="[Empty name]" ORDER="5550" SD_1="7.04" SD_2="5.19" SE="1.1936799407836087" STUDY_ID="STD-Onalan-2005" TOTAL_1="53" TOTAL_2="55" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.17737352872830914" CI_START="-0.8426264712716922" EFFECT_SIZE="-0.5100000000000007" ESTIMABLE="YES" MEAN_1="6.89" MEAN_2="7.4" MODIFIED="2014-10-09 10:40:12 +1300" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="0.46" SD_2="0.85" SE="0.1697105017721788" STUDY_ID="STD-Qublan-2009" TOTAL_1="34" TOTAL_2="32" WEIGHT="0.0"/>
<CONT_DATA CI_END="-6.982789346607637" CI_START="-13.277210653392364" EFFECT_SIZE="-10.13" ESTIMABLE="YES" MEAN_1="12.56" MEAN_2="22.69" MODIFIED="2014-10-08 13:11:28 +1300" MODIFIED_BY="[Empty name]" ORDER="5551" SD_1="6.21" SD_2="11.59" SE="1.6057492271374167" STUDY_ID="STD-Visnova-2003" TOTAL_1="71" TOTAL_2="66" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.02" MODIFIED="2014-10-08 13:06:31 +1300" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Short protocol with GnRH antagonist</NAME>
<CONT_DATA CI_END="-1.8218091697181422" CI_START="-5.298190830281856" EFFECT_SIZE="-3.5599999999999987" ESTIMABLE="YES" MEAN_1="8.81" MEAN_2="12.37" MODIFIED="2014-10-08 13:06:31 +1300" MODIFIED_BY="[Empty name]" ORDER="5552" SD_1="2.2" SD_2="3.3" SE="0.8868483523128404" STUDY_ID="STD-Doldi-2006" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-001.11" MODIFIED="2014-10-09 10:26:29 +1300" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mean or median serum androgen levels per woman</NAME>
<TR>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Metformin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-01-31 01:36:56 +1300" MODIFIED_BY="[Empty name]" ORDER="67" STUDY_ID="STD-Onalan-2005">
<TR>
<TD>
<P>No significant differences in total testosterone measures from women treated with placebo (P = 0.646)</P>
</TD>
<TD>
<P>Median 3.1; range 2.5 to 3.9</P>
</TD>
<TD>
<P>Median 3.1; range 2.4 to 3</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-31 01:37:26 +1300" MODIFIED_BY="[Empty name]" ORDER="68" STUDY_ID="STD-Tang-2006">
<TR>
<TD>
<P>Testosterone levels did not change significantly in the group taking metformin (P = 0.892); however, participants in the placebo group had a significant increase in testosterone levels (P = 0.040). In the metformin group, on the day of hCG administration, there was a significant decrease in testosterone concentration (P = 0.029) and in the free-androgen index (P = 0.004)</P>
</TD>
<TD>
<P>Baseline geometric mean: 2.03 nmol/l, geometric mean on the day of hCG administration: 1.97 nmol/l. Testosterone concentration (geometric mean: 1.96 nmol/l). Free-androgen index (geometric mean: 2.43)</P>
</TD>
<TD>
<P>Baseline geometric mean: 2.06 nmol/l, geometric mean on the day of hCG administration: 2.52 nmol/l. Testosterone concentration (geometric mean: 2.52 nmol/l). Free-androgen index (geometric mean: 3.34)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="3" ID="CMP-001.12" MODIFIED="2014-10-09 10:26:29 +1300" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Mean or median fasting insulin and glucose levels per woman</NAME>
<TR>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Metformin</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2014-03-27 04:13:39 +1300" MODIFIED_BY="[Empty name]" ORDER="69" STUDY_ID="STD-Onalan-2005">
<TR>
<TD>
<P>There were no significant changes in the glucose/insulin ratio between groups (P = 0.81)</P>
</TD>
<TD>
<P>Median 6; range 2.4 to 8.8</P>
</TD>
<TD>
<P>Median 6; range 3 to 10</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2014-01-31 02:41:42 +1300" MODIFIED_BY="[Empty name]" ORDER="70" STUDY_ID="STD-Tang-2006">
<TR>
<TD>
<P>There were no significant changes in the insulin sensitivity test (QUICKI) between baseline and the day of oocyte retrieval in the metformin group (P = 0.200) and the placebo group (P = 0.572).</P>
</TD>
<TD>
<P>Baseline: 0.377</P>
<P>At the day of oocyte retrieval: 0.417</P>
</TD>
<TD>
<P>Baseline: 0.386</P>
<P>At the day of oocyte retrieval: 0.400</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-04-10 11:53:49 +1200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-10-24 06:04:58 +1300" MODIFIED_BY="Helen E Nagels" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAa8AAANgCAYAAACbSudJAABfw0lEQVR42u29D2TX3f///yZJJonk
MplLZJJMRpJkEpPk8pGRueTy8RHJZDJxmczMRJKZycVkLpnLSJIkY2Yuk8vITHKZMZMkiZkkyfm5
n+/7vH7P13Ov5znP5+vP9vpzu/GyvV7P5/P8eZ7Hedxf5zzP6zz+YyL85z//4dVAr2qDNsH+AFL7
i6jjgAZr/Cpqc+wP+wPILF4YEQ4EJwa0PdSY7WA8GMF/GjJvwP4A8QKcB44LsAFAvADxAuwPAPEC
xAuwP0C8AOeB4wJsABAvQLwA+wNAvADxqgxLS0sYDeIF1S5eX79+NYcPH970+YcPH8z//M//mF27
dpndu3ebrq4u8/Hjx9zx9fX1uvhVfSN0rGoUr8+fP5uLFy9a22pqajKXL1/Os6+tqHf0ePR/2fx2
3b96tEfEC8ouXt+/fzeXLl0qaFxnz541f/31l/nx44d96f9z587ljj979swKGh2LOhaT9+DgoBkY
GMjZ159//mn6+/u3TbwYqVInqCHx6ujoMGtrawWNa+fOnd7PhoaGzMjISCYDfvXqlTlw4IBpb2/P
c2J79+613757e3vzrvn27Zu5cuWK/Xbe2tpq5ufn847funXLXqfjqsu7d++8+clJXr9+3ezZs8c0
NzebycnJvLo/f/7c1nHHjh3m2LFjZnZ2FudRobz1RejNmzd5X6TOnz+fmM7KykpupKY2kj08efIk
dzzUtqHj7v9CMwnxOoTs7uHDh6alpcXakcr64sWL1PVAvABSiNf09HSicbmRl2NqasqcOXMm914j
NjkgCY8cgjp0yIB7enqsE3n//r397MGDB7aj6zM5LzmUO3fu5K65ffu2zdeN9I4cOZI7du/ePTM6
Opr75q60JHS+/O7fv2+Gh4ftZ5qiOn36dF7do47m5cuX5tChQziPCuUtm1E7xD9Loq2tzTx69CjX
3mp7fTFxhNo2dDzp//j7NHYncXKCJnuKfukL1QPxAkghXj7jevv2rdm3b1/uG6j+12eOn376yU71
uG+1f/zxhxUbXx7Rb6ji+PHjmxxYVDAkVvHjjqNHj9qRWXSUtn//fm9+GoFFr1lYWMiru5yIE0uc
R2XzDo3s06CRTdq2DR1PK17F2F3o/kfrgXgBlChe+vaob5nuG+Ldu3ftaCsJnSNBy5KHnFV8miba
kX3OLHpeofPTTIWqzNHzNNrSe4mqnsfgPCqXd6j9CqFpYH1B6u7utiISHzX72jZ0PK14FWN38c98
9UC8AEoUL624io569L/m6dN+g0yTh+/8kDMrdCzkBELXOMeiKcrOzk7T19eH86hQ3oWmCH3ThhMT
E3YkPj4+bqe7NRXsE6d43lnsxSdexdhd9LNQPRAvgBLFKy5UEi89pHZoqmRjYyNv+kQPn7PkoUUR
WnKfhJbwJ00b6tr49E10iXOh/E6ePJl3jRYMJN2fxcXFuul01She+nLw5cuX3Hv9ZEOLH5KQsEVt
ZXV1NS/tUNuGjqcVr2LsLvpZqB6IF0CJ4qXFDvp2qIUUEhA98NZqLcfNmzftSkE3raiFFmNjY5ny
0LSke4iul95HHZimVjSVJ2ZmZjYt2NBqR3et8o7+Xq1QfnpQrlWS7qG9FqVEz1P6WnEo4g/acR7l
zVu2E2172Zpvqlar99yqPAnPiRMn8tIOtW3oePR/fXHTcysnUvEFG1ntLvpZqB6IF0CJ4qVvwhIw
favUS8Klz6LHr169ao9pMYccUTEGrN/26Nuo0tFzNrcy0OWh35JJRPRsQA/Zo7gly3ppxdfy8nIw
Pz2706hRqyS1Uix6nqYMlY9b4uyEDOdR/rzVzhIQZ18XLlywP1xOYm5uzi7mUbvoS4YW1sTT9rVt
6Hj0f30Rc+UqVIesdhf9LFQPxAsgg3hB3RsBjguwAUC8AOeB4wJsABAvQLwA+wNAvADxAuwPEC/A
eeC4ABsAxAsQL8D+ABAvQLwA+wPEC3AeOC7ABqDBxatawqo3anh3xKu+qDU7xgagrOJVbJTZYvCF
VXcBILWTezny9V2/neHdt7OjI16VL28j9ifEC6py5FVOg/OlFY80W8m8fBuuIl6IVyXLW4/9CfGC
bR95hUKkC22kqj3htJ9bb2/vprSSQp/7wqqnCbnuyzdNuaNlLJSXNllNCtmu49rvUEEqFczQEQoD
H+q8qpPKrD0hFUk3vredr0z1Il5J99bX3tooV3sJ6r4rgsH8/Hze8VC7xPML2Y8bxagdtJv87Oxs
qno2Qn9CvKAqxCsUIl2bmKoz6bh2mZdRa/PSaFq+0Oe+EY/vWCjfULnTjLy0Iayv3NqcWOm7DYPT
hIH35av6KE6YK/OpU6c23Q9fmepJvOL3NtTeijLgIl0r5lo8ykCoXeL5hewnKhqKbhCN8k1/Qryg
CsQrFCJd8+fxuFrRjhwKfV5sZwvlGyp3GvEKlTt+PE0YeF++iiv14cOHxDIXE0a+VsUrXs9Qe0us
kuK7pWmXeH4h+9EozYlllno2Sn9CvGDbxStNCPX4lEQ0CnLIYRfb2UL5hsqdRryylFuUGgY+/rDd
F46+3sWr0H3M0t6ltkvIfjTa0ns5fV+ssUbtT4gXVJ14xY8XcgyliEDaY6F8Q+WuhHiVGgY+5CAa
WbyKae9S2iWN/eg5maYoFflZ073FiFe99ifEC7ZdvEIh0vWwOhq6fKs6WyjfULkrIV5Zw8DHw7wr
cq6eJzhev36NeKVsb0UsTpo2zNouWe1ncXExtW01Sn9CvGDbxSsUIl0Pw6Mh2/Veq7nSdjZfWHVf
ZwvlGyp3HF850opXKAx89CH/2tqaffDuW7Ch+iBe6dpbCzY0lSdmZmY2LdjwtUuh/EL2o/RdNO3Q
wplG7E+IF2y7eIlQCPX+/n67hFbfZuWQ3YqtNJ3NF1Y9NBry5Zum3FFC4d3TiJfwhYF3Tk5TNHKe
cn7xdOQgVF4tR1aZQyOERhGvUHt//frVdHV12furBRpaUJC2XZLy89mPpgyVj1uu7oSM/oR4wTaK
F1QHcsgHDx7cFgHZTvGChnJC3ARAvGodfavVAgD3WxuNFnwLARAvQLwA8YJtZ3p62v6eRtM22mHj
5s2bVsQQL0C8ABAvQLwA+wPEC3AeOC7ABgDxAsQLsD8AxAsQL8D+APECnAeOC7ABqD/xqrVQ5DiP
6sq7Ee2nUfsM4gUVF68s58Z3R8eAcR5Z8vaFsq/X+1YLdUa8oO7FK6tBYsCIl+/zRhCvWqgz4gVV
L16hkN8rKyt27zNtAqp93RR2/cmTJzljjIcb953vrtFmoi6M+/nz5/P2pgtdHwrJ7gtvjhFUl3gl
havXxrotLS25vQTdBsfuuPYaVIBI/cjb4fYzlN1ok9loEMc0+0TKbtQH9INxRWKO7xPoK1MhkspT
TJ1Ddp10T7A/qGvxCoX8bmtrs7tMux2o1bHVSZIMMs35Loqwjj9+/Nj89ttvqa/3hWQPhTfHCGpj
5HXhwoWcs4/v4q7jPT09to3dZrLaFV124mxGdqAvR2nFK77D/6lTpzaJl69McbKWJ5R+yK4L3RPs
D+pevIoJ+R2K9ho6PzrSUodThNq01/tCsofCm2MEtSFe0VFT/JxCx7XjezyGl/aOTCte7stUUh8I
lSlO1vKE0g/ZdaHrsT+oe/FKE/JbUxKKodTd3W07ZihcSNbz42XwXe8LyR4Kb44R1OYzr5D9FGrj
+GjNl2Z8AUWpUa2zlidN1G2fXdeKKCBeUFHxihvZxMSEDcY3Pj5uN5PVtISvY2c9P+48Qtc7cSsU
kh2hakzxCtlwGnEop3hlLU8o/ZBdI17QkOIVCvmth9jRkOHxcPbxdNOc//bt27wplWgcq9D1UeIh
2UPhzTGC+hQvtXt8ms4X2DNuUydOnLDPuhyvX78uSbyylieUfsiuES9oSPEKhfzWCii32k/Cpo7u
C0UeOl//nzt3znz69MnmqcUi0QUboet9IdlD4c0xguoTL18o+7TipXbWaj3X7mNjYzZ6dXQk5Bb5
rK2t2dWsvgUbsplSxCtUnqx1Dtk14gUNKV7CF/J7bm7OPhyWA5BwaLGELxR56Hz9rzyUl66RkEUf
NoeuD4VkD4U3R7yqK29fKPu04iXc0nS9tLJveXk5d8x9yZHNSERkM/F09AVONqmfi8g+fSOlNPfS
V56sdQ7ZNeIFDStegHjhuP5/vn79mjeVDYgXIF6AeFUdmnXQAiD3OyqNmqILgQDxAsQLEK+qQ6ta
9XtHTclph42bN29aEQPECxAvQLxoAOyPmwCIFyBegP0B4gU4DxwXYAOAeAHOA8cF2AAgXoB4AfYH
iBfgPHBcgA0A4rUFxo3xI16A/QHihXHjPGhbwAagNsVL+7y5fd+0e/Xs7GzecV/48ZWVFbvPmjYa
VRqtra25TXWdscbDk2szUu31pmt0/vz8fN75oRDw0f+1oWoodHpSaHecR3XkHbI/t0eg7EWb0Ub3
wUyzD2IW+wvZe6isgHjBFopX1Okr0GM0Qmso/HhbW5vdld7tdi2BkKOIGms8PLmCTLpIyNqSR5vv
Rs8PhYCP/i/hTDo3FNod51EdefvsT7uny6acfckeJTxZxCuL/YXs3VdWQLxgi8VLYuM6c5xQ+PFC
xCO8xsOTy1nE0/Sdn7SjeOjcUGh3nEd15O2zP0UPiMfF0j6EWcQri/2F7N1XVkC8YIvFS98gdUwd
d2BgYNO3Yl/4caFpGX2b7e7uts6mmKi3WZxR2nNDod1xHtWRt8/+CkUQThqJp7URn/2F7N1XVkC8
YIvFywmQplA6OzvzdtMOhR+fmJiw32THx8ft5qaamqkW8QqFdsd5VE/eSfZXyFay2EBW+wvZu6+s
gHjBNoiXY3FxMVP4cS2GiB6Ph1cvlKeCAfqmDcslXqHQ7jiP6su7kP3Fpw19QSJLtb+QvfvKCogX
bLF4aeTkohHHFz2Ewo9rpZ9bXfjmzRsrGCHnoSlGTb+ImZmZTQs2yiVeodDuOI/qyDtkf1p96uxv
bGzMik90FOUWUKytrdkFPKXYX8jefWUFxAu2WLw0DaJnVW65ueucDl/48bm5OftAW9epY+thdsh5
KEptV1eXvUb5aiFFJcRL+EK74zyqI++Q/bml8npppeHy8nLumBMQXStR07Wl2F/I3kNlBcQLtlC8
GgVCu/MjZUC8APGqegjtjngB9geIV81BaHfEC7A/QLwA54HjAmwAEC9AvAD7A0C8APEC7A8QL8B5
4LgAGwDECxAvwP4AEC9AvAD7A8QLcB44LsAGAPECnAeOC7ABQLwA8QLsDxAvwHnguAAbAMQLcB44
LsAGAPECxAuwP0C8uAsYAY4LsAGoLbvBeHAclAFoe6hJ8cKIcByUBWhzqEnxcsbEq3Fe1ejMeGF/
AJnFi2+AANgfAOKF8wDA/gAQL5wHYH8AgHjhPAD7A0C8cB4A2B8A4oXzAOwPABAvnAdgfwCIF84D
APsDQLxwHoD9AQDihfMA7A8A8cJ5AGB/AIgXzgOwP24CAOKF8wDsDwDxwnkAYH8AiBfOAwD7A0C8
cB6A/QEgXjgPAOwPAPHCeQBgfwCIF84DsD8AxIubgPMA7A8A8apF58GL13a+AADxAkYOAIB4ASBe
AIB4AeIFAIB4AeIFAIgXAOIFAIgXIF4AAIgXIF4AgHgBIF4AgHgB4gUAgHgB4gUAgHgB4gUAiBc0
qmixRx8AIF6AeAEAIF6wlQIGAIB4AeIFAIB4AeIFAIgXAOIFAIgX1LKAAQAgXoB4AQDUi3gVWprN
ixev//CzBUC8+HYPwIgYAPGiEwLQdwAaTbzofAD0IQDECwDxAkC86HgA9CEAxIuOB0AfAkC8ABAv
AMSLjgeAeAEgXnS8WmBpaYmbUKP3gT4EiFcVdryvX7+aw4cPZz5eaEeCHTt24Jj+y/Pnz83OnTvN
8ePH7ftdu3bVXH2iaZUr3a26D4gXQB2L1/fv382lS5cSzwkdj/L06VPT39+PY/ovEq4XL15suQOs
lHg1shAgXoB4VVnH6+joMGtra4nnhI47fvz4Ydra2szGxoa3HK9evTIHDhww7e3tuc8HBwfN3r17
TVNTk+nt7c275tu3b+bKlStm9+7dprW11czPz+cdv3Xrlr1Ox1XWd+/eefNTOa9fv2727Nljmpub
zeTkZF7d3GhJI8hjx46Z2dnZxPqsrKyYixcv2rx1jcr35MmTxFFpoT3zfHVPul/x++6rT6F2ix+f
mJgw+/fvt2Xo6emxI+3QyMvXLlnuS5r7kKVNEC+ABhGv6elp7zmh444HDx4ER11KQ85RDvf9+/e5
6x4+fGg/0yhPzvfOnTu5a27fvm2mpqbs/8+ePTNHjhzJHbt3754ZHR211+qltORQffndv3/fDA8P
288+fvxoTp8+nVe36Gjp5cuX5tChQ4n1kVg/evQol7/KIqFJuu/x96G6Fyp/nFB90oiXpjUl+kpD
InLjxo2gePnaJet9Cd2HLG2CeAE0iHilPSd0XA5rdXU1mEZ0ZCTkOOW0okSdk5xi/Ljj6NGjdgQQ
HQ1oBOHLTyOY6DULCwt5dZOTdU65GKLP/ELiFap7ofLHCdUnjXhFR01fvnwxBw8eDIqXr12y3pfQ
fSi1TRAvAMSrIG/fvjUnTpwoKg99q/Yt+tDxNA6x0PlJ+cWn3aLn6Zu9G40MDAwE66RpPY1Curu7
rZj6hCP+PlT3NO0Wqk8a8YoLR9I9jI9Qy3VfQvcha5sgXgCIV6rjIyMj9tlTMXmEVif6nGShYyHH
HbrGOV5NhXV2dpq+vr7E/PWsSCOQ8fFxO72qqb0s4hWqezHileYeZLlHxYhX1vuSZoVq2jZBvAAQ
r9THtRpRjqWYPPQAfn19PfEaLdFPmp7StfFpw+gy7EL5nTx5Mu+aN2/eJNZtcXHRW28tkoiWXdOm
WcQrVPc07RaqTzyNQmVUPR2fP3+29QqJl69dst6X0H3I0iaIFwDilfq4nk8kLSgIpaFFF27BgV56
r1WDDk09adpIzMzMbFqwoVGfu3ZsbCzv92iF8tNCgqGhodwCh7Nnz256lqPVbUKLBHwjjJaWltwq
OomGpk59Tlqr7/QMy4lNqO5p2i1Un+hiB60a1SrAeBmVp65VGr///rv9MhISL1+7hO5L1vuQpU0Q
LwDEK/VxOZM0D++T0tAqRX1b16hJzjUqhFq23dXVZfPQsxMtSIjilsrrpZWGy8vLwfzu3r1rF3Zo
abZWukXP0/SU8tFUlvJ0TrMQc3NzVrh1nhysFhX4xEsr6FTH6OjQV/e0DtNXH+fsVR8Ju+oTL6OE
5qeffrILI27evGlHXyHx8rVL6L5kvQ9Z2gTxAmgw8YIGNV5sg/sEiBcdD3DK3CcAxIuOBxWmFvcZ
pA8BIF4AQB8CxIuOB4B4ASBedDwA+hAA4gUA9CEAxAsA8QJAvOh4APQhAMSrgToeDgawLQDECwcD
gG0B4lV9HS8pzHwoNL1CXWgvvX379pm//vrLbqSqfemim8A63N6D2oxVm61qQ9aNjQ0b8DAabl5o
o1btMJ6mHNpL8fr16zbf5uZmG30XBwOIF0CDiFc8zHya0PS//fabPfb06VMrHlevXrXv4zt+S9QU
At7tFq60tXmuuHbtmj0eRSHtJVhpyqFz3U7k2hH99OnTOBhAvAAaRbziYeazhqbX+2gspmhe2gk8
Hm9LIzah6Msafbm89Pfnn3/OpR0qh0aK0bS1qzkOBhAvgAYRrzhZQ9P73heKkBsdmZ05c8aOroTi
UikURtpyxGM6SehwMIB4ATSoeGUNTe97HwpRr+jLra2t9n8961LI+LTlCKUNgHgBNJB4ZQ1N73uv
tOLThvFdzBV1V8+vNGWYpRwnT57MS1sRe3EwgHgBNKh4ZQ1N73uva0dGRnJpjY2N2Wi+UbQIQ6sF
o4sx0pRD04xDQ0O5BRtnz57FwQDiBdCo4iWyhKYPvXdL5fXSSsPl5eW8458+fbL5SICylEPcvXvX
LgDRcnqtTsTBAOIF0ADiBQD0IUC86HgAiBcA4kXHA6APASBeAEAfAkC8ABAvAMSLjgdAHwJAvOh4
APQhAMQLAPECQLzoeACIFwDiRccDoA8BIF4AQB8CxIuOB4B4ASBedDwA+hAA4gUA9CFAvOh4AIgX
AOJFxwOgDwE0gnjR+QDoOwA1KV50QgD6DEBNipfrjLx48Ur3AkC8APiGDwCIFyBeAACIFyBeAIB4
ASBeAIB4AeIFAIB4AeIFAIgXAOIFAIgXIF4AAIgXIF4AAIgXIF4AgHgB4gUAgHgB4gUAgHgB4gUA
iBcA4gUAiBcgXgAAiBcgXgCAeAEgXgCAeAHiBQCAeAHiBQCIFwDiBQCIFyBeAACIFyBeAIB4ASBe
AIB4AeIFAIB4AeIFAIB4AeIFAIgXIF4AAIgXIF4AAIgXIF4AgHgBIF4AgHgB4gUAgHgB4gUAiBdA
RLTiLwAAxAsQLwAAxAsqKWAAAIgXIF4AAIgXIF4AgHgBIF4AgHhBLQsYAADiBYgXAADitXVOnFfj
vAC7x+4RL0YfQJtzD4A2R7zowEDbU3eo37bH+ujAgA1QZ6g5G8AC6cSADVBnQLxoQMAGqDNgA4gX
DQjYAHUGbADxohMDNkCdAfGiAbkJ2AB1BmwA8aIBARugzoANIF7b2oBfv341hw8fzny80C/bd+zY
gYFTx6qu88bGhrly5YrZtWuX2b9/v+nt7TWfP3/GrrF7xKuWGvD79+/m0qVLieeEjkd5+vSp6e/v
x8CpY1XX+erVq+bOnTvmx48f9jUyMmJtHLvG7hGvGmrAjo4Os7a2lnhO6LhDTqCtrc1+q/WV49Wr
V+bAgQOmvb099/ng4KDZu3evaWpqst+Co3z79s1+S969e7dpbW018/Pzecdv3bplr9NxlfXdu3fe
/FTO69evmz179pjm5mYzOTmZV7fnz5+bnTt32m/ax44dM7Ozs3TiOquzRlyyg6jtyh6wa8QL8aqh
BpyenvaeEzruePDgQfDbqdLo6emxHe39+/e56x4+fGg/0yhPnU7fih23b982U1NT9v9nz56ZI0eO
5I7du3fPjI6O5r5BKy05BF9+9+/fN8PDw/azjx8/mtOnT+fVTR38xYsX9v+XL1+aQ4cO0YnrXLwk
JPoMu0a8EK8abMDQOaHj+na6uroaTCP6DVIcP348z5GIaMdSp44fdxw9etQ6nqgT0jMMX376phq9
ZmFhIa9u+jbrnAqduD7rLCHQVKHsSs9zb9y4kfhMC7vG7hGvOhavt2/fmhMnThSVh74R+h6O63gS
hRxO9Pyk/OLTQtHz9K1U7+V8BgYG6MR1WGctzrh8+bK1BS1EUpsXGnlh19g94lXn4qVvsZqjLyaP
0CouXycvdCyaR5pOXug8PU/QVE5nZ6fp6+ujE9d5nd+8eWOfE2HXiBfi1WDipZVa6hTF5KGHx+vr
64nX6Jtx0vSKro1Pr0S/QRfK7+TJk3nXyHEl1W1xcbFunD7ilczjx49Nd3c3do14IV6NJl6ay3cP
jrOmoYfT7kGzXnqv1VUOPdjWlIeYmZnZ9GDbPbvQa2xsLO/3aIXye/TokRkaGso92D579mzeeUpf
K7OEHnD7viHTiWuzzmpjCZZYWVmxIxE9I8KuES/Eq8HESx0h6VtkmjS0mktLfPXt8uLFi3kOQw/U
u7q6bB56kB13Mm5JsV56EL+8vBzM7+7du/YBuJYxayVX9DxNrSgfTfsoT9fh6cT1U2fZkBY4uGde
SQsZsGvsHvHCcQE2QJ0B8QI6MWAD1BkQLxoQsAHqDNgA4kUDAjZAnQHxAjoxYAPUGRAvGhCwAeoM
2ADiRQMCNkCdARtAvOjEgA2E6+SrF3YPiBcNCNhA1YpX/IXdA+JFA1LvOrsXSQ6/Xl+1YmvbfT0+
APGiAak396IBR16IF3aPeG1hA/pCg/vClBcT9jx0XGkq8mxLS0tu/zUX+TXN9aEw6NgAz7zS2JLi
fGmj3GgfOX/+fKo+4cs3+lkaW8XWES/wNKAvNLgvTHkxYc9Dx5WmNi91EWLjO1+Hrg+FQccGWG2Y
xpZkzwpA6aIsq08oKGWaPpFWvEK2iq0jXhBoQF9ocF+Y8mLCnoeOF0ozWu7Q9aEw6NgA4pXWliQe
EggJxo0bN1L3ibTiFbJVbB3xgkAD+kKD++L9FBv23Hc81OGzhlWPh0HHBhCvtLbkBEThRT59+pS5
T6SxZZ+tYuuIF6RowKTQ4FnFKxT2PHQ81OGLCatOh0a8irFFceHCBTvS2grxwtYRLyihAeOhwX1h
yosJex46HurwoeuzhEHHBhq7ziFbUuRiPXMaHx/PmzZM2yfi+a6uruZ9FrJVbB3xgkAD+kKD+8KU
FxP2PHQ8JF6h60Nh0LEBxCuNLWnBxqlTp/KE5N9//83UJ6ILodbW1uxCpOjxkK1i64gXBBrQFxrc
F6a8mLDnoeMh8UqTvi8MOjaAeKWxJdl8dKm8/tfxLH3CfRFUv9JoTf0qXpaQrWLriBcY5sMB8QLs
HvGiAQEboM6ADSBedGLABqgzIF5AJwZsALsHxIsGBGyAOgM2gHjRiQEboM6AeAGdGLAB6gyIFw0I
2AB1BmwA8aITAzZAnQHxAjoxYAPUGRAvGhCwAeoM2ADiRQMCNkCdAfGiCejEgA1QZ0C8aEDABqgz
YAOIFw0I2AB1BmwA8aITAzZAnQHxAjoybU/dgbZHvGhMoM25B0CbI15b2ai8GucF2D12j3gB38QA
ABAvQLwAAPECQLwAAPECxAsAAPECxAsAEC8AxAsAEC9AvAAAEC9AvAAA8QJAvAAA8QLECwAA8QLE
CwAA8QLECwAQL0C8AAAQL0C8AAAQL0C8AADxAkC8AADxAsQLAADxAsQLABAvAMQLABAvQLwAABAv
QLwAAPECQLwAAPECxAsAAPECxAsAEC8AxAsAEC9AvAAAEC9AvAAAv8MtAMQLABAvQLwAABAvQLwA
ABAvQLwAAPECxAszAgDECxAvAADECxAvAEC8ABAvAEC8APECAEC8APECAMQLAPECAMQLEC8AAMQL
EC8AQLwAEC/I0P68eFX6hXgB4gW0PdS8rWF5gAMD2h1qzuawPsCJAW0ONWd7WCDgyIA2B8QLcGRA
mwMgXoAjA9ocAPECHBnQ5oB4AcaEI6PNARAvwJEBbV55lpaWqiqdSqeJeAEgXrR5oM2/fv1qDh8+
vOnzz58/m4sXL5rdu3ebpqYmc/nyZfPx48fEdJ4/f2527txpjh8/nrlcoTLu2rWrLPeiXOn40kzb
xxqhLyJegHhBRdr8+/fv5tKlSwXPGRwcNAMDA+bHjx/29eeff5r+/v7EtCRcL168KKpcIbssl91W
wv6LTRPxAqDDQJFt3tHRYdbW1gqec+7cOfPmzZs8oTt//nxiHvG97QrucZcgWL4yJu2bJ3Hdu3ev
HRX29vbmPtcIcWZmJm9EqHKH9t8TKysrudGmxLi1tdU8efIkryyvXr0yBw4cMO3t7cF6f/v2zVy5
csWmp7Tm5+cT65xUn+iodseOHebYsWNmdnYW8QIcGTRum09PTyees2fPHjviin+WNp9yiVeh4w8e
PDAPHz605ZOoTk5Omjt37thj79+/NydOnLDHNCV66NAh8/bt21T5tLW1mUePHuVGm6Ojo1aoouXo
6emxx5RPqN63b982U1NT9v9nz56ZI0eOFDzPV5/4qPbly5e2TogX4Mig4du80DlymGk+2w7x0nO1
uLBGHbrE4P79+1YAbty4UZL9a7QTvf7du3ep6y2xipez0Hmh+khAnQjWou3hdQDxgi0Tr6jTrjbx
UjniU3bx8koQ9u/fbz59+pTpXmhaUCOm7u5uc/To0WA5ffVOe79C9dFoS5+pTnoOiXgBjgxoc5M8
bZjms3KKV9JzqXhahYQ1zoULF+zIJ4t4TUxM2GvGx8ftlKqmBrdCvNLUR6KqqcfOzk7T19eHeAGO
DGjzQufISX758iX3Xs+PtMCjWPFaXV0t28hLixbW19cTzx8bG7PPkCRCWaYNJc7RdH1lTlNv/QQh
zbRhqD5RFhcXa6YfI16AeMGWi5dWvw0PD+cWL0gIfFNWhab23CIDrWjUKr5ixUur9fSsSav3xL17
9/LKpvdOWDVaOnXqVJ4w/PvvvwXTidPS0pJbXaiVllr4ESpnPM34gg1N+QmtgExasOGrj9B1WnEo
dE99IzrECxAvaGjxkgicPXvW/ghXL03D6YfLadNwTlZTYhqByPkWK15aeOHK4dBvzjRS0mcSRrf6
r6urK2+pvP7X8aR0oszNzdmFEiq3BEOLJELljKcZPUejVZVH6en52cLCQmJaSfURmjLU9bqXSssJ
GeIFODKgzQEQL8CRAW0O2B7iBTgyoM0B8QIcGdDmAIgX4MiANgdAvABHBrQ5IF4AODLaHADxAhwZ
0OYAiBfgyIA2B8QLAEcGW93mpea13dcD4gU4MkC8EC9sD/ECxAvK3+ZJoecvX76ctz+g9tI7f/68
/T9taPvQDuzagPb69et2P7/m5mYbPTh+TVL50lyPrSNegHhBHba5L/S8NoXVjuo6ps1ltVnt27dv
7bG0oe1D4qVIx24n9Y8fP5rTp0/nHfeVL831gHgB4gV12Oah0PMSDwmEBCMaEyttaPuQeLW3t+eF
JtGO69HjofKFrgfECxAvqMM2D4WedwKyf//+vGjEaaMDh8Qrno6EKn7cV77Q9YB4AeIFddjmaULP
K4aXRlpbIV7x46Hyha4HxAsQL6jDNg+Fnh8bG7PPnBRBOTptmDa0fTzf1dXVvM9OnjyZN+2nyMXR
46Hyha4HxAsQL6jDNveFnteCjVOnTuUJyb///mv/TxvaXiMjRVMWa2trNjpw9PijR4/M0NBQbsGF
ojZHj/vKl+Z6QLwA8YI6bfOk0PMKXR9dKq//dVykDW0v4dI5mv7TaE3L7eNluXv3rn2mpuXwWiAS
P55UvjTXY+uIFyBeQJsDIF6AIwPaHBAvABwZ0OaAeAGODGhzAMQLcGRAmwPiBYAjA9ocEC/AkQFt
DoB4AY4MaHPA9hAvwJEBbQ6IF+DIgDYHQLwARwa0OQDiBTgyoM0B8QLAkdHmAIgX4MiANgdAvABH
BrQ5IF4AODKgzQHxAhwZ0OYAiBfgyIA2B8QLAEcGddTmS0tLNB7iBYB40eabuXXrltmzZ4/ZvXu3
6erqMh8+fKiacu/atStYr+hr586dti7Xrl0zGxsbeed++vTJ9Pb2mgMHDtjzjh49aiYnJ73pRV+A
eAHiBVXS5nfv3jWjo6Pmx48f9jU0NGQ6OjpqxlYLHZdo9fX1mevXr+d91t7ebh4+fGi+fftmP/vn
n3/Mzz//bCYmJugniBcgXlBLbX7o0CHz5cuXvM80KilnvhKMlpYWs2PHDpv2ixcvNo38mpqa7MhP
wvnu3buCo6As9ZIQK03H7du3zb179zadJwGTqGVJ+/nz57Yeqs+xY8fM7OwsBoZ4AeIF29Xm6+vr
ZnBw0HR3d3vTyTKlpmMXL17MCZKEKyqOEpToyO/BgwfmypUrJY28HFHxOnLkiFlbWyvLPYsK8MuX
L+0XAEC8APGCbWjzy5cvW2ev1+vXr8uarxOuQmXRcyc3jSf0//79+0sSL4nU/fv3TU9PT0mjyaS8
9cxsamoKo0K8APGCamlzTeFpKqyS+UY/09RboZFNFvGKv5qbm209vn//njtPU5LlumcabenY8ePH
zcDAAMaFeAHiBdvd5nL4vlFKMdOGvs8K5RU9nmXkpVWS58+fN4uLi5vOa2trMx8/fixY3ydPnmS+
Z69evTLPnj0znZ2ddnEIIF6AeMEWtrmmwKJOPT5tV+mRl0Z58WnD6PL4rNOGEiM9Y3v69Gne5xoh
aeFInD///NOcOnWq6H4ioaQ/IV6AeMEWt7mm1+TY3YKJ33//3b62Sry0YGNkZCSX/9jYmDl8+HDu
uKb79MwsKnCh9DUC0yKK1dXV3GefP3+2z9eUvlZXKq/Hjx+bffv2mbm5uUz3TIs/tOJQxBegAOIF
iBdsQZtrpKKFDRrtaLGGxKzS+cY/c0vl9dJKw+Xl5dyxO3fu2LIl/Vg5qV4zMzPmzJkzeZ9pIcev
v/5q89GzNi2R13lZ75mmDCWEbum/EzJAvADxAtocEC8AHBltTpsD4gU4MqDNARAvwJEBbQ6IFwCO
DGhzQLwARwa0OQDiBTgyoM0B8QLAkQFtDogX4MiANgdAvABHBrQ5IF4AODKgzQHxAhwZ0OYAiBfg
yIA2B0C8AEcGtDkgXoAxAW0OgHgBjgxocwDEC3BkQJsD4gWAI6PNARAvwJEBbV5hlpaWaLwavz+I
FyBeUPY2//Lli7l27Zppamoyu3btMl1dXebz589VY38qU73Zeqllil4fvz/VXF+8DiBeULY2v3Hj
hhkbGzM/fvywr1u3blkBqxb7q0dbLWedauH+IF6AeEHZ23zfvn1WtBzfv38vebQTRWlfv37d7Nmz
xzQ3N5vJycm8sqysrJiLFy+a3bt3m507d5rW1lbz5MmTXJmjr9D5oXrr/1evXpkDBw6Y9vb2xM/E
4OCg2bt3rx2R9vb2bkpXx1Un3b/R0dFN+YTKkab+vjIn3Z943r56PH/+3Oa5Y8cOc+zYMTM7O4t4
AeIFtdnm3759s47Sl06hVxL37983w8PDVsQ+fvxoTp8+nXd+W1ubefToUW7kJyGI5h9PO3R+SDR6
enrsde/fv0/87MGDB+bhw4f2M4m5BPfOnTu5dHSsr68vV6dTp04VLV5p6l+ozEl5Rd+H6iHhevHi
hf3/5cuX5tChQ4gXIF5Qm23+559/mtu3b5ctX40WJIiOhYWFYFk0EshS7uj5IdF49+7dpuPxz44f
P543GhVRx37y5Enz4cOHxDplEa809S9U5jTiFaqHRHJqamrLbA+vA4gXVKTNP336ZC5fvmy/pZcL
fbuPImcaL4umxSSY3d3d5ujRo0FH7zs/q2gU+kxljo8so4ISn1aN1ymreGWtf1rxCtVDoy19JpEb
GBhAvADxgtprcwnWr7/+aqfBQulkmTaMi1e8LBMTE+bIkSNmfHzcTE9P26kxn3MOnV8O8fKN5NII
chbByVr/LOIVqocTzmfPnpnOzk47FYp4AeIFNdPmGnFpufzq6mrZ89UUW3Ta8M2bN3ll0aKH9fX1
3HuVweecQ+eXQ7y0eCGaR5wTJ07kifzr16+9+fjqlLX+WcQrVI8oi4uLFfMLiBcgXlD2Nv/777/N
mTNn8p7hlBMtRhgaGsotbjh79mxeWVpaWnKr6yRsEoboca3C0zMfJ4Ch88shXvfu3cstMtFL7zs6
OnLH4ws2dCw+XecWQqytrdnVhEnlCNUnVOb4/YkeC9VDIz6tOBQqb6FRMuIFiBdUZZsfPHgw0zRg
Mdy9e9fs37/fLtnWCrho+nNzc3YRgRynnKkWEESPa3WcnjG550yh88shXqK/v9+OipSvxMet9HNI
kFUfLf9XnaLPwZwQaNru8OHDViCSyhGqT6jM8fsTP99XD00Z6hmbyqn8nZAhXoB4AW3eAHz9+tV+
CQDEC3BkQJtXLRpFapGD+/2UdiWp1GIHxAsAR0abQ1nQqkD9fk1Tcdph4+bNm2X9eQHiBYAjA9oc
EC/AkQFtDoB4AY4MaHNAvABwZECbA+IFODKgzQEQL8CRAW0OiBcAjgxoc0C8AEcGtDkA4gU4MqDN
AdtDvABHBrQ5IF6AIwPaHADxAhwZ0OYAiBfgyIA2B8QLAEdGmwMgXoAjA9ocAPECHBnQ5mlYWlqi
YREvwJFBI7e5QtkfPny4puqkYJD0BX+dQvXbivojXoB4QUXaXFGAL126VHN2UY7y1rt4VUP9ES9A
vKAibd7R0WHW1tYqYhffvn0zV65cMbt37zatra1mfn4+7/itW7dMU1OTPa5yvHv3Lq/MDx8+NC0t
LWbHjh1m586d5sWLF7lj0Zf77NWrV+bAgQOmvb09dR4+BgcHzZ49e8y+ffvM6OjoplFNOfKLpzkx
MWH2799v0+jp6bGj4iR+/Phhrl+/bsvY3NxsJicnE0deoXMRL0C8oKbafHp6OrVdxEUjKh6FuH37
tpmamrL/P3v2zBw5ciR37N69e1YQ5FT1evDggRW6aF4XL17MOX8JlwQsqU56L2evtN6/f586jyQk
nH19ffa6jx8/mlOnTm0ShnLkF0/z+PHjts66XuJ548aNxDLev3/fDA8P58p4+vTpRPEKnYt4AeIF
NdnmlbALiZWcZSGOHj1qR2bRUZpGHNHyREcthRx9/Fj8/DR5JHHy5Enz4cOH3PuFhYVN+Zcjv3ia
0dHply9fzMGDBxPLqBFfNL9CZUx7LuIFiBcgXv8lOlKKo6lA3/lpHH2o/MXk4YgvCJEIhxZDlKNO
cbH33cP4MV8ZQ+ciXoB4Qd2KV9ZpwyyONyROxYhXMXkUIwyVqlM572HoXMQLEC9g5PVftPw+adrw
2LFjm6bYoqOdcohXMXk4Tpw4YZ8NOV6/fh0Umqz5ra6ubkpzcXEx9/7z5892gUUSmtqM5vfmzZvE
MobORbwA8QLE679owcbLly/t/zMzM5sWbIyMjOQWN4yNjeX91iwkXlrNp2dOziEXOr+YPBzxBRta
ORgSr1B+0RWTWuGpBSnxNJWP8tP1v//+u/0ZQxKPHj0yQ0NDuTKePXs2sYyhcxEvQLwA8fovWubd
1dVlnbYWM2iRQBS3rFwvrcpbXl5OLV537tyxoxo3skkqf9Y8osjZ79271y4t18rBNKM2X35uxaSe
jUnUnj9/vklsnjx5Yn766Se7BP/mzZt29OXj7t27dlGIyqky+gTWdy7iBYgX0OZ1iITYt/KPdkK8
AEcGtPm2oxGKfpumaTbtQqIRlaYRaSfEC3BkQJtXLfrxtn4bpalC7bChKTyJWCUpx36NiBfgyIA2
B0C8AEcGtDkgXgA4MqDNAfECHBnQ5gCIF+DIgDYHbA/xAhwZVFebLy0tVU0dq6ksgHgB4gVV3ObV
tLQ7VJZy3YNqSwfxAhwZ0OY1bEtbVRb6D+IFiBdsc5vrc21A29LSYvfbi24c60gKa58mLIo+Hx8f
t7tV6Ie+f/31l928VjulF8pLkYO1757y6+3t3ZRe0vG0ZUlbb232q30JVefW1ta8AJFZQpxo70K3
l6F2nJ+dnU28Nuk+p20nxAsQL2go8dLO5s5Ruo1jHcWEtY+n/9tvv9mdKZ4+fWpF6+rVq/Z9PC+l
LQfttmOanJy0m++mPZ6mLGnrrd3wp6am7P/aIiq6G34W8YqKjHbXP3ToUMHz0txnX3kRL0C8oOHE
Kx7KPnpuMWHtfenr/fr6esHrjx8/vin2V9TZh45nFS9fvSVWSXHIsoiXdoZ3Iug7L8199pUX8QLE
CxpOvHyfFRPW3pe+773SjU//RfMPHc8qXqERUznS0WhL7yW8AwMDZb3PiBfgyADxyuDEQ867WPEq
5MCjhI5Xo3iJV69e2anHzs7OvF3pS73PiBfgyADxSvgsa1j7UsRLeUWnFOOEjpdTvBQosphpw9XV
1cRyLC4uJl5bzH1GvABHBohXwmehsPZaGadnMVHHW6x4Ka/h4eFcXnqvVXdpj2cpS6jeWrChKT8x
MzOTuGAjuiBjbW3NLqqIPzvTikMRX2SR5T4jXgCIF22eQbyEL6y9VvtphJD0A+Es4iX6+/vtikSl
JyF4//596uNZyhKqt6Imd3V1WbHRYoqFhYWC5zlB0pSmxEZCFT2uKUNd75a3OyHLep8RLwDEizYH
QLwARwa0OQDiBTgyoM0B8QLAkQFtDogX4MiANgdAvABHBrQ5IF4AODKgzQHxAhwZ0OYAiBfgyKAu
2nxpaYkbC4gXIF5Q/W0eTSdpJwtsERAvQLygatscOwLECxAv2JY2D4W71958CqjY3t6e74hicbUc
g4ODZu/evXZ/vt7e3k1lSEpPrKys2P0KVRbtA6jyPHnyhMZDvAAQL9o8n1C4+56eHrvLudsA17e5
rULXP3z40J7//ft3Mzk5aTfLTZteW1ubefToUW5n9dHRUSt0gHgBIF60eR6hcPe+0PPxNBUtOJ7W
oUOHUqdXiFAASkC8AEcGDdjmaSMGpxEvpRWfToyKT9qowxoNdnd321Ai2CriBYB40eYVFa/QKCmU
3sTEhB0Jjo+Pm+npaTu1iK0iXgCIF22+ibTh7tOIl0LZr6+vFy1eCjIZvX51dRVbRbwAEC/afDNp
w90X+kyrAvUMSysWhULZDw8P5xZc6H1HR0fq9FpaWnKrC9+8eWNOnDiBrSJeAIgXbb6ZtOHuC32m
lYT6oXL0x8r9/f12BKXPtOzdrSpMk97c3Jxd4KGySES1ChJbRbwAEC/aHADxAhwZ0OYAiBfgyIA2
B8QLAEcGtDkgXoAjA9ocAPECHBnQ5oB4AeDIgDYHxAtwZECbAyBegCMD2hwQLwAcGdDmgHgBjgxo
cwDEC3BkQJsDtod4AY4MaHNAvABHBrQ5AOIFODKgzQEQL8CRAW0OiBcAjow2B0C8AEcGtDkA4gU4
MqDNvSwtLVHGGqoX4gU4Mqhom09NTdWEbezatasoe97KusXLWM72C9WjkvUspl6IFyBeULE2X1tb
Mx0dHTVhG41YxizpVfL+FJM24gWIF1SszTs7O82///5bEac7MTFh9u/fb5qamkxPT4/5+vVr7vjK
yoq5ePGi2b17t9m5c6dpbW01T548ybv+1atX5sCBA6a9vd2+j77idfv27Zu5cuWKTU9pzc/PJ45e
Si3Xw4cPTUtLi9mxY4c958WLF7lj8TI+f/7cnqNzjx07ZmZnZxPv2Y8fP8z169fNnj17THNzs5mc
nEwceYXOLdQeSeV23Lp1y94T1V1faN69e5dYL8QLEC/YtjYfGhoyo6OjqWwj7sBCjkzHjh8/bh2g
HO3g4KC5ceNG7nhbW5t59OiRPaaXyiGhil4vYdGx9+/fFyxj9P3t27ft9Kd49uyZOXLkSKJ4lVou
iZtz7BIACUHS/Y6KxMuXL82hQ4cS79n9+/fN8PCwzffjx4/m9OnTieIVOrdQe/jKfe/ePVtXV+8H
Dx7YLwOMvADxgqpq83/++cecO3euotNd0dHPly9fzMGDB73XaEQQvd452qQyRt9LrOR0Q/eg0uWK
l1HC50Q1hEaYGkE6FhYWEtMOnVvoHvjKffTo0bz09L9Gp4gXIF5QNW2+sbFhnd+HDx8qKl5xMYl+
0xeaFtSIqbu72zrP0OIEn3jF0/aJSyXLFT+u0ZYb7Q0MDHjvWbwcKmdS2qFz09hB9LOoQBfKA/EC
xAu2vc1/++038/jx40y2Ucy0oc8Z6rmTRkvj4+NmenraTg1ulXhVslyFjksMNZWp54t9fX2pxcuX
dujcrOKVJW/ECxAv2JY2TxKictqH0lpcXMy9//z5s11c4ND/6+vruferq6slidfhw4dTTxtWsly+
e6h8fcdPnjyZN3X35s2bxLRD52YVLy0miU8bRpfHI16AeEFVtnklpg21Yk2LCSQqv//+u7l06VLu
uFa9uVV8crwnTpwIioBWwem5jXOy8QUbmqITMzMz3gUb5S5X9LN4GVUOrTgU8UUScbRQRIto3CKM
s2fPJuYdOjereGnBxsjISG7BxtjYmP1CkFQvxAsQL6hb8ZII/PTTT3bRws2bN+0oxzE3N2dX3smZ
y8HHfyhdqDx37tyxowE3Ioieo+XuXV1dNj09p9IChiTxKne5op/Fy6gpQ5XHLU93QpbE3bt37UKJ
vXv32hV/vrx952YVL+GWyuullYbLy8uJ9UK8APGCumzzarU1+sDW32vuOJRkRJV6tgGIF+IFiBcg
XlAXzrrce/zVe7kQL4AUAgaIFwDiBYgXIF4AiBcgXoB4AeIFgHghXgCIF+DIgDYHQLwARwZ13ObF
hJCH2r+PiFeFbiqvxnkhXttLaHl6ucpYbemUuyzlWOa/lXVDvBh9AG1e03XfqjLUezvXWv0QL4wb
aPuy11ufK+yH9sbbt2+f+euvv+zmrNpVvVCIeEUc1h562veut7d3U3pJx9OMguP79/nC1WtjWO27
p41iW1tb8wJLZtmDUHsMKm3loR3VZ2dnE691e/4pT23qGw3qGCpvnFD5tRei9lxUvLU8AUi4j752
8aUnVlZWbHRllUXlVnncpsSIF84LsIGqFS/F9fr+/bt5+vSpFa2rV6/a9/Hdz7Xpqxy0dhvX8cnJ
SbtRa9rjaWKFRf/3havX7vEuMrFiZPl2j/flExUZ7UavzXgLnSdBHx0dze22rrpKfNKWN06o/D09
PTYfxREL1SnNffel19bWZnend3VTPSV0iBeOC7CBqhav+AgiGscqep2iAMdjZUWdfeh4VvHyhauX
s08bt8t3XE7aiYjvPO0IH49zpdFq2vLGCZXfl1Y83TT3PUvZRKGIyogXjguwgaoSr7TvNZKIT1tF
nVzoeFbxCo2YypGORlt6LwEYGBhIPK+QM4+WIU2okaRr01znq1Mx9z3+maYVNRrs7u62Ql3ugKSI
F44LsIFtE6/Qt/HQ8WoUL+e4NXXX2dlp+vr6UueXNZ9KiVcx9z362cTEhB0J6tnn9PS0nVpEvHBc
gA3UjXhpQUN0SjFO6Hg5xUvRfYuZNlxdXU0sx+LiYuK1qlt82jC6ZD2reKUtf5o6FXPfo5/pOWf0
et89QrxwXIAN1Jx4adHC8PBw7sG+3mvVXdrjoRDyWcRLU1ya8hMzMzOJCzaiCzLW1tbsoor4szMX
1Ti+yCJe95GRkVzdxsbGrAAVK15py1/os/h9DN33UHpaIelWF75588acOHEC8cJxVYZy/cK+Er/U
r4Vf/yNexYmX6O/vt9/UNeqQELjVa2mOh0LIZxGvr1+/mq6uLis2ekazsLBQ8DwnSJpak9hIqKLH
NWWo693ydidkhcrglsrrpZWGy8vLRYtX2vIX+qzQffTd91B6c3NzdoGHyiIR1QIWxKuGOvGXL1/M
tWvXrGHKAGRYnz9/zh3X/+63EDrn8uXL5uPHj4n5uN+P6EFw1nKFDKdcgfQqEZAvnmbaTrAdv/jH
7gG2zvawwAp14hs3btipADf01rcsCZhDPwLUaiR3/M8//7TfdpII/UixFPGq5u1vik0T8aLOgHhB
EZ1YuwtEH6Dqx37RUcS5c+fsfHD0+Pnz5xPziP8KPstDWJ+jyfoLe40QNaceHRGq3Gl2PAj98j7+
y/1QvdPuiuCrT3RUW2hXBBw5dQbEq6E7sRxt9Ffmmk+Orw7SZ2nzKZd4FTru+4W95r71AFbHNM+u
ue23b9+myif0y/vQL/fj79PuihDaMcC3KwKOnDoD4tXQnVjTgnK2UYcZJ8tvNSopXqFf2EsM7t+/
bwVA06OlOLT4jx9Dv9wvZleEUH18uyLgyKkzIF4N24k/ffpkp9v0rb+Q06428Qr9wt4JgrazUd2y
3AvfL+/TrLAq5oelofr4dkXAkVNnQLwashNLsH799ddNKwkLTRFWetow6blU1l/YiwsXLtiRTxbx
Cv3yvlLilaY+Sbsi4MipMyBeDdeJ5di1XF6/MI8jJ6nl9A49P4r+EDCreMV/xV7KyCv0C3utotQz
JIlQlmnD0C/vs4pX2l0FQvWJEt8VAUdOnQHxaqhO/Pfff5szZ86YDx8+FDyu1W/RX7FLCHxTVoWm
9ny/9M8iXll+Ya/R0qlTp/KE4d9//y2YTpzQL+8LlTOeZjG7IoR2DPDtioAjp86AeDVUJz548KA3
dLxE4OzZs7lftmsaLvoj5lA+oV/6ZxGvLL+w12/Vokvl9b+OJ6UTJfTL+0LljKdZzK4IvvoI364I
OHLqDIgXnRiwAeoMgHjRiQEboM6AeAGdGLAB6gyIF50YsAHqDIB40YkBG6DOQH9DvOjEgA1QZ0C8
cFyADVBnAMSLTgzYAHUGQLzoxIAN1FGdl5aWMMAGuy+IF46ronV3AR61Uzs2QJ0rlVd8N5dqaItS
y6CdY7RrTikk7XJTD3aNeOG4Klr36N6L2AB1rlReaaIt1BKKQnHp0qWS61GO+4B4NWgnDoW894We
D4WlLzakfSnpakPb69ev2/0Bm5ubbTTipLon7ed469Ytm7buiTbGjQae1HnaY1CBIdvb23HkdWr3
uk4RCbRJs9tLMvolp1Q709+RkZHE9EN2nmSHvmt89ybU5+KoX2ij7TQ2lZR20n3xlTPpvi8vL9sI
6IVEVvu3bmxsIF711olDIe99oed9x0oJaV9Kuoqc7HZmV2yy06dPZ/pGrJ3cdQ/c/VB+V65cyTu/
p6fHHotumot41Zfd6zqJm/viEt/Fv1Q703ttcp2UfsjOC9lh6BpfmXx9rhCKc5fWpnxpZ43/57vv
2kA8Lrq6H1evXmXk1SjTJ9GgiL7Q875jpYS0LyVdfQuNhjrRDu5ZnIp2bY9er/8ViTl6fnQkhnjV
p90XaudoWqXaWSj9kJ0Xuj50ja9Mvj5X6v31pZ1VvHz33QVpjaLzX79+jXjVayf2hbz3hZ73HSsl
pH0p6cZjXKkzZ3EqhaIZR9OsZQFAvNLbfciJlmpnadL32Xmh60PX+PLz9blSbcqXdjH3xXffNQ37
9u3bnLBt59Q+4lXhThwKee86eVLo+aRjpYa0LzbdQgEasziV0PWIV2PYfVYnmtXOQumH7LzQ9Wn6
nC8NX38s1aaS0i5VvOLHh4aGbFR4oen+P/74A/Gq104cCnkfxRd6Pn6sXCHts6Z78uTJvGkFRULO
4lSUfnzaMLqcF/Gqvjplad+0dh9yoqXaWSj9kJ0Xuj5Ln/PdG19/LNWm4mmH7ku8XUL3Xc/BtAhH
keG1cEXL+RGvOhWvUMh7X+h537FSQtqXkq4ewuvbl3ugq4e4WRdsaBWYS39sbCzvtyyIV3WKV9LK
0WLtPiQuWe1MDlXPqJzjDaUfsvNC14eu8eXn63Ol2pQv7fh9iS7u0GpGLZrJet814vrll1/sgpZq
6G+IV4UcVyjkvS/0fCgsfbEh7UtJV9y9e9custA3L63AyvrN3C2V10sdQctw60m8khx+vb6KsfuQ
uGS1M636k726UXya9H12npRXqG8k5Rfqc6WIly/t+H1x4qZz9aVR52a97/Pz8/az7d69A/HiWzdg
A2UfeUH9IsHWyLpqvizSJDguwAaSxAu7B6HpRI0+s6yYRLxwXIANUGfYVvQM7dy5c9u6UAPxohMD
NkCdoeZtDwukEwM2QJ0B8aITAzZAnQEQLzoxYAPUGQDxohMDNkCdAfHiRtZ0+Qmjjg3Ucp2x38a7
n4jXNnfiYn/wmeW6pHOj/5cjXDg2gHhtV95x+92ucm1FvoWCXGpH+XLmXy33E/GqEfHairx90WgB
8arVOjdqOQpFiG4UW0a8tqCxQ+HGk9LQddpHbd++fTYSrW8Epc03tU+gfkR4/vx5G2sn7cgrvvVP
tYX7xpHXXp1XVlbs3n+yRznY1tbW3Ea9P//8s/n06ZP93+1q/s8//9j32q1cx0Np+Oy3kJ0r4q+2
NHL7/8Udvq+vxdEmt66vqUza66/Q/QiV342aVCbtWB+NUuw7lrbevnL6yhZKV7j9SXW9NieOBu5M
c78RrxroxGnCjRf6X9coLo/b3fnUqVNeEVIoA3V8nf/48WPz22+/pRav+P/VFu4b8aq9OusLkHYo
dzuwSxAU8Vf8+uuv1kbFX3/9Zaeo1E/cezncUBqhL37xY3LUzsHGd14P9bU4CrDpIhcrhpY2Hi6U
b6j8UaeugJLRqMy+Y2nr7Stnlnsbf6/d9HW+u1Zt59oszf1GvGqkE6cJN17ofydGjngY9Pj/0ZGW
8nNz4MWIV7WF+0a86qPOLpijAlW6gIb/93//ZyMt6yX0pUtf8EJpZBWv6Mgga1+LIxGI9+m09yNa
fomFE5c4vmNp6+0rZ5Z7G3+vHezjMfm0C33a+4141UgnzhJu3PcAOh6OO7RgI/pNJ6t4iWoK9414
1WadFapD3/4lTHJ47lzZlZua1pSYAihqSlpo+kpTiaE0soqXr9yhvubrW6H74Su/RlR6ry+a8Y1u
fcfS1js02kl7b+PvC0WUTvI3iFcNd+Is4cZ9hpdVvJKiE6dNo5rCfSNetVdnja70zX98fNxMT0/b
MBrRc/VsSVN0TrT0ZUlBK937NGmUS7xCfa1Y8QqV3wmIm+nQ1GWaY+UQryz3Nk26WWO1IV410Imz
hBuP/q/Is+rcDk3Z+TquGyW5YXzUCRQjXtUU7hvxqr06a/FD1O7j4eYvXbpk/vd//zc3XeimDt37
NGmUS7xCfS2OgjimmTYMlT+KRp9pj6Wtt6+cWe5t/L18WnzaMOnLMuJVw504S7hx34INXeMzYIUp
0Aouna/8si7YiIcLdyOuagj3jXjVXp01knKr1zSikkBEzx0ZGbHPScbGxux7jexlg7L7tGn47DeL
eIX6WhxNtWlaT8zMzCQu2AiVX9e5qMfxRQ2+Y1kWbCSVM1Q23/2UD1P7OZ+mNpRQIl516LjShhsv
NHWnUU9zc7Nd0eObCtRxnatzJGTxpauh/+PhwkW1hPtGvGqvznNzc3ZhkpyunKYWH0TP/fvvv/OW
yLtFEv/++2/qNHz2m3Uay9fX4mgWoqury5ZLz4qSfpYSKr+mBXW9W07uxCp0LK14+coZKpvvfgq3
VF4vfcldXl5GvHBcyR0mOhW4FVRLuG9sgDpvJdvR1wDxqptOrCkVPax1vw/TN534A91KUk3hvnHk
1LmSbHdfA8SrrjqxVgBpebqG7VqZdfPmTduxtopqCveNI6fOlWS7+xogXnRiwAaoMyBeQCcGbIA6
A+JFJwZsgDoDIF50YsAGqDMgXkAnBmyAOgPiRScGbIA6AyBedGLABqgzAOJFJwZsgDoD4sWNBGyA
OgMgXnRiwAaoMwDiRScGbIA6A+IFdGJAvAAQLzoxYAPUGQDxoiMDbU/doX5tDuujIwNtzj2AmrM1
LK/MN5dX47wAu+e1ff2NHgh8+waA2vM73AJAvAAA8QLECwAA8QLECwAA8QLECwAQL0C8MCMAQLwA
8QIAQLwA8QIAxAsA8QIAxAsQLwAAxAsQLwBAvAAQLwBAvADxAgBAvADxAgDECwDxAgDECxAvAADE
CxAvAEC8ABAvAEC8APECAEC8APECAEC8APECAMQLEC8AAMQLEC8AAMQLEC8AQLwAEC8AQLwA8QIA
QLwA8QIAxAsA8QIAxAsQLwAAxAsQLwBAvAAQLwBAvADxAgBAvGDbRSv+AgBAvADxAgBAvKCSAgYA
gHgB4gUAgHgB4gUAiBcA4gUAiBfUsoABACBegHgBACBeW+fEeTXOCwAQL0YfQJsDAOKFEwPaHgDx
ApwXYAMAiBeOC7ABAEC8cFyADQAgXoDjAmwAAPHCcQE2AACIF44LsAEAxAuq1nEtLS1xoxEvAEC8
Ku+4NjY2zJUrV8yuXbvM/v37TW9vr/n8+XNReSiNcpazUs62XOmWms5WX494ASBedSNeV69eNXfu
3DE/fvywr5GREXPp0qVtE4VacrCIFwAgXtvkaDVakmg59P+ePXsS03n+/LnZuXOn2bFjhzl27JiZ
nZ3NpR/fT69QntHPlNf169dtfs3NzWZyctI78hocHDR79+41TU1NdoSYplxpRncPHz40LS0t9lql
8eLFi9zxb9++2ZHp7t27TWtrq5mfn089SsxS11D90lyPeAEgXg0rXnLWvum/qHN/+fKlOXToUGIe
IYd+//59Mzw8bPP/+PGjOX36dKIgPHjwwIqMzv3+/bt13hoxpilXSLwuXrxo3r17Z98rDaXluH37
tpmamrL/P3v2zBw5cqQo8QrVNVS/0PWIFwDi1VDipVGFpgrlFL9+/Wpu3LhhRyBJHDhwIOfMQ3mE
HHp7e7sVS8fCwkKiIBw/fjxPZEVUoHzlComXE65CxyVW8XyLEa9QXUP1C12PeAEgXg0lXlqccfny
ZTvaOHz4sB21+EZeOq605GwHBgZKEq/oCEfIeScJgs6NT01GRdZXrlJEJ17GcqUTr2uofqHrES8A
xKuhxCvOmzdv7DMVH69evbJTaJ2dnaavr69s4uUTBN9oMFSuahSvrPULXY94ASBeDS1ejx8/Nt3d
3anOXVxc9Drw+PvV1dW8z06ePJk3FSbhTEpPizDW19eLKlcpoqPRaDHThlnrGqpf6HrECwDxaijx
0jMdCZZYWVmxoxY9T0lC52tln4gvbtCKPD0/ck42uohibW3NLoyIluPRo0dmaGgotwjh7NmziYJw
79693IIFvfS+o6MjVblKES8t2NCUpJiZmUlcsFFqXUP1C12PeAEgXg0lXhIqLQZwz7xCix40NXf0
6NHcsnInGEKr4/S8zD0zcyKic5W2zo2X4+7du/bH0VoirhV3PmHp7++3S8WVvsTh/fv3qcpVinhp
EUtXV5dNU+lHhT16Xql1DdUvzfWIFwDi1TDiBdgAACBeOC7ABgAA8cJxATYAgHjhuAAbAADEC8cF
2AAAIF44LsAGABAvwHEBNgCAeOG4ABsAAMQLx5WVpaWlip6PDQAA4lXljquaHVrSThi+Xe8LET+/
UZ044gWAeOG4akhwcdrcBwDEq45HXvpf0XxbWlpyewS6zWaTuHXrlt2PT8EgJyYmMu0bqI2AtYef
NvRVXq2trebJkyfekVc85lUonULn6+/GxoY5ePCg3bswijYV1g7vjsHBQbuXYFNTk+nt7UW8AADx
qkbxkgi4yMKh3dkVmt7tdK5NZLXBbxbxamtrs7ulu53UR0dHrQj6xKtQulnSib6/du2a3b09XicJ
ltDmtxJzpfn9+3czOTlpNx9GvAAA8aoy8XLClcbhKWpxdOQyPz+fSbwKEQ3KmFa8sqQTff/27Vs7
+nLxuvT3559/zt0D1S8ey+vQoUOIFwAgXtUmXlkcXig0fZr0FMpEMbMUAFMhR9IIVqF006YTf3/m
zBk7uhIavWnkGa1ffNoxTURnxAsAEK8aEq+s6ekZmYI7jo+Pm+npaTv1WIx4ZUkn/v7Zs2f2GZnQ
sy5dX2j0Vs82AACIV0OJ16lTp8znz59z7+Oh6ePXrq6u5n2mhR7r6+uJx9OKV5Z0Cr3XAhU969KU
YRSJWTRdxAsAEK86EK/Hjx/b1YZJoemjqxXX1tbslFz0uETDrQqU8J04cSKVYGlVoZ5LaWVgmnTi
58frpEUYzc3NmxZjaDHH8PBwbiGI3nd0dCBeAIB41bJ4Ca3I08q+n376yQpI9Hy3WlHTb4cPHzbP
nz/POz43N2cXQOgcTftNTU2lEi+JjH547H58HEonfn68Tp8+fbLHJMBx+vv77chOxyW+mpJEvAAA
8aozx4WDxAYAAPFCvIC2AUC8cFyVJuu+g4B4ASBegOMCbAAA8cJxATYAAIgXjguwAQDEC3BcgA0A
IF44LsAGAADxalTHtbS0xE1HvADod9yC2nJc8SXzlcwfp8x9AkC8cFwVyQ/HiXgBIF5QNsel/Qbd
/oPaRX12dtYsLy/b6MRxFE1YwRs3NjZseoqDpU1xdW10E954DCz32cjISMHzHYpgvHfvXtPU1GR6
e3uD5SxUN9952ADdCADxqhPHFRWRly9f5iIFa4f4uOOXWF29ejWXnjaqdVGH3Sa8vpHXhQsXEs/X
Br9KX7u3SyQnJyfzdnlPKmc8L9952ADdCADxqhPHpR3htQt7HAVp7OzszPusvb3dvH79OpeeE6JC
eRQSL9/5x48ft8IVJSo8SeWMp+M7DxugGwEgXnXiuDQ60TGJx8DAQN4xTfG9ffvW/r+wsGDFy5de
lgCQhUZM8enGaCRjXzmj6fjOwwboRgCIVx05rlevXuVGWn19fbnPh4aGzLVr1+z/V65cMX/88UfF
xCsqVFnLGU876TxsgG4EgHjVoeNaXFzMO0/BGRWF+MOHD3YhxdevXysmXlpcsb6+nqou8XIm1S1+
HjbAvQBAvOrEcSnysFboifgiCjfi+uWXX0xPT08mMZLo6RnXt2/fUp1/7949Mzw8bJ976aX3HR0d
qcoZTSdUH2wAABCvOnBcmmI7evRobvm6c/yO+fl5e218x4yQGGmloH6o7H6sHDpf9Pf3mz179thr
tJLx/fv3qcoZTSdUH2wAABCvBnBcEhAt3ADECwAQr5pwXJq+02iIVXuIFwAgXjXjuPTc6ty5c3kL
NQDxAgDEC8cF2AAA4gU4LsAGABAvHBdgAwCAeOG4ABsAQLwAxwXYAADiheMCbAAAEC8cF2ADAIgX
4LgAGwBAvHBcgA0AAOKF4wJsAAAQLxwXYAMAiBeOC7ABAEC8cFyADQAA4oXzAtoeAPECnBhtDgCI
Vz04M16N8wIAxAsYgQAAIF6AeAEA4gWAeAEA4gWIFwAA4gWIFwAgXgCIFwAgXoB4AQAgXoB4AQDi
BYB4AQDiBYgXAADiBYgXAADiBYgXACBegHgBACBegHgBACBegHgBAOIFgHgBAOIFiBcAAOIFiBcA
IF4AiBcAIF6AeAEAIF6AeAEA4gWAeAEA4gWIFwAA4gWIFwAgXgCIFwAgXoB4AQAgXoB4AQB+h1sA
iBcAIF6AeAEAIF6AeAEAIF6AeAEA4gWIF2YEAIgX1JBoxV8AAIgXIF4AAIgXVFLAAAAQL0C8AAAQ
L0C8AADxAkC8AADxgloWMAAAxAsQLwAAxGvrnDivxnkBAOLF6ANocwBAvHBiQNsDIF6A8wJsAADx
wnEBNgAAiBeOC7ABAMQLcFyADQAgXjguwAYAAPHCcQE2AIB4QdU6rqWlJW404gUAiFflHdfGxoa5
cuWK2bVrl9m/f7/p7e01nz9/LioPpVHOclbK2ZYr3VLT2errES8AxKtuxOvq1avmzp075sePH/Y1
MjJiLl26tG2iUEsOFvECAMRrmxytRksSLYf+37NnT2I6z58/Nzt37jQ7duwwx44dM7Ozs7n04/vp
Fcoz+pnyun79us2vubnZTE5Oekdeg4ODZu/evaapqcmOENOUK83o7uHDh6alpcVeqzRevHiRO/7t
2zc7Mt29e7dpbW018/PzqUeJWeoaql+a6xEvAMSrYcVLzto3/Rd17i9fvjSHDh1KzCPk0O/fv2+G
h4dt/h8/fjSnT59OFIQHDx5YkdG5379/t85bI8Y05QqJ18WLF827d+/se6WhtBy3b982U1NT9v9n
z56ZI0eOFCVeobqG6he6HvECQLwaSrw0qtBUoZzi169fzY0bN+wIJIkDBw7knHkoj5BDb29vt2Lp
WFhYSBSE48eP54msiAqUr1wh8XLCVei4xCqebzHiFaprqH6h6xEvAMSrocRLizMuX75sRxuHDx+2
oxbfyEvHlZac7cDAQEniFR3hCDnvJEHQufGpyajI+spViujEy1iudOJ1DdUvdD3iBYB4NZR4xXnz
5o19puLj1atXdgqts7PT9PX1lU28fILgGw2GylWN4pW1fqHrES8AxKuhxevx48emu7s71bmLi4te
Bx5/v7q6mvfZyZMn86bCJJxJ6WkRxvr6elHlKkV0NBotZtowa11D9Qtdj3gBIF4NJV56piPBEisr
K3bUoucpSeh8rewT8cUNWpGn50fOyUYXUaytrdmFEdFyPHr0yAwNDeUWIZw9ezZREO7du5dbsKCX
3nd0dKQqVynipQUbmpIUMzMziQs2Sq1rqH6h6xEvAMSrocRLQqXFAO6ZV2jRg6bmjh49mltW7gRD
aHWcnpe5Z2ZORHSu0ta58XLcvXvX/jhaS8S14s4nLP39/XapuNKXOLx//z5VuUoRLy1i6erqsmkq
/aiwR88rta6h+qW5HvECQLwaRrwAGwAAxAvHBdgAACBeOC7ABgAQLxwXYAMAgHjhuAAbAADEC8cF
2AAA4gU4LsAGABAvHBdgAwCAeOG4imVpaamoY+U4HxsAAMRrGx1XLTu0+O730br4dsbPmhbiBQCI
F45rS+rE1kmIFwDi1SAjL/2vaL4tLS25PQLdZrNJ3Lp1y+7Hp2CQExMTmfYN1EbA2sNPG/oqr9bW
VvPkyZNU5YnHvoqmXeiYL6+ktDY2NszBgwft/oZRtPGwdoF3DA4O2v0Gm5qaTG9vL+IFAIjXVouX
HLyLLBzanV2h6d1O59pEVhv8ZhGvtrY2u1u620l9dHTUimDa8vhCsMSPpcmrUFrXrl2zO7zH6y3B
EtogVwKrNL9//24mJyftBsWIFwAgXlsoXk4o0jg8RS2Ojkrm5+cziVchokEZQ+XJIl5p8iqU1tu3
b+3oy8X00t+ff/45Vy7dg3i8r0OHDiFeAIB4baV4ZXF4odD0adJTKBPFzFIATIUcyXJ9VvHKklf0
/ZkzZ+zoSmj0ptFg9B7Epx3TRH1GvAAQL6gS8cqanp6RKbjj+Pi4mZ6etlOPlRKvrHlF3z979sw+
IxN61qXrC43eatUGAADxaijxOnXqlPn8+XPufTw0ffza1dXVvM+00GN9fT3xeDnFK2te8fdaNKJn
XZoyjCIxi6aLeAEA4lXl4vX48WO72jApNH10deDa2pqdboselyC4FX8SvhMnTmQqj1YO6tmTVv+F
joXy8qUltAijubl502IMLeYYHh7OLQTR+46ODsQLABCvahUvodV2WrX3008/WXGInu9WB2pq7fDh
w+b58+d5x+fm5uziBp2jKb2pqalM5ZGQ6MfF7gfGvmOhvHxpiU+fPtljEuk4/f39dmSn4xJoTUki
XgCAeNWQ48JBYgMAgHghXkDbACBeOK5Kk3VPQUC8ABAvwHEBNgCAeOG4ABsAAMQLxwXYAADiBTgu
wAYAEC8cF2ADAIB4NarjWlpa4qYjXgD0O25BbTmu+JL5SuaPU+Y+ASBeOK6K5IfjRLwAEC8om+PS
foNu/0HtkD47O2uWl5dt5OE4ihSswIwbGxs2PcW40oa3uja6CW88vpX7bGRkpOD5DkUn3rt3r2lq
ajK9vb3Bchaqm+88bIBuBIB41YnjiorIy5cvc1GAtUN83PFLrK5evZpLT5vQuojCbhNe38jrwoUL
iedrg1+lr53ZJZKTk5N5O7gnlTOel+88bIBuBIB41Ynj0o7w2mE9jgIwdnZ25n3W3t5uXr9+nUvP
CVGhPAqJl+/848ePW+GKEhWepHLG0/Gdhw3QjQAQrzpxXBqd6JjEY2BgIO+Ypvjevn1r/19YWLDi
5UsvS3DHQiOm+HRjNEqxr5zRdHznYQN0IwDEq44c16tXr3Ijrb6+vtznQ0ND5tq1a/b/K1eumD/+
+KNi4hUVqqzljKeddB42QDcCQLzq0HEtLi7mnafAi4ow/OHDB7uQ4uvXrxUTLy2uWF9fT1WXeDmT
6hY/DxvgXgAgXnXiuBRVWCv0RHwRhRtx/fLLL6anpyeTGEn09Izr27dvqc6/d++eGR4ets+99NL7
jo6OVOWMphOqDzYAAIhXHTguTbEdPXo0t3zdOX7H/Py8vTa+Y0ZIjLRSUD9Udj9WDp0v+vv7zZ49
e+w1Wsn4/v37VOWMphOqDzYAAIhXAzguCYgWbgDiBQCIV004Lk3faTTEqj3ECwAQr5pxXHpude7c
ubyFGoB4AQDiheMCbAAA8QIcF2ADAIgXjguwAQBAvHBcgA0AIF6A4wJsAADxwnGVl/iPmwHxAkC8
oCyOSzuxK9ZWJXA7bNS7U0+bhnYOmZmZQbwAEC8o1XEpfIgLfdKIDnMry6j7HA0tg3gBIF5QhOP6
+++/7Q+R4+eOj4+b/fv3m3379pm//vrLbpSrfQejkYodg4ODdtf5pqYm09vbm5dO9CVWVlbs6EM/
gFZara2t5smTJ96yh65R2orCrG2s3J6G0TKmuX55edm0tbVtyltRnQ8ePGg2NjbsPom6XnloF/xo
pOno/fWdJ3S/dd8RLwDEC4p0XDdu3DATExObzv3tt9+s43769KkVratXr9r38Z3aHzx4YIVDW0np
+OTkpN2UNylfCcSjR49yu8ePjo7a6Mc+QtcoD4mTi9QcL2Oa68XZs2c3CY3qprqLqChqqjUa6Tke
WDPpPKEvBrrviBcA4gVFOq4TJ06YN2/ebDrXCYF7H421FU1LU44ShChJTj2JNIEofdfEy5sm3/j1
wgWwjKIpvtevX9v/JXhTU1PB++s7T+h+674jXgCIFxTpuDSVFhefUCDJ+CgjPj1YSBiiKGzJ7du3
TXd3tw1fksap+q5JE24l7fWaenTP/xYWFvKeT2kUpXMl2PHNiqNp+M4Tut+aYkW8ABAvKNJxFRr1
ZBGv0Kgpfq2mKBUwUlNn09PTNuSKO6fQM7LQNWnEK8v1Q0ND5tq1a/Z/BeL8448/NomgG6H19fV5
xbLQeVHRR7wAEC/YppGXFiREpxRD+er5WfT81dXVoFMNXRMSryzXf/z40d6TDx8+2EUoSTvqLy4u
BstQ6DyhZ4OMvAAQLyjBcenZi6bHihUvrUIcHh7OLYbQ+46Ojjxx1POob9++2fealnMr/dyzn5BT
DV0TEq+s12vE9csvv5ienp68zzV6c5GZ44tComn4zhN6hsYzLwDEC0pwXFr1phWDxYqXUMBKjW70
g2St+tO0nEMrD/W5+7Hy3NycXdAhhy4nr4UNIacauiYkXlmvn5+ft5/FdwfRVKCel7nl+E6g4mn4
zhOaimS1IQDiBSU4Ljnq6EgJjBVfjdYqxenTp63AIV4AiBeU4Li0Ko49CP8fmvrUSLLQKsFyoGlL
3e9qswEAQLxqTrz0XEbPeOD/PaPTDhhJCzVKRfeZvQ0BEC/AcQE2AIB44bgAGwAAxAvHBdgAAOIF
OC7ABgAQLxwXYAMAgHjhuAAbAADEC8cF2AAA4oXjAmwAABAvHBdgAwCAeOG4ABsAQLwAxwXYAADi
heMCbAAAEC8cF2ADAIgX4LyAtgdAvHBiQJsDAOK1/c6MV+O8AGD7+P8AQ5m8aOR8r1cAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-10-24 10:08:01 +1300" MODIFIED_BY="Helen E Nagels" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-10-24 10:08:01 +1300" MODIFIED_BY="Helen E Nagels" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASYAAAIoCAIAAABLRNFgAAAb10lEQVR42u2dsY4TSRPHR0JCBA42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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-04-10 10:40:14 +1200" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAFQCAMAAADDW8KoAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-04-10 10:40:23 +1200" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.2 Clinical pregnancy rate per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAGACAMAAADRZd6HAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-04-10 11:53:49 +1200" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.3 Incidence of OHSS per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwkAAAGwCAMAAADVH9kqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-04-16 14:57:07 +1200" MODIFIED_BY="Helen E Nagels">
<APPENDIX ID="APP-01" MODIFIED="2015-04-16 14:57:07 +1200" MODIFIED_BY="Helen E Nagels" NO="1">
<TITLE MODIFIED="2014-01-31 01:39:34 +1300" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-04-16 14:57:07 +1200" MODIFIED_BY="Helen E Nagels">
<SUBSECTION>
<HEADING LEVEL="3">Database: Cochrane Menstrual Disorders and Subfertility Group Specialised Register</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Search strategy</HEADING>
<P>Keywords CONTAINS "PCOS" or "polycystic ovary syndrome" or "Polycystic Ovary Syndrome" or Title CONTAINS "PCOS" or "polycystic ovary syndrome" or "Polycystic Ovary Syndrome"</P>
<P>AND</P>
<P>Keywords CONTAINS "IVF" or "in-vitro fertilisation " or  "in vitro fertilization"  or "ICSI" or "intracytoplasmic morphologically selected sperm injection"  or "intracytoplasmic sperm injection"  or "Embryo Transfer"  or "ovulation" or "ovarian stimulation" or Title CONTAINS "IVF" or "in-vitro fertilisation " or  "in vitro fertilization"  or "ICSI" or "intracytoplasmic morphologically selected sperm injection"  or "intracytoplasmic sperm injection"  or "Embryo Transfer" or "ovulation" or "ovarian stimulation"</P>
<P>AND</P>
<P>Keywords CONTAINS "metformin" or Title CONTAINS "metformin"</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Database: MEDLINE via OVID &lt;1980 to 20 October 2014&gt;</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Search strategy</HEADING>
<P>1 exp Polycystic Ovary Syndrome/ (10671)<BR/>2 Polycystic Ovar$.tw. (11225)<BR/>3 (PCOS or PCOD).tw. (6980)<BR/>4 (stein-leventhal or leventhal).tw. (694)<BR/>5 (ovar$ adj (scelerocystic or polycystic or degeneration)).tw. (76)<BR/>6 or/1-5 (13885)<BR/>7 exp metformin/ (7654)<BR/>8 metformin.tw. (10249)<BR/>9 (dimethylbiguanidium or dimethylguanylguanidine or glucophage or glucovance).tw. (112)<BR/>10 or/7-9 (11652)<BR/>11 exp fertilization in vitro/ (28847)<BR/>12 (ivf or icsi).tw. (19896)<BR/>13 (in vitro fertil$ or ((intracytoplasmic or intra-cytoplasmic) adj sperm$)).tw. (21463)<BR/>14 exp embryo transfer/ or exp sperm injections, intracytoplasmic/ (16614)<BR/>15 or/11-14 (42331)<BR/>16 6 and 10 and 15 (85)<BR/>17 randomized controlled trial.pt. (397392)<BR/>18 controlled clinical trial.pt. (90499)<BR/>19 randomized.ab. (316865)<BR/>20 placebo.tw. (167401)<BR/>21 clinical trials as topic.sh. (175872)<BR/>22 randomly.ab. (227168)<BR/>23 trial.ti. (137785)<BR/>24 (crossover or cross-over or cross over).tw. (63575)<BR/>25 or/17-24 (977646)<BR/>26 exp animals/ not humans.sh. (4078006)<BR/>27 25 not 26 (901386)<BR/>28 16 and 27 (32)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Database: EBM Reviews - Cochrane Central Register of Controlled Trials &lt;September 2014&gt;</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Search strategy</HEADING>
<P>1 exp Polycystic Ovary Syndrome/ (772)<BR/>2 Polycystic Ovar$.tw. (1234)<BR/>3 (PCOS or PCOD).tw. (924)<BR/>4 (stein-leventhal or leventhal).tw. (8)<BR/>5 (ovar$ adj (scelerocystic or polycystic or degeneration)).tw. (3)<BR/>6 or/1-5 (1380)<BR/>7 exp metformin/ (1414)<BR/>8 metformin.tw. (2235)<BR/>9 (dimethylbiguanidium or dimethylguanylguanidine or glucophage or glucovance).tw. (30)<BR/>10 or/7-9 (2314)<BR/>11 exp fertilization in vitro/ (1616)<BR/>12 (ivf or icsi).tw. (2552)<BR/>13 (in vitro fertil$ or ((intracytoplasmic or intra-cytoplasmic) adj sperm$)).tw. (1822)<BR/>14 exp embryo transfer/ or exp sperm injections, intracytoplasmic/ (1055)<BR/>15 or/11-14 (3438)<BR/>16 6 and 10 and 15 (38)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Database: EMBASE via Elsevier &lt;1980 to 20 October 2014&gt;</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Search strategy</HEADING>
<P>1 exp ovary polycystic disease/ (17456)<BR/>2 polycystic ovar$.tw. (14017)<BR/>3 (PCOD or PCOS).tw. (9383)<BR/>4 (stein-leventhal or leventhal).tw. (651)<BR/>5 (ovar$ adj (scelerocystic or polycystic or degeneration)).tw. (72)<BR/>6 or/1-5 (19952)<BR/>7 exp METFORMIN/ (35310)<BR/>8 metformin.tw. (16359)<BR/>9 (dimethylbiguanidium or dimethylguanylguanidine or glucophage or glucovance).tw. (1531)<BR/>10 or/7-9 (36285)<BR/>11 exp fertilization in vitro/ (39133)<BR/>12 (ivf or icsi).tw. (29725)<BR/>13 in vitro fertil$.tw. (21547)<BR/>14 ((intracytoplasmic or intra-cytoplasmic) adj sperm$).tw. (6773)<BR/>15 exp intracytoplasmic sperm injection/ (13023)<BR/>16 exp embryo transfer/ (21002)<BR/>17 or/11-16 (61145)<BR/>18 6 and 10 and 17 (321)<BR/>19 Clinical Trial/ (834564)<BR/>20 Randomized Controlled Trial/ (351271)<BR/>21 exp randomization/ (63592)<BR/>22 Single Blind Procedure/ (18900)<BR/>23 Double Blind Procedure/ (115714)<BR/>24 Crossover Procedure/ (40361)<BR/>25 Placebo/ (246816)<BR/>26 Randomi?ed controlled trial$.tw. (104177)<BR/>27 Rct.tw. (14914)<BR/>28 random allocation.tw. (1341)<BR/>29 randomly allocated.tw. (20881)<BR/>30 allocated randomly.tw. (1949)<BR/>31 (allocated adj2 random).tw. (717)<BR/>32 Single blind$.tw. (14712)<BR/>33 Double blind$.tw. (143861)<BR/>34 ((treble or triple) adj blind$).tw. (395)<BR/>35 placebo$.tw. (202854)<BR/>36 prospective study/ (263230)<BR/>37 or/19-36 (1388883)<BR/>38 case study/ (28194)<BR/>39 case report.tw. (265152)<BR/>40 abstract report/ or letter/ (903050)<BR/>41 or/38-40 (1190552)<BR/>42 37 not 41 (1350817)<BR/>43 18 and 42 (155)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Database: LILACS &lt;1982 to 2014&gt;</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Search strategy</HEADING>
<P>((MH:C04.182.612.765$) OR (MH:C13.351.500.056.630.580.765$) OR (MH:C19.391.630.580.765$) OR (TW:"Polycystic Ovary Syndrome") OR (TW:"Síndrome del Ovario Poliquístico") OR (TW:"Síndrome do Ovário Policístico") OR (TW:"Stein-Leventhal Syndrome") OR (TW:"Síndrome de Stein-Leventhal") OR (TW:stein-leventhal) OR (TW:leventhal) OR (TW:PCOS) OR (TW:PCOD) OR (TW:Ovar$ AND (Poliquístico OR Sclerocystic OR Polycystic OR Degeneration OR Policístico OR Degeneração))) AND ((MH:D02.078.370.141.450$) OR (TW:Metformin) OR (TW:METFORMINA) OR (TW:Dimethylguanylguanidine) OR (TW:"Dimetil Guanil Guanidina") OR (TW:Dimetilguanilguanidina) OR (TW:Glucophage) OR (TW:Glucovance)) AND ((MH:E02.875.800.500$) OR (MH:E05.820.800.500$) OR (TW:Embryo Transfer) OR (TW:Transferencia de Embrión) OR (TW:Transferência Embrionária) OR (TW:Blastocyst Transfer) OR (TW:Tubal Embryo Transfer) OR (TW:Transferencia de Blastocitos) OR (TW:Transferencia Tubaria del Embrión) OR (TW:Transferência de Blastócitos) OR (TW:Transferência Tubária de Embrião) OR (TW:Transferência de Embrião) OR (MH:E02.875.800.750$) OR (MH:E05.820.800.750$) OR (TW:Fertilization in Vitro) OR (TW:Fertilización In Vitro) OR (TW:Fertilização In Vitro) OR (TW:Test-Tube Fertilization) OR (TW:Fecundación In Vitro) OR (TW:Fecundación en Probeta) OR (TW:Fertilización en Probeta) OR (TW:Fecundação In Vitro) OR (TW:Fecundação em Tubo de Ensaio) OR (TW:Fertilização em Tubo de Ensaio) OR (MH:E02.875.800.750.700$) OR (MH:E05.820.800.750.700$) OR (TW:Inyecciones de Esperma Intracitoplasmáticas) OR (TW:Injeções de Esperma Intracitoplásmicas) OR (TW:Intracytoplasmic Sperm Injections) OR (TW:ICSI) OR (TW:Inyecciones Intracitoplasmáticas de Esperma) OR (TW:IICE) OR (TW:Injeções Intracitoplásmicas de Esperma) OR (TW:assisted reproductive technique) OR (TW:in vitro fertilization) OR (TW:in vitro fertilisation) OR (TW:FIV) OR (TW:IVF))<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;20 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;117 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;117 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;185 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;97 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;span&gt;10 full-text articles excluded:&lt;/span&gt;&lt;/p&gt;&lt;p&gt;3 = not RCTs&lt;/p&gt;&lt;p&gt;2 = data irregularities&lt;/p&gt;&lt;p&gt;1 = control group did not meet inclusion criteria&lt;/p&gt;&lt;p&gt;4 = participants did not meet inclusion criteria&lt;/p&gt;&lt;p&gt;and there is 1 study awaiting classification&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="150"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>